<SEC-DOCUMENT>0001193125-25-039211.txt : 20250227
<SEC-HEADER>0001193125-25-039211.hdr.sgml : 20250227
<ACCEPTANCE-DATETIME>20250227160520
ACCESSION NUMBER:		0001193125-25-039211
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250222
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250227
DATE AS OF CHANGE:		20250227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scilex Holding Co
		CENTRAL INDEX KEY:			0001820190
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39852
		FILM NUMBER:		25678658

	BUSINESS ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303
		BUSINESS PHONE:		(650) 516-4310

	MAIL ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Scilex Holding Company/DE
		DATE OF NAME CHANGE:	20221117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vickers Vantage Corp. I
		DATE OF NAME CHANGE:	20200804
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d859484d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sclxw="http://imetrix.edgar-online.com/20250222" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2025-02-22_to_2025-02-22">Scilex Holding Co</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-298">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-02-22_to_2025-02-22">0001820190</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="sclxw-20250222.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-02-22_to_2025-02-22"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-02-22</xbrli:startDate> <xbrli:endDate>2025-02-22</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2025-02-22_to_2025-02-22_us-gaap-StatementClassOfStockAxis_sclxw-CommonStockParValue0.0001PerShare2Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclxw:CommonStockParValue0.0001PerShare2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-02-22</xbrli:startDate> <xbrli:endDate>2025-02-22</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2025-02-22_to_2025-02-22_us-gaap-StatementClassOfStockAxis_sclxw-WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclxw:WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-02-22</xbrli:startDate> <xbrli:endDate>2025-02-22</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:7pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-325">8-K</ix:nonNumeric></span></p> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:7pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">PURSUANT TO SECTION 13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF THE SECURITIES EXCHANGE ACT OF 1934</p> <p style="margin-top:7pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-02-22_to_2025-02-22" format="ixt:datemonthdayyearen" id="ixv-326">February&#160;22, 2025</ix:nonNumeric></p> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:7pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">SCILEX HOLDING COMPANY</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-02-22_to_2025-02-22" format="ixt-sec:stateprovnameen" id="ixv-327">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-328">001-39852</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-329">92-1062542</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(State or other jurisdiction<br/>of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Commission<br/>File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-330">960 San Antonio Road</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-331">Palo Alto</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-02-22_to_2025-02-22" format="ixt-sec:stateprovnameen" id="ixv-332">California</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-333">94303</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including zip code)</p> <p style="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-334">(650)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-335">516-4310</ix:nonNumeric></span></p> <p style="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-02-22_to_2025-02-22" format="ixt-sec:boolballotbox" id="ixv-336">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-02-22_to_2025-02-22" format="ixt-sec:boolballotbox" id="ixv-337">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-02-22_to_2025-02-22" format="ixt-sec:boolballotbox" id="ixv-338">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-02-22_to_2025-02-22" format="ixt-sec:boolballotbox" id="ixv-339">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act</p> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-02-22_to_2025-02-22_us-gaap-StatementClassOfStockAxis_sclxw-CommonStockParValue0.0001PerShare2Member" id="ixv-340">Common stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-02-22_to_2025-02-22_us-gaap-StatementClassOfStockAxis_sclxw-CommonStockParValue0.0001PerShare2Member" id="ixv-341">SCLX</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-02-22_to_2025-02-22_us-gaap-StatementClassOfStockAxis_sclxw-CommonStockParValue0.0001PerShare2Member" format="ixt-sec:exchnameen" id="ixv-342">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-02-22_to_2025-02-22_us-gaap-StatementClassOfStockAxis_sclxw-WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member" id="ixv-343">Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-02-22_to_2025-02-22_us-gaap-StatementClassOfStockAxis_sclxw-WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member" id="ixv-344">SCLXW</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-02-22_to_2025-02-22_us-gaap-StatementClassOfStockAxis_sclxw-WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member" format="ixt-sec:exchnameen" id="ixv-345">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-02-22_to_2025-02-22" format="ixt-sec:boolballotbox" id="ixv-346">&#9746;</ix:nonNumeric></p> <p style="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2025-02-22_to_2025-02-22" format="ixt-sec:boolballotbox" id="ixv-347">&#9746;</ix:nonNumeric></p> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido Rest of World License Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously announced by Scilex Holding Company (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221;) on October&#160;8, 2024, the Company entered into that certain Rest of World License Term Sheet (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">ROW Term Sheet</span></span>&#8221;) with certain investors, pursuant to which the parties agreed to negotiate in good faith additional agreements required to effectuate such term sheet. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;22, 2025 (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Lido Effective Date</span></span>&#8221;), Scilex Pharmaceuticals Inc. (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Scilex Pharma</span></span>&#8221;) entered into a License Agreement (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Lido License Agreement</span></span>&#8221;) with RoyaltyVest Ltd. (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Licensee</span></span>&#8221;) with respect to services, compositions, products, dosages and formulations comprising lidocaine that have been or are later developed by or on behalf of Scilex Pharma, including the product and any future product defined as a &#8220;Product&#8221; under Scilex Pharma&#8217;s existing (i)&#160;Product Development Agreement, dated as of May&#160;11, 2011, with Oishi Koseido Co., Ltd. (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Oishi</span></span>&#8221;) and Itochu Chemical Frontier Corporation (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Itochu</span></span>&#8221;), as amended, and (ii)&#160;the associated Commercial Supply Agreement, dated February&#160;16, 2017, between Scilex Pharma, Oishi and Itochu, as amended, which include (a)&#160;ZTlido (lidocaine topical system) 1.8%, including the composition of matter with the NDC <span style="white-space:nowrap"><span style="white-space:nowrap">69557-111-30</span></span> and <span style="white-space:nowrap">(b)&#160;SP-103</span> (collectively, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Lido Product</span></span>&#8221;). The Lido License Agreement supersedes and replaces the ROW Term Sheet. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Lido License Agreement, Scilex Pharma granted to the Licensee during the Lido License Term (as defined below) a worldwide (other than the United States and certain territories stated in the Lido License Agreement), exclusive, <span style="white-space:nowrap">non-transferable</span> right, license and interest in, to, and under all Product Rights Controlled (each as defined therein) by Scilex Pharma to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit all Lido Products, in all cases solely for commercialization of the Lido Products outside of the United States and certain territories stated in the Lido License Agreement (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Lido Licensee Territory</span></span>&#8221;). The Licensee granted to Scilex Pharma a <span style="white-space:nowrap">non-exclusive,</span> <span style="white-space:nowrap">non-transferable,</span> right and license under the Licensee <span style="white-space:nowrap">Non-Blocking</span> Patents (as defined therein)&#160;(i) in the Licensor Territory (as defined therein), to develop, manufacture, obtain and maintain regulatory approvals for, commercialize and otherwise exploit Lido Product for commercialization of Lido Products in the Licensor Territory in the Field (each as defined therein), and (ii)&#160;worldwide, to develop and manufacture Lido Product for commercialization in the Licensor Territory in the Field (each as defined therein). Each of the Licensee and Scilex Pharma will receive 50% of the Net Revenue (as defined therein) generated, and the Licensee shall effect the foregoing by paying to Scilex Pharma its share of the Net Revenue on a quarterly basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Lido License Agreement, the Licensee shall (i)&#160;use commercially reasonable efforts to obtain and maintain regulatory approval for the Lido Product in at least one Major Market Country (as defined therein) within 18 months after the Lido Effective Date, and (ii)&#160;commit $200,000, or its equivalent in kind, annually towards such efforts until it obtains regulatory approval for the Lido Product in the Lido Licensee Territory. Scilex Pharma shall use commercially reasonable and diligent efforts to obtain and maintain regulatory approvals for <span style="white-space:nowrap">SP-103</span> and all existing Lido Products in each country or jurisdiction in the Licensor Territory (as defined therein). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Promptly after the Lido Effective Date, Scilex Pharma is required to (i)&#160;facilitate an introduction between Oishi, Itochu, and the Licensee, and (ii)&#160;use reasonable efforts to cause each of Oishi and Itochu to accept a direct engagement with the Licensee for the manufacturing or supply of the Lido Product in finished dosage form. In addition, Scilex Pharma agreed to appoint the Licensee as its exclusive distributor of the Lido Product in the Licensee Territory during the Lido License Term. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of the Lido License Agreement commences on the Lido Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Lido License Term</span></span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Lido License Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Lido License Agreement, a copy of which is filed herewith as Exhibit 10.1 and is incorporated herein by reference. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Parent Guarantee for Lido License Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;22, 2025, in connection with Lido License Agreement, the Company entered into that certain Parent Guarantee for Lidocaine License Agreement (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Parent Guarantee</span></span>&#8221;) with the Licensee, pursuant to which the Company agreed to guarantee the due and proper performance of Scilex Pharma&#8217;s obligations under the Lido License Agreement on the terms and conditions set forth in the Parent Guarantee. Pursuant to the terms of the Parent Guarantee, the Company shall provide the Licensee with written notice of any Change of Control (as defined therein) of Scilex Pharma within five business days after the consummation of such Change of Control, and the Parent Guarantee and the guarantee obligations shall automatically terminate upon the consummation of such Change of Control. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Parent Guarantee does not purport to be complete and is qualified in its entirety by reference to the full text of the Parent Guarantee, a copy of which is filed herewith as Exhibit 10.2 and is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d859484dex101.htm">License Agreement (ZTlido), dated February&#160;22, 2025, by and between Scilex Pharmaceuticals Inc. and RoyaltyVest Ltd. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d859484dex102.htm">Parent Guarantee for Lidocaine License Agreement, dated February&#160;22, 2025, by and between Scilex Holding Company and RoyaltyVest Ltd. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">#</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of&#160;1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">SCILEX HOLDING COMPANY</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jaisim Shah</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Jaisim Shah</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer and President</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February&#160;27, 2025 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d859484dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIDOCAINE LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>dated as of February&nbsp;22, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>by and between </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX
PHARMACEUTICALS INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>as Licensor </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROYALTYVEST LTD.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>as Licensee </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;I DEFINED TERMS AND RULES OF CONSTRUCTION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Defined Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rules of Construction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;II REPRESENTATIONS AND WARRANTIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Mutual Representation and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Licensor Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Licensor Covenant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Mutual Covenant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Disclaimer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;III LICENSES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Licenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Sublicenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Access to Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Territory</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;IV DEVELOPMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Development by Licensor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Development by Licensee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Data Exchange and Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;V REGULATORY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulatory Responsibilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Coordination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulatory Assistance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Adverse Events Reporting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Remedial Actions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Additional Compensation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;VI SUPPLY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Supply of Product</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Quality Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;VII COMMERCIALIZATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Appointment as Exclusive Distributor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Diligence</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exclusivity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Assistance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Coordination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Product Trademarks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;VIII GOVERNANCE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Joint Steering Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Joint Commercialization Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Alliance Managers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Scope of Governance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;IX FINANCIAL TERMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Revenue Share</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Revenue Reports and Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payment Provisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Records; Audits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;X INDEMNITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>By Licensor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>By Licensee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Procedure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Consequential Damages</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;XI CONFIDENTIALITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Permitted Disclosure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Public Announcement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;XII REGISTERED IP RIGHTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Prosecution and Maintenance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Enforcement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Third-Party Infringement Claims</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Registration of License</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Registered IP Rights Licensed from Third Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;XIII TERM AND TERMINATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination by Licensee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination for Cause</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effects of Expiration or Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;XIV DISPUTE RESOLUTION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>General</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Continuance of Rights and Obligations during Pendency of Dispute Resolution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Escalation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Arbitration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Injunctive Relief</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;XV MISCELLANEOUS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Force Majeure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Successors and Assigns</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rights in Bankruptcy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Performance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Independent Nature of Relationship</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-Contravention</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governing Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendments; No Waivers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Third Party Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Table of Contents and Headings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Exhibits </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit A:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Licensed Patents</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit B:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Licensed Marks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit C:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Licensor Territory</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LIDOCAINE LICENSE AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This LIDOCAINE LICENSE AGREEMENT (this &#147;<U>Agreement</U>&#148;), dated as of February&nbsp;22, 2025 (the &#147;<U>Effective
Date</U>&#148;), is by and between SCILEX PHARMACEUTICALS INC., a Delaware corporation (&#147;<U>Licensor</U>&#148;), and ROYALTYVEST LTD., a British Virgin Islands corporation (&#147;<U>Licensee</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>W</U> <U>I</U> <U>T</U> <U>N</U> <U>E</U> <U>S</U> <U>S</U> <U>E</U> <U>T</U> <U>H</U>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Licensor, Licensor Parent (as defined below), and Licensee entered into that Rest of World License Term Sheet, dated as of
October&nbsp;8, 2024 (the &#147;<U>Term Sheet</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the Term Sheet, the parties are to negotiate in good
faith additional agreements required to effectuate the Term Sheet, including this Agreement, and accordingly desire to enter into this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the mutual agreements, representations and warranties set forth herein and of other good
and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties covenant and agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;I </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>DEFINED TERMS
AND RULES OF CONSTRUCTION </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1 <U>Defined Terms</U> . The following terms, as used herein, have the following respective
meanings, and grammatical variations have corresponding meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Adverse Event</U>&#148; means any unwanted or harmful medical
occurrence in a patient or subject who is administered a Product, including any undesirable sign (including abnormal laboratory findings of clinical concern). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; means, with respect to any designated Person, any other Person that, directly or indirectly, controls, is
controlled by or is under common control with such designated Person. For purposes of this definition, &#147;<U>control</U>&#148; of a Person means the possession, directly or indirectly, of the power to direct or cause the direction of the
management and policies of such Person, whether through the ownership of Equity Interests, by contract or otherwise, and the terms &#147;<U>controlled</U>&#148; and &#147;<U>controlling</U>&#148; have meanings correlative to the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Agreement</U>&#148; has the meaning set forth in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Applicable Law</U>&#148; means, with respect to any Person, all laws, rules, regulations and orders of Governmental Authorities
applicable to such Person, the conduct of its business, or any of its properties, products or assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148;
means any day that is not a Saturday, Sunday or other day on which commercial banks in New York City are authorized or required by Applicable Law to remain closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>CMO</U>&#148; has the meaning set forth in Section&nbsp;6.1(c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Commercialization</U>&#148; means, with respect to the Product, any and all
processes and activities directed to selling, offering for sale (including any application for marketing and pricing and reimbursement approvals), distributing, detailing, marketing, advertising, promoting, packaging, storing, transporting,
distributing, importing, and other commercial exploitation activities; provided, however, that Commercialization shall exclude Development and Manufacturing activities (including manufacturing activities related to Commercialization).
&#147;<U>Commercialize</U>&#148; and &#147;<U>Commercializing</U>&#148; shall have their correlative meanings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Commercially
Reasonable and Diligent Efforts</U>&#148; means, measured objectively from the perspective of a prudent executive in the pharmaceutical industry, deploying those efforts and resources necessary and useful to obtain the stated objective without
consideration of the economic impact of any payment obligations under this Agreement and includes expenditures of amounts typical to achieve the obligation, delegating to Third Parties such obligation solely as is prudent, and is limited only as to
the absence of an obligation not to take unreasonable, unwarranted or impractical efforts and expenditures of time and money out of all proportion to economic reality. For the avoidance of doubt, Commercially Reasonable and Diligent Efforts may not
and, as a covenant, shall not include consideration of other products or projects of the obligor and/or the potential impact on the short term economic status of the obligor. Both Parties agree the foregoing standard is not vague. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Commercially Reasonable Efforts</U>&#148; means, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) with respect to any Intellectual Property Rights in any country, efforts or actions that would be commercially reasonable for an owner and
licensor of such Intellectual Property Rights in such country, which owner and licensor is entitled to the full economic benefit of such Intellectual Property Rights without regard to the transactions contemplated by this Agreement or any other
business of, or assets owned by, such owner and licensor; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) for purposes of Development, obtaining and maintaining Regulatory
Approvals, and Commercialization, with respect to the efforts to be expended, or considerations to be undertaken, by a Party with respect to any objective, activity or decision to be undertaken hereunder, reasonable, good faith efforts to accomplish
such objective, activity or decision as a prudent company in the biotechnology industry of a size comparable to such Party and its Affiliates, taken as a whole, would normally use to accomplish a similar objective, activity or decision under similar
circumstances, it being understood and agreed that with respect to the Exploitation of Products, such Party may take into account: (i)&nbsp;issues of efficacy, safety, and expected and actual approved labeling, (ii)&nbsp;the expected and actual
competitiveness of alternative products sold by third parties in the marketplace, (iii)&nbsp;the likelihood of Regulatory Approval or pricing restrictions given the regulatory structure involved, including regulatory or data exclusivity, and
(iv)&nbsp;the expected and actual profitability of the Products, all as measured by the facts and circumstances in existence at the time such efforts are due. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Compliance Laws</U>&#148; means all Applicable Laws relating to (a)&nbsp;the prevention of bribery, corruption, fraud, or improper
payments, money laundering or counter-terrorist financing or (b)&nbsp;export controls, economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by any Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Confidential Information</U>&#148; has the meaning set forth in Section&nbsp;11.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Contract</U>&#148; means any mortgage, indenture, lease, contract, covenant,
arrangement, instrument, commitment, purchase order, license, or agreement of any kind, whether oral or written. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Control</U>&#148; (including any variations such as &#147;<U>Controlled</U>&#148; and &#147;<U>Controlling</U>&#148;), in the context
of Intellectual Property Rights, data and/or other information or assets, means that such Party owns or possesses rights to such Intellectual Property Rights, data and/or other information or assets, as applicable, sufficient to grant the applicable
license or sublicense under this Agreement, without violating the terms of an agreement with a Third Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Development</U>&#148; means <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical research and drug development
activities, including but not limited to toxicology, pharmacology, statistical analysis, clinical studies (including <FONT STYLE="white-space:nowrap">pre-</FONT> and post-approval studies), regulatory affairs, and regulatory activities pertaining to
designing and carrying out clinical studies and obtaining Regulatory Approvals (excluding regulatory activities directed to obtaining pricing and reimbursement approvals). &#147;Develop&#148; and &#147;Developing&#148; shall have their correlative
meanings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Development Agreement</U>&#148; means the Product Development Agreement, dated as of May&nbsp;11, 2011, by and among
Stason Pharmaceuticals, Inc., Oishi Koseido Co., Ltd (&#147;<U>Oishi</U>&#148;) and Itochu Chemical Frontier Corporation (&#147;<U>Itochu</U>&#148;), as amended by (a)&nbsp;the First Amendment to Product Development Agreement, dated as of
April&nbsp;2, 2013, by and among Scilex Pharmaceuticals, LLC, Oishi and Itochu, (b)&nbsp;the Second Amendment to Product Development Agreement, dated as of February&nbsp;20, 2017, by and among Licensor, Oishi and Itochu, (c)&nbsp;the Third Amendment
to Product Development Agreement, dated as of August&nbsp;29, 2018, by and among Licensor, Oishi and Itochu, (d)&nbsp;the Fourth Amendment to Product Development Agreement, dated as of December&nbsp;13, 2019, by and among Licensor, Oishi and Itochu
and (e)&nbsp;the Fifth Amendment to Product Development Agreement, dated as of April&nbsp;30, 2021, by and among Licensor, Oishi and Itochu. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disclosing Party</U>&#148; has the meaning set forth in Section&nbsp;11.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Dollar</U>&#148; or the sign &#147;<U>$</U>&#148; means United States dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Equity Interests</U>&#148; means, with respect to any Person, all of the (a)&nbsp;shares of capital stock of (or other ownership or
profit interests in) such Person, (b)&nbsp;warrants, options or other rights for the purchase or acquisition from such Person of shares of capital stock of (or other ownership or profit interests in) such Person, (c)&nbsp;securities convertible into
or exchangeable for shares of capital stock of (or other ownership or profit interests in) such Person or warrants, rights or options for the purchase or acquisition from such Person of such shares (or such other interests), and (d)&nbsp;other
ownership or profit interests in such Person (including partnership, member, membership or trust interests therein), whether voting or nonvoting, and whether or not such shares, warrants, options, rights or other interests are outstanding on any
date of determination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exploit</U>&#148; and &#147;<U>Exploitation</U>&#148; means, with respect to a product such as a Product,
the research, study, development, formulation, processing, engineering, manufacture, testing, seeking and obtaining Regulatory Approval, use, sale, offer for sale (including marketing and promotion) and distribution (including importing, exporting,
transporting, customs clearance, warehousing, invoicing, storage, handling and delivering) or other commercialization of such product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA</U>&#148; means the U.S. Food and Drug Administration and any successor agency thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Field</U>&#148; means the prevention, diagnosis, treatment, or cure of any disease,
state, condition, or other indication in humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; means generally accepted accounting principles in effect in the
United States from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GCP</U>&#148; means all applicable Good Clinical Practice standards for the design, conduct,
performance, monitoring, auditing, recording, analyses, and reporting of clinical trials, including, as applicable (a)&nbsp;as set forth in the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals
for Human Use Harmonized Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) and any other guidelines for good clinical practice for trials on medicinal products in the applicable territory, (b)&nbsp;the Declaration of Helsinki
(2004)&nbsp;as last amended at the 52nd World Medical Association in October 2000 and any further amendments or clarifications thereto, (c)&nbsp;U.S. Code of Federal Regulations Title 21, Parts 50 (Protection of Human Subjects), 56 (Institutional
Review Boards) and 312 (Investigational New Drug Application), as may be amended from time to time, or (d)&nbsp;the equivalent Applicable Laws in the applicable territory, each as may be amended and applicable from time to time and in each case,
that provide for, among other things, assurance that the clinical data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GLP</U>&#148; means all applicable Good Laboratory Practice standards, including, as applicable, as set forth in the then current
good laboratory practice standards promulgated or endorsed by the U.S. Food and Drug Administration as defined in 21 C.F.R. Part 58, or the equivalent Applicable Laws in the applicable territory, each as may be amended and applicable from time to
time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GMP</U>&#148; means good manufacturing practices and standards for the production of drugs promulgated or endorsed by the
FDA, as set forth in 21 C.F.R. Parts 210, 211, 600 through 680, 820, and 1271, as applicable, or comparable regulatory standards promulgated by any other Governmental Authority in the applicable territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governmental Authority</U>&#148; means the government of any other nation or any political subdivision thereof, whether state or
local, and any agency, authority (including supranational authority), commission, instrumentality, regulatory body, court, central bank or other Person exercising executive, legislative, judicial, taxing, regulatory or administrative powers or
functions of or pertaining to government, including each patent office, the FDA and any other government authority in any country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">In-License</FONT></U>&#148; means each license, settlement agreement or other agreement or
arrangement between Licensor or any of its Affiliates and any Third Party pursuant to which Licensor or any of its Affiliates obtains a license or sublicense or a covenant not to sue or similar grant of rights to any patents or other intellectual
property rights of such Third Party that is necessary for the Exploitation of a Product in the Field in the Licensee Territory. Without limiting the foregoing, the Development Agreement and the Supply Agreement constitute <FONT
STYLE="white-space:nowrap">In-Licenses.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property Rights</U>&#148; means any and all of the following:
(a)&nbsp;Patents, (b) all rights in <FONT STYLE="white-space:nowrap">Know-How,</FONT> (c)&nbsp;all rights in Trademarks, and (d)&nbsp;all other forms of intellectual property or proprietary rights of any kind in any jurisdiction throughout the
world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Joint Commercialization Committee</U>&#148; or &#147;<U>JCC</U>&#148; means the joint commercialization committee,
comprising representatives of Licensor and Licensee, described in Section&nbsp;8.2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Joint Steering Committee</U>&#148; or &#147;<U>JSC</U>&#148; means the joint
steering committee, comprising representatives of Licensor and Licensee, described in Section&nbsp;8.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT
STYLE="white-space:nowrap">Know-How</FONT></U>&#148; means any and all technical, scientific, regulatory, and other information, results, knowledge, techniques and data, in whatever form and whether or not confidential, patented or patentable,
including inventions, invention disclosures, discoveries, plans, processes, practices, methods, knowledge, trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> instructions, skill, experience, ideas, concepts, data (including biological,
chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, safety, quality control, and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data), formulae, formulations, compositions, specifications, marketing,
commercialization, pricing, distribution, cost, sales and manufacturing data or descriptions, and all chemical or biological materials and other tangible materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Licensed IP Rights</U>&#148; means the Licensed Patents, the Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> rights to
data, contracts, or any other right Controlled by Licensor that are reasonably necessary or useful to Develop, Manufacture, obtain or maintain Regulatory Approvals for, or Commercialize Product in the Field in the Licensee Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT></U>&#148; means all <FONT STYLE="white-space:nowrap">Know-How</FONT>
(including all trade secret and <FONT STYLE="white-space:nowrap">know-how</FONT> rights in and to the foregoing) Controlled by Licensor as of the Effective Date or at any time during the Term that are reasonably necessary or useful to Develop,
Manufacture, obtain or maintain Regulatory Approvals, or Commercialize Product in the Field in the Licensee Territory. Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> includes all <FONT STYLE="white-space:nowrap">Know-How</FONT> received
by Licensor under or in connection with the Development Agreement or the Supply Agreement that is reasonably necessary or useful to Develop, Manufacture, obtain or maintain Regulatory Approvals for, Commercialize, and otherwise Exploit Products in
the Field in the Licensee Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Licensed Marks</U>&#148; means the Trademarks that are Controlled by Licensor and used in
connection with the packaging and labeling of Product, as listed on Exhibit&nbsp;B, together with all rights in the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Licensed Patents</U>&#148; means (a)&nbsp;the Patents listed on Exhibit&nbsp;A, together with all Patents that claim priority from,
or common priority with, any of the foregoing, as well as (b)&nbsp;all Patents Controlled by Licensor as of the Effective Date or at any time during the Term that are reasonably necessary or useful to Develop, Manufacture, obtain or maintain
Regulatory Approvals for, or Commercialize Product in the Field in the Licensee Territory. Licensed Patents include all Patents claiming or covering Product, or composition of matter, formulation, or methods of manufacture or use thereof, that are
Controlled by Licensor or any of its Affiliates, whether as of the Effective Date or at any time during the Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Licensee
Development Activities</U>&#148; means all research, Development, Manufacturing, and other activities reasonably required to support Regulatory Filings for Product in the Licensee Territory for use in the Field. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Licensee <FONT STYLE="white-space:nowrap">Non-Blocking</FONT> Patents</U>&#148; means all Patents Controlled by Licensee as of the
Effective Date or at any time during the Term that are reasonably necessary or useful to Develop, Manufacture, obtain or maintain Regulatory Approvals for, or Commercialize Product in the Field in the Licensor Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Licensee Supply Agreement</U>&#148; has the meaning set forth in Section&nbsp;6.1(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Licensee Territory</U>&#148; means the entire world other than the Licensor Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Licensor Development Activities</U>&#148; means all research, Development,
Manufacturing, and other activities reasonably required to support Regulatory Filings for <FONT STYLE="white-space:nowrap">SP-103.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Licensor Development Agreements</U>&#148; means all Contracts between Licensor and any other Person related to the performance of any
Licensor Development Activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Licensor Parent</U>&#148; means Scilex Holding Company, a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Licensor Regulatory Agreements</U>&#148; means all Contracts between Licensor and any other Person related to Licensor&#146;s
performance of Section&nbsp;5.1(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Licensor Territory</U>&#148; means, subject to Section&nbsp;3.4, the countries listed on
Exhibit&nbsp;C, together with their respective territories and possessions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Major Market Country</U>&#148; means the following
countries in the Licensee Territory: Canada, the United Kingdom of Great Britain and Northern Ireland, and each member country of the European Economic Area as of the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Manufacture</U>&#148; means activities directed to manufacturing, processing, packaging, labeling, filling, finishing, assembly,
shipping, storage, or freight of any pharmaceutical or biologic product (or any components or process steps involving any product or any companion diagnostic), placebo, or comparator agent, as the case may be, including quality assurance and
stability testing, characterization testing, quality control release testing of drug substance and drug product, quality assurance batch record review and release of product, process development, qualification, and validation, <FONT
STYLE="white-space:nowrap">scale-up,</FONT> <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical, and commercial manufacture and analytic development, and product characterization, but excluding activities directed to Development.
&#147;Manufacturing&#148; and &#147;Manufactured&#148; shall have their correlative meanings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Net Revenue</U>&#148; means
(a)&nbsp;for so long as aggregate Net Sales and Net Sublicensing Revenue are less than aggregate Qualifying Expenses, zero dollars&nbsp;($0), and (b)&nbsp;thereafter, the sum of Net Sales and Net Sublicensing Revenue, less all Qualifying Expenses.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Net Sales</U>&#148; means, with respect to any Product, the total amount received or recognized as revenue by Licensee in
respect of sales by Licensee to customers of the Products, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of the Products, including: (a)&nbsp;cash discounts,
quantity discounts, promotional discounts, stocking or other promotional allowances; (b)&nbsp;sales and excise taxes, customs and any other indirect taxes; (c)&nbsp;freight, insurance and other transportation charges; (d)&nbsp;returns, recalls, and
returned goods allowances; (e)&nbsp;retroactive corrections including price adjustments and corrections for billing errors or shipping errors; and (f)&nbsp;chargebacks, rebates, administrative fees, any other allowances actually granted or allowed
to any entity including group purchasing organizations, managed health care organizations and to governments, including their agencies, or to trade customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net Sales shall not include transfers or dispositions for charitable, promotional, <FONT STYLE="white-space:nowrap">pre-clinical,</FONT>
clinical, regulatory, or governmental purposes. Net Sales shall not include sales between or among Licensee or its Affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Net Sublicensing Revenue</U>&#148; means the total amount received or recognized as
revenue by Licensee in consideration for the grant by Licensee of a license, immunity, or other right under the Licensed IP Rights to Commercialize a Product, but excluding (a)&nbsp;equity or debt investments in, or loan proceeds to, Licensee,
(b)&nbsp;payments by Sublicensees for bona fide research, development, manufacturing or commercialization activities (including payments for full-time equivalents), and (c)&nbsp;amounts received to reimburse Licensee for Development or similar
services conducted for Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Non-Blocking</FONT> License</U>&#148; has the meaning set forth
in Section&nbsp;3.1(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Out-License</FONT></U>&#148; means each license, settlement agreement
or other agreement or arrangement between Licensor or any of its Affiliates and any Third Party pursuant to which Licensor or any of its Affiliates grants a license, sublicense or similar grant of any Product Application, Regulatory Approval or
Intellectual Property Right that is necessary or reasonably useful for the Exploitation of a Product in the Field in the Licensee Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Party</U>&#148; means Licensor or Licensee, as the context requires, and &#147;<U>Parties</U>&#148; means, together, Licensor and
Licensee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Patents</U>&#148; means any and all issued patents and pending patent applications, including without limitation, all
provisional applications, substitutions, continuations, <FONT STYLE="white-space:nowrap">continuations-in</FONT> part, divisions, and renewals, all letters patent granted thereon, and all <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">patents-of-addition,</FONT></FONT> reissues, reexaminations, <I>inter partes</I> reviews, and extensions or restorations by existing or future extension or restoration mechanisms (including regulatory extensions), and all
supplementary protection certificates, together with any foreign counterparts thereof anywhere. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means any
natural person, firm, corporation, limited liability company, partnership, joint venture, association, joint-stock company, trust, unincorporated organization, Governmental Authority or any other legal entity, including public bodies, whether acting
in an individual, fiduciary or other capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Product</U>&#148; means services, compositions, products, dosages, and
formulations comprising lidocaine that have been or are later developed by or on behalf of Licensor, including the product and any future product defined as a &#147;Product&#148; under the Development Agreement and the Supply Agreement, which
include&nbsp;(a) ZTlido (lidocaine topical system) 1.8%, including the composition of matter with the NDC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">69557-111-30,</FONT></FONT> and
<FONT STYLE="white-space:nowrap">(b)&nbsp;SP-103.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Product Application</U>&#148; means an application for Regulatory
Approval to research, study, develop, formulate, process, engineer, manufacture, test, use, market, sell, offer for sale and distribute a product or drug in a country or region, including (a)&nbsp;a New Drug Application, (b)&nbsp;an Investigational
New Drug Application, (c)&nbsp;any corresponding foreign application in any country or jurisdiction in the world and (d)&nbsp;all supplements, amendments, variations, extensions and renewals thereof that may be filed with respect to the foregoing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Product Rights</U>&#148; means all rights, tangible and otherwise, with respect to any Product, including all rights to develop,
<FONT STYLE="white-space:nowrap">out-license,</FONT> sell, offer to sell, make, have made, import, export and otherwise commercialize or derive profit including the Licensed IP Rights and all Regulatory Approvals and other Regulatory Filings related
to a Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Filings</U>&#148; means, collectively, all reports, schedules, forms, statements and other documents
required to be filed by Licensor or Licensor Parent under the Securities Act of 1933, as amended, and the Securities Exchange Act, as amended, including pursuant to Section&nbsp;13(a) or 15(d) thereof, since January 1, 2024 (the foregoing materials,
including the exhibits thereto and documents incorporated by reference therein). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Qualifying Expenses</U>&#148; means, to the extent not already accounted for in the
definition of &#147;Net Sales&#148; or &#147;Net Sublicensing Revenue,&#148; the fully-burdened costs to Licensee incurred or accrued in connection with the Development, Manufacture, obtaining and maintaining Regulatory Approval, and
Commercialization of Product, including all amounts paid to Licensor, Oishi or Itochu related to Products and all amounts paid to Third Parties in connection with any rights under Third-Party Intellectual Property Rights to Develop, Manufacture,
obtain or maintain Regulatory Approval, or Commercialize Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Receiving Party</U>&#148; has the meaning set forth in
Section&nbsp;11.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Regained Territory</U>&#148; has the meaning set forth in Section&nbsp;3.4(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registered IP Rights</U>&#148; means the Licensed Patents within the Licensee Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Regulatory Approval</U>&#148; means, collectively, all regulatory approvals, licenses, permissions, allowances, registrations,
certificates, authorizations, permits and supplements thereto, as well as associated materials pursuant to which a human pharmaceutical product may be researched, studied, developed, formulated, processed, engineered, manufactured, tested, held,
imported, transported, used, marketed, promoted, sold, offered for sale and distributed in a jurisdiction, issued by the appropriate Regulatory Authority, including, to the extent required by Applicable Law for the sale of Product, all pricing
approvals and pricing restrictions, and governmental reimbursement approvals and restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Regulatory Authority</U>&#148;
means a Governmental Authority with responsibility for the approval, authorization, registration, permission or allowance of the research, study, development, formulation, processing, engineering, manufacturing, testing, holding, importing,
transporting, use, marketing, promotion and sale or offering for sale of pharmaceuticals or other regulation of pharmaceuticals in any country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Regulatory Filing</U>&#148; means any Product Application, or any other licenses, applications, registrations, notifications,
submissions and authorizations made to or received from a Regulatory Authority in a jurisdiction necessary to obtain a Regulatory Approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Royalty Agreement</U>&#148; means the Purchase and Sale Agreement, dated as of October&nbsp;8, 2024, by and among Licensor, Licensor
Parent, Efshar Hataya Ltd., Oramed Pharmaceuticals Inc., and 3i, LP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SEC</U>&#148; means the U.S. Securities and Exchange
Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">SP-103</FONT></U>&#148; means the lidocaine product currently in Development and
referred to by Licensor as <FONT STYLE="white-space:nowrap">&#147;SP-103.&#148;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sublicensee</U>&#148; means a Third Party
to whom Licensee has granted a sublicense, immunity or other right under the Licensed Patents to Develop or Commercialize Product, in the Licensee Territory, pursuant to Section&nbsp;3.2, provided such sublicense has not expired or been terminated.
&#147;<U>Sublicense</U>&#148; means an agreement or arrangement granting such rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Supply Agreement</U>&#148; means the Commercial Supply Agreement, effective
February&nbsp;16, 2017, by and among Licensor, Oishi and Itochu, as amended by (a)&nbsp;the First Addendum to Commercial Supply Agreement, dated as of August&nbsp;31, 2017, by and among Licensor, Oishi and Itochu, (b)&nbsp;the Second Addendum to
Commercial Supply Agreement, dated as of May&nbsp;9, 2018, by and among Licensor, Oishi and Itochu and (c)&nbsp;the Third Addendum to Commercial Supply Agreement, dated as of August&nbsp;30, 2018, by and among Licensor, Oishi and Itochu. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Withholding</U>&#148; has the meaning set forth in Section&nbsp;9.3(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Third Party</U>&#148; means any Person that is not a Party or an Affiliate of a Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trademarks</U>&#148; means trademarks, service marks, service marks, trade names, logos, packaging design, slogans, internet domain
names, and other indicia of origin, registered or unregistered, as well as all applications for and registrations of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>U.S.</U>&#148; or &#147;<U>United States</U>&#148; means the United States of America, its fifty (50)&nbsp;states, each territory
thereof and the District of Columbia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2 <U>Rules of Construction</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Unless the context otherwise requires, in this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a term has the meaning assigned to it and an accounting term not otherwise defined has the meaning assigned to it in
accordance with GAAP; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) words of the masculine, feminine, or neuter gender means and include the correlative words of
other genders; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the terms &#147;include,&#148; &#147;including&#148; and similar terms shall be construed as if
followed by the phrase &#147;without limitation&#148;; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) unless otherwise specified, references to a contract or
agreement include references to such contract or agreement as from time to time amended, restated, reformed, supplemented or otherwise modified in accordance with its terms (subject to any restrictions on such amendments, restatements, reformations,
supplements or modifications set forth herein), and include any annexes, exhibits and schedules hereto or thereto, as the case may be; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) any reference to any Person shall be construed to include such Person&#146;s successors and assigns (subject to any
restrictions on assignment, transfer or delegation set forth herein) and any reference to a Person in a particular capacity excludes such Person in other capacities; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) references to any Applicable Law shall include such Applicable Law as from time to time in effect, including any
amendment, modification, codification, replacement, or reenactment thereof or any substitution therefor; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) the word
&#147;will&#148; will be construed to have the same meaning and effect as the word &#147;shall&#148;; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) term &#147;or&#148; has the inclusive meaning represented by the
phrase &#147;and/or&#148;; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) the words &#147;hereof,&#148; &#147;herein,&#148; &#147;hereunder&#148; and similar terms
shall refer to this Agreement as a whole and not to any particular provision hereof, and Article, Section and Exhibit references herein are references to Articles and Sections of, and Exhibits to, this Agreement unless otherwise specified; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) the definitions of terms shall apply equally to the singular and plural forms of the terms defined; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) in the computation of a period of time from a specified date to a later specified date, the word &#147;from&#148; means
&#147;from and including&#148; and each of the words &#147;to&#148; and &#147;until&#148; means &#147;to but excluding&#148;; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) where any payment is to be made, any funds are to be applied, any notice is to be given, or any calculation is to be made
under this Agreement on a day that is not a Business Day, unless this Agreement otherwise provides, such payment shall be made, such funds shall be applied and such calculation shall be made on the succeeding Business Day, and payments shall be
adjusted accordingly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The provisions of this Agreement shall be construed according to their fair meaning and neither for nor against
any Party irrespective of which Party caused such provisions to be drafted. Each Party acknowledges that it has been represented by an attorney in connection with the preparation and execution of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;II </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>REPRESENTATIONS AND WARRANTIES </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1 <U>Mutual Representation and Warranties</U>. Each Party represents and warrants to the other Party as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Such Party is duly organized, validly existing and in good standing under the laws of the jurisdiction of its formation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Such Party (i)&nbsp;has the requisite power and authority and the legal right to enter into this Agreement and to perform its obligations
hereunder; and (ii)&nbsp;has taken all requisite action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of such
Party, and constitutes a legal, valid, binding obligation, enforceable against such Party in accordance with its terms. All rights and licenses purported to be granted in this Agreement are duly granted hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Such Party has taken all necessary action on its part to authorize the execution and delivery of this Agreement and this Agreement has
been duly executed and delivered on behalf of such Party and constitutes a legal, valid, binding obligation, enforceable against such Party in accordance with its terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Such Party will not (i)&nbsp;promise, offer, or give (and has not promised, offered, or
given) anything of value to any government employee or individual acting in an official capacity for the purpose of securing an improper or undue advantage; (ii)&nbsp;accept or receive (and has not accepted or received) any unlawful contributions,
payments, expenditures, or gifts; (iii)&nbsp;do (and has not done) business with any country or person that is the subject of sanctions imposed or administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Control or the UN
Security Council or any governmental agency in a jurisdiction in which SOBI is organized or doing business; or (iv)&nbsp;violate (and has not violated) any applicable U.S. or export restriction, anti-boycott regulation, or other Applicable Laws.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) All necessary consents, approvals, and authorizations of all Governmental Authorities and other persons or entities required to be
obtained by such Party in connection with this Agreement have been obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The execution and delivery of this Agreement and the
performance of such Party&#146;s obligations hereunder (i)&nbsp;do not and will not conflict with or violate any requirement of Applicable Laws, regulations or orders of governmental bodies; and (ii)&nbsp;do not and will not conflict with, or
constitute a default under, any contractual obligation of such Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) As of the Effective Date, there is no action or proceeding
pending against such Party that questions in any material respect the validity of this Agreement or any action taken by such Party in connection with the execution of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The operation of the business of such Party and its Affiliates is being, and has been, conducted in material compliance with all
Applicable Laws, including Compliance Laws. Neither such Party nor any of its Affiliates has received any written notice to the effect that the operation of the business of such Party or its Affiliates is not, and was not, in material compliance
with any such Applicable Laws, including Compliance Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To the maximum extent permitted by Applicable Law, during the Term of this
Agreement, neither Party will Commercialize a lidocaine tape product in the Licensor Territory or the Licensee Territory except for Products under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2 <U>Licensor Representations and Warranties</U>. Except as otherwise disclosed in any of the Public Filings (excluding
(i)&nbsp;any disclosures in any &#147;risk factors&#148; section that do not constitute statements of fact, (ii)&nbsp;any disclosures in any forward-looking statement disclaimers, and (iii)&nbsp;any other disclosures that are generally cautionary,
predictive, or forward-looking in nature), Licensor hereby makes each of the following representations and warranties to Licensee: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
All Licensed IP Rights that Licensor claims or purports to own or control in whole or in part are solely owned or controlled (respectively) by Licensor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) To Licensor&#146;s knowledge, all Licensed IP Rights are valid, subsisting, and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Patents set forth on Exhibit&nbsp;A constitute all of the Licensed Patents as of the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Licensor has the right to grant the licenses and other rights purported to be granted herein and has not granted to any Third Party any
license or other interest in the Product Rights (i)&nbsp;for the Product within the Licensee Territory and the Field or (ii)&nbsp;that would conflict with the licenses and interests granted to Licensee hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) To Licensor&#146;s knowledge, there is no Third-Party Patent that would be infringed
(i)&nbsp;by practicing any process or method or by making, using, or selling any composition which is claimed or disclosed in the Licensed Patents or which constitutes Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> to Commercialize the
Product in the Field in the Licensee Territory, or (ii)&nbsp;by making, using or selling Product in the Licensee Territory.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) All data, information, and results of experimentation and testing provided by Licensor hereunder will, to Licensor&#146;s knowledge, be
complete and accurate in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Licensed IP Rights constitute all of rights, properties, and assets of Licensor
that are necessary and, subject to Section&nbsp;2.2(e), sufficient to enable Licensee to Develop, Manufacture, obtain and maintain Regulatory Approvals, and Commercialize Product in the Field in the Licensee Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Licensor has provided Licensee with a true and correct copy of each <FONT STYLE="white-space:nowrap">In-License</FONT> (together with all
amendments, addenda, modifications and restatements thereof) as of the Effective Date. The <FONT STYLE="white-space:nowrap">In-Licenses</FONT> are in full force and effect in accordance with their terms. The only
<FONT STYLE="white-space:nowrap">In-Licenses</FONT> as of the Effective Date are the Development Agreement and the Supply Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)
After giving effect to this Agreement, there exist no breaches, defaults or events which would (with the giving of notice, the passage of time or both) give rise to a breach, default or other right to terminate or modify the Development Agreement.
Licensor has not transferred or granted, and Licensor shall not transfer or grant, to any other Person any license or other interest in the Development Agreement that would conflict with the rights and licenses granted to Licensee herein. Without
limiting the foregoing, Licensor has obtained prior to the Effective Date such consents as may be required by the Development Agreement to grant the rights to Licensee purported to be granted in this Agreement, in the form and substance acceptable
to Licensee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3 <U>Licensor Covenant</U>. Licensor hereby covenants to Licensee as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Neither Licensor, nor any of its Affiliates, shall transfer, convey or assign any of the Product Rights to any Person unless such Person
agrees in writing to the applicable terms and conditions of this Agreement, and Licensor shall promptly notify Licensee in writing of any transfer, conveyance or assignment of any of the Product Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Licensor shall timely pay in full all amounts required to be paid by Licensor, and timely perform in full all obligations required to be
performed by Licensor, under all <FONT STYLE="white-space:nowrap">In-Licenses</FONT> Without the prior express written consent of Licensee, Licensor shall not (and shall take no action or make no omission to) modify or waive any provision of any <FONT
STYLE="white-space:nowrap">In-License</FONT> that could impair the value of the licenses to Licensee herein, or to terminate or have terminated any <FONT STYLE="white-space:nowrap">In-License.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If the Development Agreement is terminated for any reason, Licensor shall use reasonable efforts to cause the licensor(s) thereunder to
grant a direct license under the Licensed IP Rights to Licensee containing terms and conditions no less favorable to Licensee than the terms of the Development Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4 <U>Mutual Covenant</U>. Each Party covenants to the other Party that in the course of performing its obligations or
exercising its rights under this Agreement, it shall comply with all Applicable Laws, including as applicable, GMP, GCP, and GLP standards, and shall not employ or engage any party who has been debarred by any Regulatory Authority, or, to such
Party&#146;s knowledge, is the subject of debarment proceedings by a Regulatory Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.5 <U>Disclaimer</U>. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS
ARTICLE&nbsp;II, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, REGARDING THE LICENSED IP RIGHTS, PRODUCT OR ANY OTHER MATTER, INCLUDING ANY REPRESENTATION OR WARRANTY REGARDING MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE OR <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT</FONT> OR VALIDITY OF ANY PATENTS ISSUED OR PENDING. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;III </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>LICENSES </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1
<U>Licenses</U>.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions of this Agreement,
Licensor hereby grants to Licensee during the Term a worldwide exclusive (even as to Licensor), <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except in connection with a permitted assignment of this Agreement) right, license and interest
in, to, and under all Product Rights Controlled by Licensor, to Develop, Manufacture, obtain and maintain Regulatory Approvals for, Commercialize, and otherwise Exploit all Products, in all cases solely for Commercialization of the Products in the
Licensee Territory in the Field. Without limiting the foregoing: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Licensor hereby grants to Licensee an exclusive (even
as to Licensor), <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except in connection with a permitted assignment of this Agreement), right and license under the Licensed IP Rights (A)&nbsp;in the Licensee Territory, to Develop,
Manufacture, obtain and maintain Regulatory Approvals for, Commercialize, and otherwise Exploit Product for Commercialization of Products in the Licensee Territory in the Field, and (B)&nbsp;worldwide, to Develop and Manufacture Product for
Commercialization in the Licensee Territory in the Field. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Licensor hereby grants to Licensee an exclusive (even as to
Licensor), <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except in connection with a permitted assignment of this Agreement), right of reference under any and all Regulatory Approvals and Regulatory Filings Controlled by Licensor that
are related to Product to Develop, Manufacture, obtain and maintain Regulatory Approvals for, and Commercialize Product in the Licensee Territory in the Field. Licensee shall have the right to grant further rights of reference, through multiple
tiers, to Sublicensees and Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Licensor reserves for itself the exclusive right under the Licensed IP Rights (i)&nbsp;in the
Licensor Territory, to Develop, Manufacture, obtain and maintain Regulatory Approvals for, Commercialize, and otherwise Exploit Product for Commercialization in the Licensor Territory in the Field, and (ii)&nbsp;worldwide, to Develop and Manufacture
Product for Commercialization in the Licensor Territory in the Field. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Licensor shall not grant or purport to grant to any Person (and
shall cause its Affiliates not to grant to any Person) any right or license to Develop, obtain or maintain Regulatory Approvals for, Manufacture, or Exploit any Product for Commercialization in the Licensee Territory in the Field. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Subject to the terms and conditions of this Agreement, Licensee hereby grants to
Licensor a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except in connection with a permitted assignment of this Agreement), right and license under the Licensee <FONT
STYLE="white-space:nowrap">Non-Blocking</FONT> Patents (i)&nbsp;in the Licensor Territory, to Develop, Manufacture, obtain and maintain Regulatory Approvals for, Commercialize, and otherwise Exploit Product for Commercialization of Products in the
Licensor Territory in the Field, and (ii)&nbsp;worldwide, to Develop and Manufacture Product for Commercialization in the Licensor Territory in the Field (the <U><FONT STYLE="white-space:nowrap">&#147;Non-Blocking</FONT> License</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Except as set forth herein, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise,
under any <FONT STYLE="white-space:nowrap">Know-How,</FONT> Trademarks, or Patents of the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2
<U>Sublicenses</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Licensee shall have the right, in accordance with this Section&nbsp;3.2, to engage: (i)&nbsp;its Affiliates as
sublicensees of its rights hereunder (including with respect to the Licensed IP Rights) in the Licensee Territory; or (ii)&nbsp;a Third Party as a Sublicensee of its rights hereunder in the Licensee Territory for the purpose of obtaining and
maintain Regulatory Approvals and interacting with Regulatory Authorities, Developing, Manufacturing or Commercializing Product in each case jointly with, or for the benefit of, Licensee. Licensee may grant sublicenses hereunder to such Affiliates
and Third Parties solely on the terms set forth in this Section&nbsp;(a) and Section&nbsp;(b) below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Licensee shall remain
responsible for any actions of its Affiliates and Sublicensees exercising sublicense rights under this Section&nbsp;3.2 with respect to the rights and licenses granted by Licensor to Licensee under this Agreement to the same extent as if such
actions had been by Licensee itself. Promptly following the execution of each Sublicense to a Sublicensee, Licensee shall provide Licensor with an executed copy of such Sublicense; provided, however, that Licensee shall have the right to redact any
confidential terms from the copy provided to Licensor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The rights and obligations under this Section&nbsp;3.2 will apply to the <FONT
STYLE="white-space:nowrap">Non-Blocking</FONT> License, <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3 <U>Access to Licensed <FONT
STYLE="white-space:nowrap">Know-How</FONT></U>. Licensor shall provide or make available to Licensee the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> that exists as of the Effective Date and any additional Licensed <FONT
STYLE="white-space:nowrap">Know-How</FONT> (to the extent that such Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> comes to Licensor&#146;s attention during the Term of this Agreement), the foregoing of which is reasonably necessary for
the Licensee to Develop and Manufacture Product for Commercialization in the Licensee Territory in the Field under this Agreement. Any costs in providing access to Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> under this Section&nbsp;3.3
is at Licensee&#146;s sole cost, provided that such costs are reasonable and <FONT STYLE="white-space:nowrap">agreed-to</FONT> by Licensee in advance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.4 <U>Territory</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Licensee shall have the right, from time to time upon written notice, to remove any country or territory from the Licensee Territory (the
&#147;<U>Removed Territory</U>&#148;). The Licensee Territory will then automatically exclude the Removed Territory for all purposes thereafter, and the Removed Territory will automatically be added to the Licensor Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If at any time during the Term, Licensor has or obtains the right to Develop, obtain or
maintain Regulatory Approvals for, Manufacture, or Commercialize Product for use in the Field in a particular country or jurisdiction within the Licensor Territory that is not the United States or a Removed Territory (such country or jurisdiction,
the &#147;<U>Regained Territory</U>&#148;), then Licensor shall promptly provide Licensee with written notice thereof. At Licensee&#146;s option, exercisable by providing written notice thereof to Licensor, the Regained Territory will be excluded
from the Licensor Territory and will be added to the Licensee Territory, which will be effective upon such written notice without further action by the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;IV </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>DEVELOPMENT
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1 <U>Development by Licensor</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Licensor shall use Commercially Reasonable and Diligent Efforts to perform the Licensor Development Activities at its own expense and
shall do so in accordance with this Agreement, GLP, GCP, GMP, and all Applicable Laws. Licensor shall keep Licensee reasonably informed of its progress in performing the Licensor Development Activities. Without limiting the generality of the
foregoing, following the end of each calendar quarter, Licensor shall prepare and provide Licensee with a reasonably detailed written report describing in detail its progress in performing the Licensor Development Activities sufficient to enable
Licensee to understand and monitor Licensor&#146;s diligence and the results thereof, through such date of such report. Such reports will be discussed at the meetings of the JSC (or subcommittee established by the JSC). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Licensor shall use reasonable efforts to cause Licensee to be a designated third-party beneficiary of each Licensor Development Agreement,
entitled to the rights and benefits of each Licensor Development Agreement as Licensor is so entitled. Licensor shall provide Licensee with a copy of each Licensor Development Agreement promptly after entering into it. Licensor shall timely pay in
full all amounts required to be paid by Licensor, and timely perform in full all obligations required to be performed by Licensor, under all Licensor Development Agreements. Licensor promptly shall provide Licensee with copies of all notices and
other deliveries received under any Licensor Development Agreement. Without the prior express written consent of Licensee, Licensor shall not (and shall take no action or make no omission to) modify or waive any provision of any Licensor Development
Agreement that may reasonably impair the value of the licenses granted to Licensee herein, or to terminate or have terminated any Licensor Development Agreement if doing so may reasonably impair the value of the licenses granted to Licensee herein.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2 <U>Development by Licensee</U>. Licensee shall use Commercially Reasonable Efforts to perform the Licensee Development
Activities at its own expense and shall do so in accordance with this Agreement, GLP, GCP, GMP, and all Applicable Laws. Licensee shall keep Licensor reasonably informed of its progress in performing the Licensee Development Activities. Without
limiting the generality of the foregoing, following the end of each calendar quarter, Licensee shall prepare and provide Licensor with a reasonably detailed written report describing in detail its progress in performing the Licensee Development
Activities sufficient to enable Licensor to understand and monitor Licensor&#146;s diligence and the results thereof, through such date of such report. Licensor shall provide Licensee with all assistance that Licensee may reasonably request in
connection with the Licensee Development Activities. Such reports will be discussed at the meetings of the JSC (or subcommittee established by the JSC). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3 <U>Data Exchange and Use</U>. Each Party shall promptly provide the other
Party with copies of all data and results and all supporting documentation (e.g. protocols, case report forms, analysis plans) generated from its Development of Product. Licensee shall have the right to use the data provided by Licensor for the
purpose of obtaining and maintaining Regulatory Approval for and Commercializing Product in the Field in the Licensee Territory. Licensor shall have the right to use the data provided by Licensee for the purpose of obtaining and maintaining
Regulatory Approval for and Commercializing Product in the Licensor Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;V </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>REGULATORY </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1 <U>Regulatory Responsibilities</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Licensee shall use Commercially Reasonable Efforts to obtain and maintain Regulatory Approvals for Product in the Licensee Territory.
Without limiting the foregoing, (i)&nbsp;Licensee shall use Commercially Reasonable Efforts to obtain and maintain Regulatory Approval for Product in at least one (1)&nbsp;Major Market Country, within eighteen&nbsp;(18) months after the Effective
Date, and (ii)&nbsp;Licensee shall commit two hundred thousand dollars&nbsp;($200,000), or its equivalent in kind, annually towards such efforts until it obtains Regulatory Approval for Product in the Licensee Territory. Licensee shall keep Licensor
reasonably informed with respect thereto through the JSC (or a subcommittee established by the JSC). To the extent permitted by Applicable Law, as between the Parties, Licensee (or its designee) shall own all right, title, and interest in and to,
and shall be the holder of, all Regulatory Approvals of Product in the Licensee Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Licensor shall use Commercially Reasonable
and Diligent Efforts to obtain and maintain Regulatory Approvals for <FONT STYLE="white-space:nowrap">SP-103</FONT> and all existing Products in each country or jurisdiction in the Licensor Territory.<SUP STYLE="font-size:75%; vertical-align:top">
</SUP>Licensor shall keep Licensee reasonably informed with respect thereto through the JSC (or a subcommittee established by the JSC). Licensor shall use reasonable efforts to cause Licensee to be a designated third-party beneficiary of each
Licensor Regulatory Agreement, entitled to the rights and benefits of each Licensor Regulatory Agreement as Licensor is so entitled. Licensor shall provide Licensee with a copy of each Licensor Regulatory Agreement promptly after entering into it.
Licensor shall timely pay in full all amounts required to be paid by Licensor, and timely perform in full all obligations required to be performed by Licensor, under all Licensor Regulatory Agreements. Licensor promptly shall provide Licensee with
copies of all notices and other deliveries received under any Licensor Regulatory Agreement. Without the prior express written consent of Licensee, Licensor shall not (and shall take no action or make no omission to) modify or waive any provision of
any Licensor Regulatory Agreement if doing so may reasonably impair the value of the licenses or rights granted to Licensee herein, or to terminate or have terminated any Licensor Regulatory Agreement if doing so may reasonably impair the value of
the licenses or rights granted to Licensee herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2 <U>Coordination</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each Party shall provide to the other Party for review and comment drafts of all Regulatory Filings for Product no later than
thirty&nbsp;(30) days before the planned submission. Such Party shall consider in good faith all comments from the other Party with respect thereto. Each Party shall notify the other Party of any substantive Regulatory Filings for Product and any
other substantive documents, comments, or other correspondences related thereto submitted to or received from any Regulatory Authority and shall provide the other Party with copies thereof as soon as reasonably practical. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Party shall provide the other Party with notice of any meeting or discussion with
any Regulatory Authority related to Product no later than five&nbsp;(5) Business Days after receiving notice thereof. Such Party shall lead any such meeting or discussion and the other Party shall have the right to attend and participate in any such
meeting or discussion unless prohibited or restricted by Applicable Laws or the applicable Regulatory Authority. At such Party&#146;s request, the other Party shall reasonably cooperate with such Party in preparing for any such meeting or
discussion. If the other Party does not participate in such meeting or discussion, then such Party shall provide the other Party with a written summary thereof promptly following the issuance or approval of the corresponding official minutes by the
applicable Regulatory Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If any Regulatory Authority takes or gives notice of its intent to take any regulatory action with
respect to any activity of a Party relating to any Product, then such Party shall notify the other Party of such contact, inspection, or notice or action within five (5)&nbsp;Business Days after receipt of such notice (or, if action is taken without
notice, within five (5)&nbsp;Business Days of such Party becoming aware of such action). The other Party shall have the right to review any responses to the Regulatory Authority that pertain to such Product, and such Party shall consider such
comments in good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3 <U>Regulatory Assistance</U>. Upon Licensee&#146;s reasonable request, Licensor shall provide
Licensee with reasonable assistance in Licensee&#146;s efforts to obtain and maintain Regulatory Approvals for Product in the Licensee Territory, including access to Regulatory Approvals, Regulatory Filings, and other required materials and
documents in Licensor&#146;s possession and required by Licensee or Regulatory Authorities for Regulatory Approval of Product in the Licensee Territory. Licensor shall also provide reasonable support to address questions from Licensee in preparing
Regulatory Filings and communicating with Regulatory Authorities regarding Product in the Licensee Territory. Licensee shall reimburse Licensor for the costs and expenses incurred by Licensor to provide such regulatory assistance to Licensee for
such cooperation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.4 <U>Adverse Events Reporting</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Promptly following the Effective Date, but in no event later than one hundred eighty (180)&nbsp;days thereafter, Licensee and Licensor
shall develop and agree to the worldwide safety and pharmacovigilance procedures for the Parties with respect to Products, such as safety data sharing and exchange, Adverse Events reporting and prescription events monitoring in a written agreement
(the &#147;<U>Pharmacovigilance Agreement</U>&#148;). Such agreement shall describe the coordination of collection, investigation, reporting, and exchange of information concerning Adverse Events or any other safety problem of any significance, and
product quality and product complaints involving Adverse Events, sufficient to permit each Party, its Affiliates, licensees, or sublicensees to comply with its legal obligations. The Pharmacovigilance Agreement shall be promptly updated if required
by changes in Applicable Law. Each Party hereby agrees to comply with its respective obligations under the Pharmacovigilance Agreement and to cause its Affiliates, licensees and sublicensees to comply with such obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Licensee shall be responsible for complying with all Applicable Laws governing Adverse Events in the Licensee Territory, and Licensor
shall be responsible for complying with all Applicable Laws covering Adverse Events in the Licensor Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Licensor shall hold and control the global safety database for all Products and for the
exchange by the Parties in English of any information which a Party becomes aware of concerning any Adverse Event experienced by a subject or patient being administered any Product, including any such information received by either Party from any
Third Party (subject to receipt of any required consents from such Third Party). Each Party and its Affiliates, licensees and sublicensees shall have the right to disclose such information if such disclosure is reasonably necessary to comply with
Applicable Laws or requirements of any applicable Regulatory Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.5 <U>Remedial Actions</U>. Each Party shall notify
the other immediately, and promptly confirm such notice in writing, if it obtains information indicating that any Product may be subject to any recall, corrective action or other regulatory action by any Governmental Authority or Regulatory
Authority (a &#147;<U>Remedial Action</U>&#148;). The Parties shall coordinate with each other regarding any Remedial Action in accordance with the procedures set forth in Section&nbsp;5.2, <I>mutatis mutandis</I>. The Parties shall assist each
other in gathering and evaluating such information as is necessary to determine the necessity of conducting a Remedial Action with respect to either the Licensee Territory or the Licensor Territory. Licensee shall have sole discretion with respect
to any matters relating to any Remedial Action in the Licensee Territory, including the decision to commence such Remedial Action and the control over such Remedial Action. Each Party shall, and shall ensure that its Affiliates and sublicensees
shall, maintain adequate records to permit the Parties to trace the distribution and use of the Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.6 <U>No
Additional Compensation</U>. The Parties acknowledge and agree that the consideration for the provision of any services by Licensor under this Article&nbsp;V is included in the payments payable by Licensee to Licensor pursuant to this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;VI </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>SUPPLY
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1 <U>Supply of Product</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Promptly after the Effective Date, Licensor shall (i)&nbsp;facilitate an introduction between Oishi, Itochu, and Licensee, and
(ii)&nbsp;use reasonable efforts to cause each of Oishi and Itochu to accept a direct engagement with Licensee for the manufacturing or supply of the Product in finished dosage form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Should Oishi and Itochu decline to provide approval for a direct engagement with Licensee, Licensor shall use diligent efforts (i)&nbsp;to
obtain written approval, in such form and substance as may be satisfactory to Licensee, from each of Oishi and Itochu to enable Licensee to place purchase orders for Product from Oishi and/or Itochu under the Supply Agreement, as agent or consigning
party, for delivery to Licensee or its designee, and (ii)&nbsp;to provide Licensee with the rights and benefits of the Supply Agreement for Product in the Licensee Territory. Licensee shall advance to Oishi and Itochu all amounts that would be
payable under an applicable purchase order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Licensee shall have the right to obtain from Licensor or, at Licensee&#146;s option and
subject to the consent of the applicable contract manufacturer, any of Licensor&#146;s contract manufacturers of Product (each a &#147;<U>CMO</U>&#148;) Product in finished dosage form. Upon Licensee&#146;s request, Licensor shall negotiate with
Licensee, or shall use Commercially Reasonable and Diligent Efforts to cause the CMO to negotiate with Licensee at terms to be agreed upon between them, as applicable, a definitive agreement for the supply within the Licensee Territory of Product
(the &#147;<U>Licensee Supply Agreement</U>&#148;). The transfer price for Products from Licensor will equal Licensor&#146;s actual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs to Manufacture or
have Manufactured Product for the Licensee Territory, and Licensee shall have the right to audit Licensor&#146;s books and records to verify the transfer price. The transfer price (EXW CMO&#146;s facility (Incoterms 2020)) for Products from a CMO
will be fixed and negotiated in good faith by Licensee and such CMO. The Licensee Supply Agreement will include supply for all of Licensee&#146;s clinical and commercial requirements for Product.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2 <U>Quality Agreement</U>. Together with the Licensee Supply Agreement,
Licensee and Licensor shall negotiate (or Licensor shall use Commercially Reasonable Efforts to cause its applicable CMO to negotiate) and enter into a commercially reasonable and customary quality agreement related to the supply of Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;VII </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>COMMERCIALIZATION </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1 <U>Appointment as Exclusive Distributor</U>. Licensor hereby appoints Licensee as Licensor&#146;s exclusive distributor of
Product in the Licensee Territory during the Term, and Licensee hereby accepts such appointment. Licensee (itself or through its Affiliates or subdistributors) shall have the sole right to Commercialize Product in the Licensee Territory. Licensee
shall have the right, in its sole discretion, to appoint its Affiliates, and Licensee and its Affiliates shall have the right, in their sole discretion, to appoint any other subdistributors, in the Licensee Territory or in any country or other
jurisdiction of the Licensee Territory, to distribute, market, sell, and otherwise Commercialize Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2
<U>Diligence</U>. Licensee shall use Commercially Reasonable Efforts to Commercialize one or more Products in the Licensee Territory in the Field after receiving Regulatory Approval therefor. Licensor shall use Commercially Reasonable and Diligent
Efforts to Commercialize each existing Product and <FONT STYLE="white-space:nowrap">SP-103</FONT> in each country in the Licensor Territory after receiving Regulatory Approval therefore and to maximize sales of Product in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.3 <U>Exclusivity</U>. To the maximum extent permitted by Applicable Law, each Party, whether by itself or through an Affiliate
or (sub)licensee, shall not Commercialize or provide Product (a)&nbsp;to any Person in the other Party&#146;s Territory other than to the other Party or its designee, or (b)&nbsp;to any Third Party if the Party, its relevant Affiliate or
(sub)licensee knows, or has reason to know, that Products sold or provided to such Third Party may be sold, transferred, or otherwise Commercialized, directly or indirectly, for use in the other Party&#146;s Territory. Neither Party shall enter into
any agreement with any Person that would conflict with or interfere with the foregoing obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.4 <U>Assistance</U>.
Upon Licensee&#146;s reasonable request, Licensor shall reasonably assist Licensee in the Commercialization of Products, and Licensee shall reimburse all reasonable expenses and costs incurred by Licensor for such assistance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.5 <U>Coordination</U>. The Parties recognize that they may benefit from the coordination of certain activities in support of
the Commercialization of Product across their territories. As such, the Parties may coordinate such activities where appropriate, including scientific and medical communication and product positioning. If the Parties agree to jointly conduct any
specific Commercialization activities for the benefit of the Product in both Parties&#146; territories, the Parties shall negotiate and agree on the details of such activities, including allocation of responsibilities, budget and cost sharing,
through the JCC. Each Party shall have the right, at its sole and exclusive discretion, to determine pricing for Product in its territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.6 <U>Product Trademarks</U>. Licensor hereby grants to Licensee, during the
Term and subject to the terms and conditions of this Agreement, a royalty-free, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under Licensor&#146;s rights to use such Licensed Marks in connection with the Commercialization of the
Products in the Field in the Licensee Territory in compliance with Applicable Laws and this Agreement. Licensee shall comply with Licensor&#146;s brand usage guidelines provided to Licensee in its use of the Licensed Marks. Licensee may also brand
the Products in the Licensee Territory using other trademarks, logos, and trade names specific for the Products that differ from the Licensed Marks and do not contain the name of Licensor (the &#147;<U>Product Marks</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;VIII </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>GOVERNANCE
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.1 <U>Joint Steering Committee</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Within thirty (30)&nbsp;calendar days following the Effective Date, the Parties shall establish a JSC to oversee, review, and coordinate
the activities of the Parties under this Agreement, including, the Development and Commercialization of the Product in the Field in the Licensor Territory and the Licensee Territory, subject to the provisions of this Section&nbsp;8.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The JSC shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Review and discuss market access and price/branding positioning strategies for Product in the Field in the Licensee
Territory (and substantive amendments and updates thereto); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Review and discuss the Parties&#146; progress reports
provided hereunder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Provide a forum for resolving matters referred to the JSC pursuant to the procedures set forth
in Section&nbsp;8.1(e) below; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Perform such other duties and responsibilities as are specifically assigned to the
JSC by mutual written agreement of the Parties, except where in conflict with any provision of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The JSC shall be
composed of an equal number of representatives from each of Licensee and Licensor, selected by such Party. Unless the Parties otherwise agree, the exact number of representatives for each of Licensee and Licensor shall be, with respect to the JSC,
two (2)&nbsp;representatives. Either Party may replace its respective JSC representatives at any time with prior written notice to the other Party; provided that the criteria for composition of the JSC set forth in the preceding sentence continues
to be satisfied following any such replacement of a Party&#146;s representative on the JSC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The JSC shall meet at least twice a year,
or at such other intervals as agreed to by the Parties. All JSC meetings may be conducted by telephone, video-conference or in person as determined by the JSC. Each Party shall bear its own personnel and travel costs and expenses relating to JSC
meetings. With the consent of the Parties (not to be withheld unreasonably), other appropriate employee representatives of the Parties may attend the JSC meeting as <FONT STYLE="white-space:nowrap">non-voting</FONT> observers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Decisions for the JSC shall be made as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Decisions of the JSC shall be made by unanimous vote, with at least one (1)&nbsp;representative from each Party
participating in any vote. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event that the JSC does not reach consensus with respect to a particular matter
within five (5)&nbsp;Business Days after the matter is submitted to the JSC, then either Party may, by written notice to the other Party, have such matter referred to (A)&nbsp;Licensor&#146;s Chief Executive Officer on the part of Licensor and
(B)&nbsp;Licensee&#146;s Chief Executive Officer on the part of Licensee (collectively, &#147;<U>Senior Executives</U>&#148;) who shall meet promptly and negotiate in good faith to attempt to resolve the dispute. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) If, despite such good faith efforts, the Senior Executives are unable to resolve such dispute during such meeting, then:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(A) if such dispute relates to any activities the sole occurrence and effect of which are in the Licensee Territory, then
Licensee shall have the right to cast the deciding vote on such matter; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(B) for any other matters to be decided by the
JSC, Licensee shall have the right to cast the deciding vote on such matter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) For clarity, neither Party shall have
the right to cast a deciding vote to excuse itself from any of its obligations specifically enumerated under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.2 <U>Joint Commercialization Committee</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Within thirty (30)&nbsp;calendar days following the Effective Date, the Parties shall establish a JCC to oversee, review and coordinate
the activities of the Parties regarding the Commercialization of the Product in the Licensor Territory and the Licensee Territory, subject to the provisions of this Section&nbsp;8.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The JCC shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Review and discuss market access and reimbursement/pricing strategies for Product (and substantive amendments and updates
thereto), including formulary strategy; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Provide a forum for coordination of each Party&#146;s activities described in
Section&nbsp;7.5; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Perform such other duties and responsibilities as are specifically assigned to the JCC by
mutual written agreement of the Parties, except where in conflict with any provision of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The JCC shall be composed of
an equal number of representatives from each of Licensee and Licensor, selected by such Party. Unless the Parties otherwise agree, the exact number of representatives for each of Licensee and Licensor shall be, with respect to the JCC, two
(2)&nbsp;representatives. Either Party may replace its respective JCC representatives at any time with prior written notice to the other Party; provided that the criteria for composition of the JCC set forth in the preceding sentence continues to be
satisfied following any such replacement of a Party&#146;s representative on the JCC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The JCC shall meet at least twice a year, or at such other intervals as agreed to by the
Parties. All JCC meetings may be conducted by telephone, video-conference or in person as determined by the JCC. Each Party shall bear its own personnel and travel costs and expenses relating to JCC meetings. With the consent of the Parties (not to
be withheld unreasonably), other appropriate employee representatives of the Parties may attend the JCC meeting as <FONT STYLE="white-space:nowrap">non-voting</FONT> observers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Decisions for the JCC shall be made as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Decisions of the JCC shall be made by unanimous vote, with at least one (1)&nbsp;representative from each Party
participating in any vote. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event that the JCC does not reach consensus with respect to a particular matter
within five (5)&nbsp;Business Days after the matter is submitted to the JCC, then either Party may, by written notice to the other Party, have such matter referred to the Parties&#146; respective Senior Executives, who shall meet promptly and
negotiate in good faith to attempt to resolve the dispute. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) If, despite such good faith efforts, the Senior
Executives are unable to resolve such dispute during such meeting, then: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(A) if such dispute relates to any activities the
sole occurrence and effect of which are in the Licensee Territory, then Licensee shall have the right to cast the deciding vote on such matter; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(B) for any other matters to be decided by the JCC, Licensee shall have the right to cast the deciding vote on such matter.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) For clarity, neither Party shall have the right to cast a deciding vote to excuse itself from any of its obligations
specifically enumerated under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.3 <U>Alliance Managers</U>. Promptly following the Effective Date, each
Party shall appoint a person to act as its alliance manager to coordinate its business activities under this Agreement (each such person, an &#147;<U>Alliance Manager</U>&#148;). Each Party shall notify in writing the other Party as soon as
practicable upon making, and changing, this appointment. The Alliance Managers shall be the primary business contacts under this Agreement and are charged with ensuring a collaborative alliance environment to ensure timely development and
Commercialization of Product in the Licensee Territory and the Licensor Territory. The Alliance Manager shall respond to all reasonable requests and other communications from either Party, the JCC, and the JSC and shall address any other issues
raised by the same regarding the management, exchange of information, or conduct of the activities of the Parties under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.4 <U>Scope of Governance</U>. Notwithstanding the creation of the JSC and JCC, each Party shall retain the rights, powers and
discretion granted to it under this Agreement, and the JSC and JCC shall not be delegated or vested with rights, powers or discretion unless such delegation or vesting is expressly provided herein, or the Parties expressly so agree in writing. The
JSC and JCC shall not have the power to amend or modify this Agreement, and no decision of the JSC or JCC shall be in contravention </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of any terms and conditions of this Agreement. The Alliance Managers shall not have any rights, powers, or discretion, except as expressly granted to the Alliance Managers under this Agreement
and in no event shall the Alliance Managers have any power to modify or amend this Agreement. It is understood and agreed that issues to be formally decided by the JSC and JCC are only those specific issues that are expressly provided in this
Agreement to be decided by the JSC and JCC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;IX </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>FINANCIAL TERMS </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.1 <U>Revenue Share</U>. Subject to the terms and conditions of this Agreement, the Parties shall share all Net Revenue as
follows: fifty percent&nbsp;(50%) to Licensor, and fifty percent&nbsp;(50%) to Licensee. Licensee shall effect the foregoing by paying to Licensor its share of the Net Revenue (the &#147;<U>Net Revenue Payment</U>&#148;) on a quarterly basis on the
terms of this Article&nbsp;IX. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.2 <U>Revenue Reports and Payments</U>. Within sixty (60)&nbsp;calendar days after the end
of each calendar quarter during the Term, Licensee shall deliver to Licensor a report setting forth for such calendar quarter (a)&nbsp;the calculation of Net Revenue, if any, which shall have accrued in such calendar quarter, and the Net Revenue
Payment due to Licensor for such quarter; (b)&nbsp;the applicable withholding taxes, if any, required by law to be deducted with respect thereto such sales; and (c)&nbsp;the applicable exchange rate, if any, as determined below. With respect to Net
Revenue received in United States dollars, all amounts shall be expressed in United States dollars. With respect to Net Revenue received in a currency other than United States dollars, all amounts shall be expressed both in the currency in which the
amount is invoiced (or received as applicable) and in the United States dollar equivalent. The United States dollar equivalent shall be calculated using the average of the exchange rate (local currency per US$1) which corresponds to the rate for
such currency reported in <U>The Wall Street Journal</U>, Internet U.S. Edition at www.wsj.com, as of the last Business Day of each calendar month within such calendar quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.3 <U>Payment Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Net Revenue Payment shown to have accrued by each report provided for under Section&nbsp;9.2 shall be due on the date that such report
is due. Payment of the Net Revenue Payment may be made, in whole or in part, in advance of such due date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If at any time legal
restrictions prevent the prompt remittance of part or all Net Revenue Payment with respect to any country in where a Product is sold, the Parties shall negotiate in good faith a reasonable solution, which may include Licensee&#146;s right to make
such payments by depositing the amount thereof in local currency to Licensor&#146;s account in a bank or other depository institution in such country or by depositing the amount thereof from another Licensee account. Upon the expiration of such
legal restrictions, the Parties shall evaluate any difference between (i)&nbsp;the payments actually made by Licensee hereunder, and (ii)&nbsp;the amounts that should have been paid by Licensee, and the Parties shall remit payments accordingly to
resolve any discrepancies. If the payment rate specified in this Agreement should exceed the permissible rate established in any country, then the payment rate in such country shall be adjusted to the highest legally permissible or
government-approved rate. The Parties hereby agree that neither Party shall be in breach of this Agreement so long as such Party is using good faith efforts to remit payments owed pursuant to this Section&nbsp;9.3(b). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Licensee shall be entitled to deduct the amount of any withholding taxes, value-added
taxes or other taxes, levies or charges with respect to such amounts payable by Licensee or any taxes required to be withheld by Licensee (a &#147;<U>Tax Withholding</U>&#148;) to the extent Licensee pays to the appropriate Governmental Authority on
behalf of Licensor such Tax Withholding. Licensee shall use reasonable efforts to minimize any such Tax Withholding required to be withheld on behalf of Licensor by Licensee. Licensee promptly shall deliver to Licensor proof of payment of all such
Tax Withholding, together with copies of all communications from or with such Governmental Authority with respect thereto. If any Tax Withholding is necessary and would cause the Net Revenue to not be split in accordance with Section&nbsp;9.1, then
the Parties agree to take any such action as may be necessary to ensure Net Revenue (less any Tax Withholding) is shared equally. The Parties hereby agree that neither Party shall be in breach of this Agreement so long as such Party is using
reasonable efforts to complete the Net Revenue Payment in accordance with this Section&nbsp;9.3(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.4 <U>Records;
Audits</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Licensee shall, and shall ensure that its Affiliates, maintain complete and accurate records in sufficient detail as may
be necessary to permit Licensor to verify the accuracy of the reports provided under Section&nbsp;9.2 and the calculation of royalty payments and any payments with respect thereto for a period of three (3)&nbsp;years after the calendar quarter to
which such report pertains. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Upon the written request of Licensor and not more than once in each calendar year, Licensee shall permit
an independent certified public accounting firm of nationally recognized standing selected by Licensor and reasonably acceptable to Licensee, at Licensor&#146;s expense, to have access during normal business hours to such of the financial records of
Licensee as may be reasonably necessary to verify the accuracy of the Net Revenue Payment reports and any payments with respect thereto hereunder (other than records for which Licensor has already conducted an audit under this Section). If such
accounting firm concludes that additional amounts were owed during the audited period, Licensee shall pay such additional amounts within forty-five (45)&nbsp;days after the date Licensor delivers to Licensee such accounting firm&#146;s written
report so concluding, plus interest from the original due date. The fees charged by such accounting firm shall be paid by Licensor; provided, however, if the audit discloses an underpayment by Licensee of more than seven and a half percent (7.5%) of
the Net Revenue Payment payable by Licensee, then Licensee shall pay the reasonable fees and expenses charged by such accounting firm. Licensor shall cause its accounting firm to retain all financial information subject to review under this
Section&nbsp;9.4(b) in strict confidence; provided, however, that Licensee shall have the right to require that such accounting firm, prior to conducting such audit, enter into an appropriate <FONT STYLE="white-space:nowrap">non-disclosure</FONT>
agreement with Licensee regarding such financial information. No other information shall be shared. Licensor shall treat all such financial information as Licensee&#146;s confidential information, and shall not disclose such financial information to
any Third Party, except to Oishi and Itochu as required in the Development Agreement and the Supply Agreement, or use it for any purpose other than as specified in this Section&nbsp;9.4(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;X </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>INDEMNITY
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.1 <U>By Licensor</U>. Licensor shall indemnify, defend, and hold harmless Licensee, its Affiliates, and its and their
respective shareholders or members, officers, directors, agents, and representatives (the &#147;<U>Licensee Indemnitees</U>&#148;), from and against any and all losses, liabilities, damages and expenses (including reasonable attorneys&#146; fees and
costs) (collectively, &#147;<U>Losses</U>&#148;) incurred by any Licensee Indemnitee resulting from any claim, demand, action or proceeding brought by any Third Party (each a &#147;<U>Claim</U>&#148;) to the extent resulting from or arising out of:
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Development, Manufacture, or Commercialization of Product by or on behalf of
Licensor, its (sub)licensees for the Licensor Territory, or their respective Affiliates, customers or end users; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any breach of any
representation, warranty, or covenant of Licensor in this Agreement (or any alleged conduct that, if true, would constitute such a breach); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Any negligence, gross negligence, or willful misconduct by Licensor, its Affiliates, or their respective agents or representatives in
performing its obligations or exercising its rights hereunder or related to Product (or any alleged conduct that, if true, would constitute negligence, gross negligence, or willful misconduct). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.2 <U>By Licensee</U>. Licensee shall indemnify, defend, and hold harmless Licensor, its Affiliates, and its and their
respective officers, directors, agents, and representatives (the &#147;<U>Licensor Indemnitees</U>&#148;), from and against any and all Losses incurred by any Licensor Indemnitee resulting from any Claim to the extent resulting from or arising out
of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Development, Manufacture, or Commercialization of Product by or on behalf of Licensee, its (sub)licensees, or their
respective Affiliates, customers or end users; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any breach of any representation, warranty, or covenant of Licensee in this Agreement
(or any alleged conduct that, if true, would constitute such a breach); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Any negligence, gross negligence, or willful misconduct by
Licensee, its Affiliates, or their respective agents or representatives in performing its obligations or exercising its rights hereunder or related to Product (or any alleged conduct that, if true, would constitute negligence, gross negligence, or
willful misconduct). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.3 <U>Procedure</U>. A Party seeking indemnification (the &#147;<U>Indemnitee</U>&#148;) shall
promptly notify the other Party (the &#147;<U>Indemnifying Party</U>&#148;) in writing of a Claim; provided that an Indemnitee&#146;s failure to give such notice or delay in giving such notice shall not affect such Indemnitee&#146;s right to
indemnification under this Article&nbsp;X except to the extent that the Indemnifying Party has been prejudiced by such failure or delay. The Indemnifying Party shall have the right to control the defense of all indemnification Claims hereunder. The
Indemnitee shall have the right to participate at its own expense in the Claim with counsel of its own choosing. The Indemnifying Party shall consult with the Indemnitee in good faith with respect to all
<FONT STYLE="white-space:nowrap">non-privileged</FONT> aspects of the defense strategy. The Indemnitee shall cooperate with the Indemnifying Party as reasonably requested, at the Indemnifying Party&#146;s sole cost and expense. The Indemnifying
Party shall not settle any Claim without the Indemnitee&#146;s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.4 <U>No Consequential Damages</U>. NOTWITHSTANDING ANYTHING TO THE CONTRARY HEREIN, EXCEPT WITH RESPECT TO A BREACH OF
Section&nbsp;4.1, Section&nbsp;4.2, Section&nbsp;5.1, OR ARTICLE&nbsp;XI OR WITH RESPECT TO EITHER PARTY&#146;S OBLIGATIONS TO INDEMNIFY, DEFEND AND HOLD HARMLESS PURSUANT TO THIS ARTICLE&nbsp;X, NEITHER
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS MEMBERS NOR ANY OF ITS OR THEIR RESPECTIVE AFFILIATES, OFFICERS, DIRECTORS, EMPLOYEES AND AGENTS FOR ANY SPECIAL, INDIRECT, INCIDENTAL OR
CONSEQUENTIAL DAMAGES, WHETHER FORESEEABLE OR NOT, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE OR OTHERWISE, ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;XI </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>CONFIDENTIALITY </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.1 <U>Confidentiality</U>. Except as provided in this <U>Article</U><U></U><U>&nbsp;XI</U> or otherwise agreed in writing by
the Parties, the Parties agree that, during the Term and until for a period of five&nbsp;(5) years thereafter, each Party (the &#147;<U>Receiving Party</U>&#148;) shall keep confidential, and shall not publish or otherwise disclose and shall not use
for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder), any information (whether written or oral, or in electronic or other form) furnished to it by or
on behalf of the other Party (the &#147;<U>Disclosing Party</U>&#148;) pursuant to this Agreement, including the terms of this Agreement (such information, &#147;<U>Confidential Information</U>&#148; of the Disclosing Party), except for that portion
of such information that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) was already in the Receiving Party&#146;s possession on a
<FONT STYLE="white-space:nowrap">non-confidential</FONT> basis prior to its disclosure to it by the Disclosing Party, or becomes known to the Receiving Party from a source other than the Disclosing Party and its representatives without any breach of
this Agreement, in each case as evidenced by written records (<U>provided</U> that if such information was disclosed to the Receiving Party on a <FONT STYLE="white-space:nowrap">non-confidential</FONT> basis by a source that is not the Disclosing
Party, such source to the knowledge of the Receiving Party had the right to disclose such information to the Receiving Party without any legal, contractual or fiduciary obligation to, any person with respect to such information); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) is or becomes generally available to the public other than as a result of an act or omission by the Receiving Party or its Affiliates in
breach of this Agreement; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) was independently developed by the Receiving Party, as evidenced by written records, without use of or
reference to the Confidential Information or in violation of the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.2 <U>Permitted Disclosure</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the event that the Receiving Party or its Affiliates or any of its or its Affiliates&#146; representatives are requested by a
governmental or regulatory authority or required by Applicable Law, regulation or legal process (including the regulations of a stock exchange or governmental or regulatory authority or the order or ruling of a court, administrative agency or other
government or regulatory body of competent jurisdiction) to disclose any Confidential Information, the Receiving Party shall promptly, to the extent permitted by Applicable Law, notify the Disclosing Party in writing of such request or requirement
so that the Disclosing Party may seek an appropriate protective order or other appropriate remedy (and if the Disclosing Party seeks such an order or other remedy, the Receiving Party will provide such cooperation, at the Receiving Party&#146;s sole
expense, as the Disclosing Party shall reasonably request). If no such protective order or other remedy is obtained and the Receiving Party or its Affiliates or its or its Affiliates&#146; representatives are, in the view of their respective counsel
(which may include their respective internal counsel), legally required to disclose Confidential Information, the Receiving Party or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its Affiliates or its or its Affiliates&#146; representatives, as the case may be, shall only disclose that portion of the Confidential Information that their respective counsel advises that the
Receiving Party or its Affiliates or its or its Affiliates&#146; representatives, as the case may be, are required to disclose and will exercise commercially reasonable efforts, at the Disclosing Party&#146;s sole expense, to obtain reliable
assurance that confidential treatment will be accorded to that portion of the Confidential Information that is being disclosed. In any event, the Receiving Party will not oppose action by the Disclosing Party to obtain an appropriate protective
order or other reliable assurance that confidential treatment will be accorded the Confidential Information. Notwithstanding the foregoing, notice to the Disclosing Party shall not be required where disclosure is made (i)&nbsp;in response to a
request by a governmental or regulatory authority having competent jurisdiction over the Receiving Party, its Affiliates or its or its Affiliates&#146; representatives, as the case may be, or (ii)&nbsp;in connection with a routine examination by a
regulatory examiner, where in each case such request or examination does not expressly reference the Disclosing Party, its Affiliates, or this Agreement. The Receiving Party may disclose Confidential Information to its Affiliates, its and their
employees, directors, officers, contractors, agents, and representatives, and to potential or actual acquirers, business partners, merger partners, permitted assignees, investment bankers, investors, limited partners, partners, lenders, or other
financing sources, and their respective directors, employees, contractors and agents; <U>provided</U> that such person or entity agrees to confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations with respect thereto at least
as stringent as those specified for in this <U>Article</U><U></U><U>&nbsp;XI</U>. Further, notwithstanding anything contained in this <U>Article</U><U></U><U>&nbsp;XI</U> to the contrary, Licensor may disclose Confidential Information to the extent
such disclosure is reasonably necessary to comply with the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or with any rule, regulation or legal process promulgated by the SEC or a stock exchange, subject to
Licensor&#146;s obligations set forth in <U>Section</U><U></U><U>&nbsp;11.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.3 <U>Public Announcement</U>. No Party
shall, and each Party shall cause its Affiliates not to, without the prior written consent of the other Parties (which consent shall not be unreasonably withheld or delayed), issue any press release or make any other public disclosure with respect
to this Agreement except if and to the extent that any such release or disclosure is required by Applicable Law, by the rules and regulations of any securities exchange or market on which any security of such Party may be listed or traded or by any
Governmental Authority of competent jurisdiction, in which case, the Party proposing to issue such press release or make such public disclosure shall, to the extent reasonably practicable, (a)&nbsp;provide to the other Parties a copy of such
proposed release or disclosure and (b)&nbsp;consider in good faith any comments or changes that the other Party may propose or suggest; <U>provided</U> that a Party may freely make any public disclosure identical to a disclosure previously reviewed
by the other Party in accordance with the foregoing clauses (a)&nbsp;and (b). Notwithstanding the foregoing, Licensee understands and agrees that Licensor Parent intends to file with the SEC a Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> describing the material terms of the transactions contemplated by this Agreement and file this Agreement as an exhibit thereto or to another filing with the SEC, <U>provided</U>, that Licensor shall
(i)&nbsp;provide to Licensee a draft of such filings with the SEC and (ii)&nbsp;consider in good faith any comments or changes that Licensee may propose or suggest. Licensor and Licensee shall jointly prepare a press release for dissemination
promptly following the Effective Date, such press release to be agreed upon by Licensee and Licensor Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;XII </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>REGISTERED IP RIGHTS </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.1 <U>Prosecution and Maintenance</U>.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as otherwise set forth in this Section&nbsp;12.1, as between the Parties, Licensor shall have the sole right, at its sole expense,
to prepare, file, prosecute and maintain the Registered IP Rights in the Licensee Territory. Licensee shall assist Licensor, upon request and at Licensor&#146;s sole expense, and to the extent commercially reasonable, in connection therewith.
Licensor shall consider in good faith the interests of Licensee in so doing. Without limiting the foregoing, Licensor shall (i)&nbsp;provide Licensee with any patent application within the Registered IP Rights filed by Licensor reasonably in advance
of filing and receive and incorporate reasonable comments by Licensee thereon; (ii)&nbsp;provide Licensee with any such patent application filed by Licensor promptly after such filing; (iii)&nbsp;provide Licensee with copies of all material
correspondence and communications received regarding such patent applications and patents and incorporate reasonable comments by Licensee thereon; (iv)&nbsp;provide Licensee with copies of all material correspondence and communications sent
regarding such patents and patent applications promptly after such filing; and (v)&nbsp;notify Licensee of any interference, opposition, reexamination request, nullity proceeding, appeal or other similar action, review it with Licensee as reasonably
requested, and receive and may incorporate reasonable comments by Licensee thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If Licensor elects (i)&nbsp;to abandon the
prosecution or maintenance of any patent or patent application within the Registered IP Rights in the Licensee Territory, or (ii)&nbsp;elects not to file a patent application in the Licensee Territory for any Product, then Licensor shall promptly
notify Licensee in writing at least thirty (30)&nbsp;days before the abandonment or applicable filing deadline therefore, and Licensee shall have the right, upon providing written notice to Licensor of Licensee&#146;s election to do so, at
Licensee&#146;s expense, to file, prosecute, continue to prosecute and/or maintain, as applicable, such patent or patent application. In such case, Licensee shall keep Licensor reasonably informed on matters regarding such filing, prosecution and
maintenance, including by providing Licensor with a copy of any and all correspondence between Licensee and the relevant patent office, providing Licensor with sufficient time to review and comment on such communications (excluding any <FONT
STYLE="white-space:nowrap">non-substantive</FONT> correspondence or communications), and Licensee shall consider in good faith the requests and suggestions of Licensor with respect to such communications. With respect to the activities set forth in
this Section&nbsp;12.1(b) that are continued by Licensee, Licensor shall provide a power of attorney and relevant files and other information owned or controlled by Licensor pertaining to such patents or patent applications, as soon as reasonably
practical after receiving such written election by Licensee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.2 <U>Enforcement</U>.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each Party shall promptly notify the other Party in writing of any actual or
threatened infringement, violation or misappropriation known to such Party of any Registered IP Rights or Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> in the Licensee Territory and shall provide the other Party with the available
evidence, if any, of such infringement, violation or misappropriation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) As between the Parties, Licensee shall have the first right,
but not the obligation, to initiate proceedings or take other appropriate action, at its expense, to enforce the Registered IP Rights or Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> in the Licensee Territory against any Third Party.
Licensee shall consider in good faith the interests of Licensor in so doing and shall have the right to join Licensor as a nominal party plaintiff if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required therefor. Licensee shall have full control over its conduct, including the defense to validity challenges and settlement thereof; provided, however, that (i)&nbsp;Licensee shall use
reasonable efforts to keep Licensor reasonably informed on matters regarding such enforcement, and (ii)&nbsp;Licensor may veto any actions of Licensee that could materially adversely affect the Product Rights or the ability of either Party to
Commercialize Product. In any event, the Parties shall assist one another and cooperate in any such litigation at the other&#146;s reasonable request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) With respect to any action to enforce the Registered IP Rights or Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> in the
Licensee Territory to abate any infringement, misappropriation or other violation thereof, all monies recovered upon the final judgment or settlement of any such action: (i)&nbsp;first, shall be applied to reimburse the costs and expenses (including
reasonable attorneys&#146; fees and costs) of Licensee and Licensor, and (ii)&nbsp;second, shall be deemed Net Revenue and will be shared equally between the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.3 <U>Third-Party Infringement Claims</U>. If the Manufacture, sale, or use of Product in the Licensee Territory pursuant to
this Agreement results in a claim, suit, or proceeding alleging patent infringement against Licensor or Licensee (or their respective Affiliates, licensees or Sublicensees) (collectively, &#147;<U>Infringement Actions</U>&#148;), such Party shall
promptly notify the other Party hereto in writing. Neither Party shall settle such Infringement Action, nor make any admissions, nor assert any position in such Infringement Action, in a manner that would adversely affect the Product, the
Manufacture, use or sale or Commercialization of the Product, or either Party&#146;s rights in the Licensed IP Rights, without the prior written consent of the other Party, which shall not be unreasonably withheld, conditioned or delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.4 <U>Registration of License</U>. Licensee shall have the right to register or record its license under the Registered IP
Rights with the relevant Governmental Authorities in the Licensee Territory. Licensee shall, at its expense, prepare and deliver to Licensor such instruments and other documents reasonably necessary and in proper form for such registration. The
Parties shall reasonably agree on the form of documents to be used for such purpose, and shall cooperate to preserve confidentiality of this Agreement to the extent permitted under Applicable Laws in the Licensee Territory. Licensor shall execute
and return to Licensee such instruments and documents promptly after mutual agreement on the form and receipt thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.5
<U>Registered IP Rights Licensed from Third Parties</U>. Each Party&#146;s rights under this Article&nbsp;XII with respect to any Registered IP Right that is licensed by Licensor from a Third Party pursuant to an
<FONT STYLE="white-space:nowrap">In-License</FONT> shall be subject to the rights retained by such Third Party pursuant to the applicable <FONT STYLE="white-space:nowrap">In-</FONT> License, and Licensor shall use reasonable efforts to cause such
Third Party to agree to the provisions of this Article&nbsp;XII. If Licensor has the right under any <FONT STYLE="white-space:nowrap">In-License</FONT> to control, comment on, or otherwise provide input on the patent prosecution, maintenance,
defense, or enforcement of any such Registered IP Right, then, (a)&nbsp;Licensee shall receive the benefit of Licensor&#146;s rights to the extent Licensee is provided such rights under this Agreement; and (b)&nbsp;without limiting the foregoing,
Licensor shall permit Licensee to exercise such rights on Licensor&#146;s behalf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;XIII </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>TERM AND TERMINATION </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.1 <U>Term</U>. The term of this Agreement commences on the Effective Date and continues until expiration of the last to expire
Licensed Patents, unless earlier terminated pursuant to Section&nbsp;13.2 or Section&nbsp;13.3 below (such period, the &#147;<U>Term</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.2 <U>Termination by Licensee</U>. Licensee may terminate this Agreement, for
any reason or no reason, upon ninety&nbsp;(90) days&#146; prior written notice of termination to Licensor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.3
<U>Termination for Cause</U>. Either Party may terminate this Agreement upon or after the material breach of this Agreement by the other Party if such other Party has not cured such breach within sixty (60)&nbsp;calendar days after receipt of
express written notice thereof and intent to terminate; provided, however, if any default is not capable of being cured within such sixty&nbsp;(60) day period, then the Parties shall negotiate in good faith and agree on a remediation plan allowing
the breaching Party to cure the breach within an additional period of sixty (60)&nbsp;days. If the breaching Party is diligently undertaking to cure such breach in accordance with such plan, then the
<FONT STYLE="white-space:nowrap">non-breaching</FONT> Party shall have no right to terminate this Agreement for such breach before the end of the sixty (60)&nbsp;days&#146; additional cure period. For clarity, (a)&nbsp;any material breach of any <FONT
STYLE="white-space:nowrap">In-License</FONT> by Licensor, or (b)&nbsp;the termination of any <FONT STYLE="white-space:nowrap">In-License</FONT> by or because of Licensor shall constitute a material breach by Licensor of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.4 <U>Effects of Expiration or Termination</U>.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Termination or expiration of this Agreement for any reason shall not constitute a waiver or release of, or otherwise be deemed to
prejudice or adversely affect, any rights, remedies or claims, whether for damages or otherwise, that a Party may have hereunder or that may arise out of or in connection with such termination or expiration. Termination of this Agreement by a Party
shall be without prejudice to other remedies such Party may have at law or equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Upon (i)&nbsp;expiration (but not termination) of
this Agreement, or (ii)&nbsp;the termination of this Agreement by Licensee for Licensor&#146;s material breach pursuant to Section&nbsp;13.3, subject to the terms and conditions of the Development Agreement, Licensor shall hereby grant to Licensee a
worldwide exclusive, perpetual, irrevocable, royalty free, sublicensable right, license and interest in, to, and under Product Rights to Develop, Manufacture, obtain and maintain Regulatory Approvals for, Commercialize, and otherwise Exploit all
Products in the Licensee Territory in the Field. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Upon the termination of this Agreement for any reason (except if Licensee terminates
this Agreement for Licensor&#146;s material breach pursuant to Section&nbsp;13.3), the following provisions apply: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)
After a wind-down period of three (3)&nbsp;months, Licensor shall have a reversion of all rights previously licensed to Licensee hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Licensee shall provide and assign to Licensor or its designee all Regulatory Approvals for the Products to the extent
possible under Applicable Law, at Licensor&#146;s sole cost and expense. Licensor shall grant to Licensee a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right of reference (with the right to grant further rights of reference
through multiple tiers) under all such Regulatory Approvals to Develop, Manufacture, obtain and maintain Regulatory Approvals for, and Commercialize any product other than Product in the Licensee Territory. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Licensee shall use Commercially Reasonable Efforts to provide assistance, at Licensor&#146;s expense, as may be
reasonably necessary for Licensor or its designee to commence or continue the Commercialization of the Products in the Licensee Territory for a period of at least one hundred eighty (180)&nbsp;days after the effective date of such termination (the
&#147;<U>Transition Period</U>&#148;). Additionally, Licensee shall, at Licensor&#146;s expense, provide Licensor with electronic copies of any promotional and marketing materials generated by or on behalf of Licensee (which
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
are suitable for use in deriving and creating additional promotional and marketing materials) with respect to Products prior to the effective date of expiration or termination. Upon
Licensor&#146; request and Licensee&#146;s election, Licensee shall continue to Commercialize the Products in the Licensee Territory for up to six (6)&nbsp;months after the effective date of expiration or termination of this Agreement, subject to
reimbursement by Licensor of Licensee&#146;s reasonable costs and expenses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) If at the time of such termination, any
clinical trials for the Products are being conducted by or on behalf of Licensee, its Affiliates or Sublicensees, then Licensee shall, and shall cause its Affiliates and Sublicensees to, (A)&nbsp;continue to conduct such clinical trial during the
Transition Period or another period of time as reasonably necessary to ensure patient safety, and (B)&nbsp;after such period, to (x)&nbsp;cooperate with Licensor to transfer the conduct of all such clinical trials to Licensor or its designee or
(y)&nbsp;continue to conduct such clinical trials, at Licensor&#146;s cost, for so long as necessary to enable such transfer to be completed without interruption of any such clinical trials, and (C)&nbsp;Licensor shall assume any and all liability
and costs for such clinical trial after the effective date of such termination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) At Licensor&#146;s election and
request, Licensee shall transfer to Licensor or its designee all of the inventory of Product then in possession or control of Licensee, its Affiliates or Sublicensees; provided that Licensor shall pay Licensee the fair market value for such
Products. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) At the Disclosing Party&#146;s election, the Receiving Party shall return (at Disclosing Party&#146;s
expense) or destroy all tangible materials comprising, bearing, or containing any Confidential Information of the Disclosing Party that are in the Receiving Party&#146;s or its Affiliates&#146; or Sublicensees&#146; possession or control and provide
written certification of such destruction (except to the extent any information is the Confidential Information of both Parties or to the extent that the Receiving Party has the continuing right to use the Confidential Information under this
Agreement); provided that the Receiving Party may retain one copy of such Confidential Information for its legal archives. Notwithstanding anything to the contrary set forth in this Agreement, the Receiving Party shall not be required to destroy
electronic files containing such Confidential Information that are made in the ordinary course of its business information <FONT STYLE="white-space:nowrap">back-up</FONT> procedures pursuant to its electronic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The following provisions shall survive the termination or expiration of this Agreement for any reason: Article&nbsp;I, Section&nbsp;2.5,
Section&nbsp;9.4 (for the period set forth therein), Article&nbsp;X, Article&nbsp;XI, this Section&nbsp;13.4, Article&nbsp;XIV, and Article&nbsp;XV. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;XIV </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>DISPUTE
RESOLUTION </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.1 <U>General</U>. The Parties recognize that a claim, dispute or controversy may arise relating to this
Agreement or to the breach, enforcement, interpretation or validity of this Agreement (a &#147;<U>Dispute</U>&#148;). Any Dispute, including Disputes that may involve the Affiliates of any Party, shall be resolved in accordance with this
Article&nbsp;XIV. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.2 <U>Continuance of Rights and Obligations during Pendency of Dispute Resolution</U>. If there are any
Disputes in connection with this Agreement, including Disputes related to termination of this Agreement under Section&nbsp;13.3, all rights and obligations of the Parties shall continue until such time as any Dispute has been resolved in accordance
with the provisions of this Article&nbsp;XIV. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.3 <U>Escalation</U>. Any Dispute shall be referred to the Executive Officers
for attempted resolution. In the event the Executive Officers are unable to resolve such Dispute within thirty (30)&nbsp;days of such Dispute being referred to them, then, upon the written request of either Party to the other Party, the Dispute
shall be subject to arbitration in accordance with Section&nbsp;14.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.4 <U>Arbitration</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If the Parties fail to resolve the Dispute through escalation to the Executive Officers under Section&nbsp;14.3, and a Party desires to
pursue resolution of the Dispute, the Dispute shall be submitted by either Party for final resolution by arbitration by the American Arbitration Association (&#147;<U>AAA</U>&#148;) under the Commercial Arbitration Rules, excepted as modified
herein. Any disputes concerning the propriety of the commencement of the arbitration or the scope or applicability of this agreement to arbitrate shall be finally settled by the arbitrator. The arbitration shall be conducted by an arbitrator,
mutually agreeable by each Party, experienced in technology development and shall include a written record of the arbitration hearing. In the event an arbitrator cannot be selected by mutual consent, then such arbitrator shall be selected by random
selection from a list provided by each Party. The Parties reserve the right to object to any individual who shall be employed by or affiliated with a competing organization or entity. The seat of arbitration shall be New York City, New York and the
language of the proceedings, including all communications, shall be English. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Parties agree that any award or decision made by the
arbitral tribunal shall be final and binding upon them and may be enforced in the same manner as a judgment or order of a court of competent jurisdiction, and the Parties undertake to carry out any award without delay. The arbitral tribunal shall
render its final award or decision within nine (9)&nbsp;months from the date on which the request for arbitration by one of the Parties wishing to have recourse to arbitration is received by the AAA. The arbitral tribunal shall resolve the Dispute
by applying the provisions of this Agreement and the governing law set forth in Section&nbsp;15.10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) By agreeing to arbitration, the
Parties do not intend to deprive any court of its jurisdiction to issue, at the request of a Party, a <FONT STYLE="white-space:nowrap">pre-arbitral</FONT> injunction, <FONT STYLE="white-space:nowrap">pre-arbitral</FONT> attachment or other order to
avoid irreparable harm, maintain the status quo, preserve the subject matter of the Dispute, or aid the arbitration proceedings and the enforcement of any award. Without prejudice to such provisional or interim remedies in aid of arbitration as may
be available under the jurisdiction of a competent court, the arbitral tribunal shall have full authority to grant provisional or interim remedies and to award damages for the failure of any Party to the dispute to respect the arbitral
tribunal&#146;s order to that effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) EACH PARTY WAIVES ITS RIGHT TO TRIAL OF ANY ISSUE BY JURY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Any decision or award as a result of any such arbitration proceeding shall be in writing and shall provide an explanation for all
conclusions of law and fact and shall include the assessment of costs, expenses, and reasonable attorneys&#146; fees. The arbitrators will be authorized to award compensatory damages, but will not be authorized to (i)&nbsp;award <FONT
STYLE="white-space:nowrap">non-economic</FONT> damages (other than specific performance or injunctive relief), (ii)&nbsp;award punitive damages or any other damages expressly excluded under this Agreement, or (iii)&nbsp;reform, modify or materially
change this Agreement or any other agreements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contemplated hereunder; provided<I>, </I>however<I>,</I> that the damage limitations described in clauses (i)&nbsp;and (ii)&nbsp;will not apply if such damages are statutorily imposed. Each Party
shall bear its own attorney&#146;s fees, costs, and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the administrator and the arbitrators; provided, however, that the arbitrators shall be
authorized to determine whether a Party is the prevailing party, and if so, to award to that prevailing party reimbursement for any or all of its reasonable attorneys&#146; fees, costs and disbursements (including, for example, expert witness fees
and expenses, photocopy charges, travel expenses, etc.), or the fees and costs of the administrator and the arbitrators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.5 <U>Injunctive Relief</U>. Each Party agrees that, due to the unique nature of the transactions contemplated by this
Agreement, the breach of this Agreement will cause irreparable harm and significant injury to the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party, the extent of which will be difficult to ascertain and for which there will be no adequate
remedy at law. Accordingly, and notwithstanding anything in Section&nbsp;14.4 to the contrary, in the event of a Party&#146;s breach of any of the provisions of this Agreement, the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party may, in
its discretion, in addition to any other right or available remedy, seek and obtain from any court of competent jurisdiction anywhere in the world an immediate injunction and other equitable relief restraining such breach or any threatened breach
and to specific performance of any provision of this Agreement, without the necessity of posting any bond or other security (or the minimum required by law, if any), proving actual damages, showing irreparable harm, balancing of harms, consideration
of the public interest, or inadequacy of monetary damages as a remedy. Each Party hereby waives, and agrees not to assert, any opposition to the foregoing. This Section&nbsp;14.5 will apply notwithstanding anything to the contrary in this
Article&nbsp;XIV. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;XV </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>MISCELLANEOUS </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.1 <U>Force Majeure</U>. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or
breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is unforeseeable, is caused by or results from causes beyond the reasonable control of the affected Party, and is not
due to such Party&#146;s negligence, which may include embargoes, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, pandemics, epidemics or other
acts of God or any other deity (or orders of any Governmental Authority related to any of the foregoing). The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and the affected Party
shall promptly undertake all reasonable efforts necessary to remedy such force majeure circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.2 <U>Notices</U>.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (a)&nbsp;upon receipt, when delivered personally; (b)&nbsp;upon
receipt, when sent by electronic mail (provided that such sent email is kept on file (whether electronically or otherwise) by the sending party and the sending party does not receive an automatically generated message from the recipient&#146;s email
server that such <FONT STYLE="white-space:nowrap">e-mail</FONT> could not be delivered to such recipient); or (c)&nbsp;one (1) Business Day after deposit with an overnight courier service with next day delivery specified, in each case, properly
addressed to the party to receive the same. The mailing addresses and <FONT STYLE="white-space:nowrap">e-mail</FONT> addresses for such communications shall be: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">if to Licensor, to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Scilex Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">960
San Antonio Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94303 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Email: SLincoln@scilexholding.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with copies to (which shall not constitute notice): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Paul Hastings LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1117 S.
California Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94304 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Jeffrey T. Hartlin; Elizabeth A. Razzano </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Email: jeffhartlin@paulhastings.com; elizabethrazzano@paulhastings.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">if to Licensee, to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">RoyaltyVest Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Sea Meadow
House </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Waterfront Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Road
Town, British Virgin Islands </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Eli Hassett </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Email: eli@hassett.biz </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with
copy to (which shall not constitute notice): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Morrison&nbsp;&amp; Foerster LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">12531 High Bluff Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Suite 200
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Matthew A. Ferry </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Email: mferry@mofo.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Party may, by
notice given in accordance herewith to the other Party, designate any further or different address to which subsequent notices, consents, waivers and other communications shall be sent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.3 <U>Successors and Assigns</U>. Licensor shall not be entitled to assign any of its rights or delegate any of its obligations
under this Agreement without the prior written consent of Licensee, except that Licensor may, without such consent, assign this Agreement in its entirety to any permitted assignee or successor to Licensor&#146;s rights and obligations under the
Royalty Agreement. Licensee shall have the right to assign its rights and delegate its obligations under this Agreement, in whole or in part, (a)&nbsp;upon Licensor&#146;s prior written consent (not to be unreasonably withheld, conditioned, or
delayed) or (b)&nbsp;with or without such consent to any Affiliate or any successor to all or substantially all of Licensee&#146;s assets or business to which this Agreement relates in whole or in part. For purposes of the foregoing an assignment or
delegation &#147;in part&#148; will include with respect to a particular country or jurisdiction and/or with respect to any particular Product. Upon any such assignment in part, the Parties shall amend this Agreement
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accordingly and Licensor shall enter into such agreement with Licensee&#146;s successor thereto as may be reasonably necessary or useful to effectuate or evidence such assignment and delegation
in part. Any purported assignment or delegation in violation of this Section&nbsp;15.3 will be void. Subject to the foregoing, this Agreement shall inure to the benefit of and be binding on the Parties&#146; successors and permitted assignees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.4 <U>Rights in Bankruptcy</U>. All rights and licenses granted under or pursuant to this Agreement by Licensor to Licensee
are, and shall otherwise be deemed to be, for purposes of Section&nbsp;365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, licenses of right to &#147;intellectual property&#148; as defined under
Section&nbsp;101 of the U.S. Bankruptcy Code. The Parties agree that Licensee, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code or any analogous
provisions in any other country or jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.5 <U>Performance</U>. Licensee may discharge any obligation and exercise
any right hereunder through any of its Affiliates or Sublicensees. Licensee hereby guarantees performance by its Affiliates and Sublicensees of Licensee&#146;s obligations under this Agreement, and Licensee shall cause its Affiliates and
Sublicensees to comply with the provisions of this Agreement in connection with such performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.6 <U>Fees</U>. Promptly
after the Effective Date, Licensee shall cause an invoice to be sent to Licensor for all attorney&#146;s fees incurred by the members of Licensee in the negotiation and drafting of this Agreement. Licensor shall pay such invoice within thirty
(30)&nbsp;days after receipt of such invoice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.7 <U>Independent Nature of Relationship</U>. The relationship between
Licensor and Licensee is solely that of licensor and licensee, and neither Party has any fiduciary or other special relationship with the other Party or any of its Affiliates. This Agreement is not a partnership or similar agreement, and nothing
contained herein shall be deemed to constitute Licensor and Licensee as a partnership, an association, a joint venture, or any other kind of entity or legal form for any purposes, including any tax purposes. The Parties agree that they shall not
take any inconsistent position with respect to such treatment in a filing with any Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.8 <U>Entire
Agreement</U>. This Agreement, together with the Exhibits and Schedules hereto, constitute a complete and exclusive statement of the terms of agreement between the Parties, and supersede all prior agreements, understandings and negotiations, both
written and oral, between the Parties, with respect to the subject matter of this Agreement, provided that nothing in this Agreement will supersede the Royalty Agreement, which is and will remain in full force and effect in accordance with its
terms. Without limiting the foregoing, this Agreement supersedes and replaces in its entirety the Term Sheet, which shall be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.9 <U><FONT STYLE="white-space:nowrap">Non-Contravention</FONT></U>. Neither Party shall take any action to contravene or
interfere with any rights granted to the other Party hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.10 <U>Governing Law</U>. THIS AGREEMENT SHALL BE GOVERNED
BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL SUBSTANTIVE LAWS OF THE STATE OF NEW YORK WITHOUT REFERENCE TO THE RULES THEREOF RELATING TO CONFLICTS OF LAW OTHER THAN SECTION <FONT STYLE="white-space:nowrap">5-1401</FONT> OF THE GENERAL
OBLIGATIONS LAW OF THE STATE OF NEW YORK, AND THE OBLIGATIONS, RIGHTS AND REMEDIES OF THE PARTIES HEREUNDER SHALL BE DETERMINED IN ACCORDANCE WITH SUCH LAWS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.11 <U>Severability</U>. If any term or other provision of this Agreement is
held to be invalid, illegal or incapable of being enforced in accordance with the terms hereunder, all other conditions and provisions of this Agreement will nevertheless remain in full force and effect so long as the economic or legal substance of
the transaction contemplated by this Agreement is not affected in any manner materially adverse to either Party. Upon any such determination, the Parties shall negotiate in good faith to modify this Agreement so as to effect their original intent as
contemplated by this Agreement to the greatest extent possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.12 <U>Counterparts</U>. This Agreement may be signed in
any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each Party shall have received a counterpart
hereof signed by the other Party. Any counterpart may be executed by facsimile or other similar means of electronic transmission, including &#147;PDF&#148;, and such facsimile or other electronic transmission shall be deemed an original. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.13 <U>Amendments; No Waivers</U>. Neither this Agreement nor any term or provision hereof may be amended, supplemented,
restated, waived, changed or modified except with the written consent of both Parties. No failure or delay by any Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise
thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. No notice to or demand on any Party in any case shall entitle it to any notice or demand in similar or other circumstances. No waiver or
approval hereunder shall, except as may otherwise be stated in such waiver or approval, be applicable to subsequent transactions. No waiver or approval hereunder shall require any similar or dissimilar waiver or approval thereafter to be granted
hereunder. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.14 <U>No Third Party Rights</U>. Other than the Parties, no Person will have any legal or equitable right, remedy or claim
under or with respect to this Agreement. This Agreement may not be amended or terminated, and any provision of this Agreement may be waived, without the consent of any Person who is not a Party. Licensor shall have the right enforce any legal or
equitable right, remedy or claim under or with respect to this Agreement for the benefit of Licensor Indemnitees and Licensee shall have the right to enforce any legal or equitable right, remedy or claim under or with respect to this Agreement for
the benefit of the Licensee Indemnitees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.15 <U>Table of Contents and Headings</U>. The Table of Contents and headings of
the Articles and Sections of this Agreement have been inserted for convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">{SIGNATURE PAGE FOLLOWS} </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Agreement as of the day and year first
written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>LICENSOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>SCILEX PHARMACEUTICALS INC.</B>, a Delaware corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jaisim Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jaisim Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer and Secretary</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Lidocaine License Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LICENSEE:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROYALTYVEST LTD.,</B> a British Virgin Islands corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eli Hassett</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Eli Hassett</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Lidocaine License Agreement</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d859484dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;22, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">960 San Antonio Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94303 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Stephen Ma </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>VIA EMAIL </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Parent Guarantee for Lidocaine License Agreement (this &#147;<U>Side Letter</U>&#148;)
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is
made to that Lidocaine License Agreement, dated as of February&nbsp;22, 2025 (the &#147;<U>License Agreement</U>&#148;), between Scilex Pharmaceuticals, Inc. (&#147;<U>Licensor</U>&#148;) and RoyaltyVest Ltd. (&#147;<U>Licensee</U>&#148;). All
capitalized terms used but not defined in this Side Letter have their respective meanings set forth in the License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, Scilex Holding
Company (&#147;<U>Scilex</U>&#148;) is an Affiliate who is the ultimate parent company of Licensor; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, Licensee desires Scilex to guarantee the
due and proper performance of Licensor&#146;s obligations under the License Agreement and otherwise, and Scilex is willing to grant the performance guarantee hereinafter provided. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the mutual agreements, representations and warranties set forth herein and of other good and valuable
consideration, the receipt and adequacy of which are hereby acknowledged, the parties covenant and agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1
<U>Representations and Warranties</U>. Scilex represents and warrants to Licensee as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Scilex is duly organized, validly
existing and in good standing under the laws of the jurisdiction of its formation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Scilex (i)&nbsp;has the requisite power and
authority and the legal right to enter into this Side Letter and to perform its obligations hereunder; and (ii)&nbsp;has taken all requisite action on its part to authorize the execution and delivery of this Side Letter and the performance of its
obligations hereunder. This Side Letter has been duly executed and delivered on behalf of Scilex, and constitutes a legal, valid, binding obligation, enforceable against Scilex in accordance with its terms. All rights purported to be granted in this
Side Letter are duly granted hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) All necessary consents, approvals and authorizations of all Governmental Authorities and
other persons or entities required to be obtained by Scilex in connection with this Side Letter have been obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The execution and
delivery of this Side Letter and the performance of Scilex&#146;s obligations hereunder (i)&nbsp;do not and will not conflict with or violate any requirement of Applicable Laws, regulations or orders of governmental bodies; and (ii)&nbsp;do not and
will not conflict with, or constitute a default under, any contractual obligation of Scilex. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) As of the effective date of this Side
Letter, there is no action or proceeding pending against Scilex that questions in any material respect the validity of this Side Letter or any action taken by Scilex in connection with the execution of this Side Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The operation of the business of Scilex and its Affiliates is being, and has been, conducted in material compliance with all Applicable
Laws, including Compliance Laws. Neither Scilex nor any of its Affiliates has received any written notice to the effect that the operation of the business of Scilex or its Affiliates is not, and was not, in material compliance with any such
Applicable Laws, including Compliance Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2 <U>Performance Guarantee</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In consideration of Licensee entering into the License Agreement with Licensor, Scilex hereby covenants and agrees unconditionally with
Licensee, its successors and assigns that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Licensor shall properly, diligently and in good time observe the provisions of and perform
and discharge any and all its obligations contained in or arising from the License Agreement, as supplemented and amended from time to time; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) If Licensor defaults in any manner whatsoever in the due and proper performance of the License Agreement, or commits any breach of the
provisions thereof or of any of the duties above mentioned, Scilex shall, forthwith upon written request from Licensee so to do, assume and properly and diligently perform and discharge any and all of said obligations or duties remaining
unfulfilled; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Scilex shall pay to Licensee on demand all monies due and owing by Licensor to Licensee under the License
Agreement or pursuant to any claim made by Licensee relating to or arising out of the License Agreement (collectively, the &#147;<U>Guarantee</U>&#148;). Without limiting the generality of the foregoing, Scilex and Licensor will be jointly and
severally liable for any and all obligations and liabilities of Licensor under or in connection with the License Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Guarantee shall be a primary obligation of Scilex and accordingly Licensee shall not
be obliged before enforcing the Guarantee to take any action in court against Licensor, to make any claim against or any demand of Licensor, to enforce any other security held by it in respect of the obligations of Licensor under the License
Agreement or to exercise any diligence against Licensor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Scilex shall, on demand, indemnify and hold Licensee harmless from and
against any and all losses and expenses, of whatsoever nature (including, without limitation, all legal fees and expenses), in any way connected with breach by Licensor of its obligations contained in or arising from the License Agreement, and any
supplement or amendments thereto, and/or breach by Scilex of the duties described herein, whether or not any such breach is caused, wholly or in part, by negligence of Licensor or Scilex. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Guarantee shall be in addition to, and not in substitution for, any rights or remedies that Licensee may have against Licensor arising
under the License Agreement or otherwise, and Scilex shall not be released from the obligations hereunder by reason of any time or forbearance granted by Licensee to Licensor or Scilex. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Any material breach of the Side Letter (including the Guarantee) by Scilex shall constitute a material breach by Licensor of the License
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) In the event of any Claim or dispute arising out of or relating to the Guarantee, the provisions of the License Agreement
with regard to applicable law and conflict resolution shall apply as if fully repeated herein. An award obtained pursuant to the License Agreement by Licensee against Licensor shall also be binding on Scilex. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Scilex agrees that the Guarantee and Scilex&#146;s obligations under this Article&nbsp;I are irrevocable, continuing, absolute, and
unconditional and will not be reduced, discharged or otherwise adversely affected, and Scilex hereby irrevocably waives any defenses to enforcement it may have (now or in the future) thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.3 <U>Termination</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Scilex shall provide Licensee with written notice of any Change of Control of Licensor within five (5)&nbsp;Business Days after the
consummation of such Change of Control, and this Side Letter and the Guarantee shall automatically terminate upon the consummation of such Change of Control. &#147;<U>Change of Control</U>&#148; means the occurrence of any one of the following
events, whether in one transaction or in a series of related transactions: (i)&nbsp;a Third Party acquires, directly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or indirectly, shares of Licensor representing fifty percent (50%) or more of the voting shares (where voting refers to being entitled to vote for the election of directors) then outstanding of
Licensor; (ii)&nbsp;Licensor consolidates with or merges into a Third Party, or a Third Party consolidates with or merges into Licensor, in either event pursuant to a transaction in which more than fifty percent (50%) of the voting shares of the
acquiring or resulting Person outstanding immediately after such consolidation or merger are not held by the holders of the outstanding voting shares of Licensor preceding such consolidation or merger; (iii)&nbsp;Licensor assigns, conveys,
transfers, leases or otherwise disposes of all or substantially all of its assets to a Third Party; or (iv)&nbsp;Licensor&#146;s permitted assignment of its rights and delegation of its obligations under the License Agreement to a Third Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Termination of this Side Letter for any reason shall not constitute a waiver or release of, or otherwise be deemed to prejudice or
adversely affect, any rights, remedies or claims, whether for damages or otherwise, that a party may have hereunder or that may arise out of or in connection with such termination. Termination of this Side Letter by a party shall be without
prejudice to other remedies such party may have at law or equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;II </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>MISCELLANEOUS </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1 <U>Entire Agreement</U>. This Side Letter constitutes a complete and exclusive statement of the terms of agreement between
the parties, and supersede all prior agreements, understandings and negotiations, both written and oral, between the parties, with respect to the subject matter of this Side Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2 <U>Governing Law</U>. THIS SIDE LETTER SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL SUBSTANTIVE LAWS OF
THE STATE OF NEW YORK WITHOUT REFERENCE TO THE RULES THEREOF RELATING TO CONFLICTS OF LAW OTHER THAN SECTION <FONT STYLE="white-space:nowrap">5-1401</FONT> OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK, AND THE OBLIGATIONS, RIGHTS AND
REMEDIES OF THE PARTIES HEREUNDER SHALL BE DETERMINED IN ACCORDANCE WITH SUCH LAWS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3 <U>Counterparts</U>. This Side
Letter may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Side Letter shall become effective when each party shall have
received a counterpart hereof signed by the other party. Any counterpart may be executed by facsimile or other similar means of electronic transmission, including &#147;PDF&#148;, and such facsimile or other electronic transmission shall be deemed
an original. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4 <U>Amendments; No Waivers</U>. Neither this Side Letter nor any term or
provision hereof may be amended, supplemented, restated, waived, changed or modified except with the written consent of both parties. No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver
thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. No notice to or demand on any party in any case shall entitle it to any notice or demand
in similar or other circumstances. No waiver or approval hereunder shall, except as may otherwise be stated in such waiver or approval, be applicable to subsequent transactions. No waiver or approval hereunder shall require any similar or dissimilar
waiver or approval thereafter to be granted hereunder. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Side Letter as of the day and year first written above.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>SCILEX:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>SCILEX HOLDING COMPANY</B>, a Delaware corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jaisim Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jaisim Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer and President</TD></TR></TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LICENSEE:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROYALTYVEST LTD.</B>, a British Virgin Islands corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eli Hassett</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Eli Hassett</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Director</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>sclxw-20250222.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 2/28/2025 12:28:17 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:sclxw="http://imetrix.edgar-online.com/20250222"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://imetrix.edgar-online.com/20250222"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" namespace="http://fasb.org/us-types/2024" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sclxw-20250222_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sclxw-20250222_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sclxw-20250222_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="sclxw_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="sclxw_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="sclxw_CommonStockParValue0.0001PerShare2Member" name="CommonStockParValue0.0001PerShare2Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member" name="WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>sclxw-20250222_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 2/28/2025 12:28:19 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="sclxw-20250222.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="sclxw-20250222.xsd#sclxw_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="sclxw_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="sclxw-20250222.xsd#sclxw_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="sclxw_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="sclxw-20250222.xsd#sclxw_CommonStockParValue0.0001PerShare2Member" xlink:type="locator" xlink:label="sclxw_CommonStockParValue0.0001PerShare2Member" />
    <link:loc xlink:href="sclxw-20250222.xsd#sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member" xlink:type="locator" xlink:label="sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="sclxw_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclxw_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sclxw_CommonStockParValue0.0001PerShare2Member" order="24" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member" order="25" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="28.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="29.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="32.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="33.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="34.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="35.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="36.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="37.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="38.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="39.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="40.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="41.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="42.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="43.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="44.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="45.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="46.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="47.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="48.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="49.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="50.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="51.001" priority="2" use="optional" />
  </link:definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>sclxw-20250222_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 2/28/2025 12:28:17 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="sclxw-20250222.xsd#sclxw_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="sclxw_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclxw_DocumentAndEntityInformationTable" xlink:to="sclxw_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="sclxw_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="sclxw_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="sclxw-20250222.xsd#sclxw_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="sclxw_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="sclxw_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="sclxw_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="sclxw_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="sclxw-20250222.xsd#sclxw_CommonStockParValue0.0001PerShare2Member" xlink:type="locator" xlink:label="sclxw_CommonStockParValue0.0001PerShare2Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclxw_CommonStockParValue0.0001PerShare2Member" xlink:to="sclxw_CommonStockParValue0.0001PerShare2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="sclxw_CommonStockParValue0.0001PerShare2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Value 0.0001 Per Share 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="sclxw_CommonStockParValue0.0001PerShare2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Par Value 0.0001 Per Share 2 [Member]</link:label>
    <link:loc xlink:href="sclxw-20250222.xsd#sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member" xlink:type="locator" xlink:label="sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member" xlink:to="sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>sclxw-20250222_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 2/28/2025 12:28:17 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="sclxw-20250222.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="sclxw-20250222.xsd#sclxw_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="sclxw_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="sclxw_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="sclxw-20250222.xsd#sclxw_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="sclxw_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationTable" xlink:to="sclxw_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="sclxw-20250222.xsd#sclxw_CommonStockParValue0.0001PerShare2Member" xlink:type="locator" xlink:label="sclxw_CommonStockParValue0.0001PerShare2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sclxw_CommonStockParValue0.0001PerShare2Member" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="sclxw-20250222.xsd#sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member" xlink:type="locator" xlink:label="sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="48.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="49.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="50.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclxw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="51.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46513391979840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 22, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclxw_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Scilex Holding Co<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001820190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 22,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">92-1062542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">960 San Antonio Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo Alto<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">516-4310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclxw_CommonStockParValue0.0001PerShare2Member', window );">Common Stock Par Value 0.0001 Per Share 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclxw_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SCLX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member', window );">Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclxw_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SCLXW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclxw_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclxw_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclxw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclxw_CommonStockParValue0.0001PerShare2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclxw_CommonStockParValue0.0001PerShare2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( *F 6UK\ !LC[@   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( *F 6UJ97)PC$ 8  )PG   3
M      "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ J8!;
M6M[W$RHO!0  @Q8  !@              ("!#0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( *F 6UJ?H!OPL0(  .(,   -
M      "  7(-  !X;"]S='EL97,N>&UL4$L! A0#%     @ J8!;6I>*NQS
M    $P(   L              ( !3A   %]R96QS+RYR96QS4$L! A0#%
M  @ J8!;6APX9>H_ 0  / (   \              ( !-Q$  'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( *F 6UHD'INBK0   /@!   :
M  "  :,2  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M *F 6UIED'F2&0$  ,\#   3              "  8@3  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  -(4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d859484d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="d859484d8k.htm">d859484d8k.htm</File>
    <File>sclxw-20250222.xsd</File>
    <File>sclxw-20250222_def.xml</File>
    <File>sclxw-20250222_lab.xml</File>
    <File>sclxw-20250222_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d859484d8k.htm": {
   "nsprefix": "sclxw",
   "nsuri": "http://imetrix.edgar-online.com/20250222",
   "dts": {
    "inline": {
     "local": [
      "d859484d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "sclxw-20250222.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "sclxw-20250222_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sclxw-20250222_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sclxw-20250222_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 30,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 26
   },
   "report": {
    "R1": {
     "role": "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-02-22_to_2025-02-22",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d859484d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-02-22_to_2025-02-22",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d859484d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sclxw_CommonStockParValue0.0001PerShare2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://imetrix.edgar-online.com/20250222",
     "localname": "CommonStockParValue0.0001PerShare2Member",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Par Value 0.0001 Per Share 2 [Member]",
        "terseLabel": "Common Stock Par Value 0.0001 Per Share 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "sclxw_DocumentAndEntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://imetrix.edgar-online.com/20250222",
     "localname": "DocumentAndEntityInformationLineItems",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sclxw_DocumentAndEntityInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://imetrix.edgar-online.com/20250222",
     "localname": "DocumentAndEntityInformationTable",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "sclxw_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://imetrix.edgar-online.com/20250222",
     "localname": "WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member]",
        "terseLabel": "Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://imetrix.edgar-online.com//20250222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-25-039211-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-039211-xbrl.zip
M4$L#!!0    ( *F 6UH_Q/6;21<  +V+   .    9#@U.30X-&0X:RYH=&WM
M/?MSXCC2O^>O4#$[MTE5>!C(BV1RE64RN[G-)"G(W.QWOTP)6X!NC,5*=@+W
MUW_=DFQL,(\DD&1VLU4[P5B/5K^[U1(G_QP-?'+'I.(B^/"S4ZK\3%C@"H\'
MO0\_G[6;%Q<___-TZZ0?0C-H&JB&Q_B'0C\,AXUR>=21?DDQM]03=V5X4:Y6
MJO6";1BI8C@>,I6T[E+5*0G9*\=O,LT#$031(&E\?W]?TL-C!R^49>Q1AD9%
M:,4D=^-^(Y\'WS/=[FNZDW-T=%36;^.F,RV3":J52JV,KSM4L;BY<OW1?=*>
M#U@H^:C$O!Z511% :U9RQ0 7L5>I5JL)0(KG@0-3..4_/E^VW3X;T"(/5$@#
M-YDL"N5<T([*\#9NR)6H5YV#!>NP+9(.HWEM'6BKU_''+ZW+2?,PO_VD:3F4
M-%!=(0<T!+[!D?:*E6JQNI\:I A\D1DHYI-EXQP6:TZ"2YB<+UKJ%!;QK3?%
MG[;Q?MF\3+%GC])A+G?BBS1SSF<O%(P""@BC'OP)>>BST\/B[R=E\W'K!-B&
M$NQ>9']&_.Y#H2F"D 5A\188ND!<\_2A$+)16-;#E:%7V0Q("#GI"&]\>N+Q
M.Z+"L<\^%#RNACX=H\2PPBDYX:,&MF;2?N:>QP+S&9I<&7$AW/M0^$V_^@:2
M^NT\  #'+=;C"JD07M$!0!/ OS !XXW\]QK:4=AB76@524VV;R@ FOS5;Z%(
M/15.VR[WV8C\)GQ4**0I3LH9H&: G,Q_-F"!!_^'GWS:>^C$>K%\=%>L'AT6
M3KO45VS9S+GH:<+\DOH7@<=&O[/Q+'YF&CP00150"H? ]D>56?C*4[24K,LD
M*&>FX!EU%2@H5"4PUR95H9X)E>^'@N*#H9]\UY>X2*TDB[$.+(V4%[^GTI4"
M^77Y+&6[W,P2];,2D32/6A4T+'XUN5; ;]R-:6HEC]S#+[J<2:)QR'(55?/B
M]RR%ICLCU+GC#X&$PDL>04?)\",-V>D$MKCGY-T$5F].V_A-,FTR3SF#G<=A
MZYM5?,5V").@Z#5]JM1UMQT*]_O9B*MOAMA-,1B(0'][0^6_J1^Q2@GQ=,-D
MNT\EJWYF@PZ3SX!^BT/60W#MLP?SC88^=WEHX" >V.Y >S@%N\;&W#463O4B
M&ZLN\J2<.^>$)A/@_HZ\\I5*M![J5MR (/=!V*\#IO%WW4VA^)RZ_;/P+#@?
M,>ERQ6Y !4(+QRGM56*$.W\!KEH_.OX"_%>>TO3EM$-3!L<'_J3<'^Q5I#[O
M!0T7UF(X(O7^GGMAOW%8VN/!<:JMS[KA\8#*'@^*^+E!:!2*^!O)>WW[%0XW
MC =#5[789_HM1$?#9(A0#!NIQXX(0S'0WW2$!-#C;YSAB"CA<X^\J^C_"J?_
M>.?L5XY/RL-Y$]663U1]]$2I8>LP")E= .D":8J*_X\UG,/DN4L'W!\W;H'K
M%;EB]Z0E!C0XUN_N#=P=\/..<\CSY>KB]OPC:=^>W9ZWYX-3>29PVN?-+ZV+
MVXOS-CF[^DC._VC^=G;UZSEI7G_^?-%N7UQ?/0G&ZCI@_$I5'USF4 2[Y&.I
M62+5RE[]: JNR:0'*S!FEA^6"50N8^X_BC'!; [#+&\>&R&M.N]G%[^BD$X6
M$^N(/'H=/!-/?;IN?28G:DB#1 WU><B*\(W+P*^_EW18.)T;[7P4;H1:.A43
M/CS8J57W"B;VS(82)V6$Z_2->3; /&L1=E!'K?.K6](ZO[ENW;Z\\KGYTFI_
M.0. ;J\)*,M;T(C$J9'K%G'VMKV=EP?P^A.Y_>V<I!1YHL3/FK<$7CM'M?I\
M.)^+L.@!$=$E+384,B3;\3.CX $Q%1)V!RV)U*^9M].8GP^)-<2-=J/.C7?U
M8%5A<FVH+L*&A[XJ=.][=#P&B%B05B7[H--81T94CHVP5*N[!(>:U2YO:F7=
M:J5:7P?W9>T1P81LD8^*)J?46)8+/&TW+R[/_R"_75]^O+CZ%;VCF[.K_[/&
MA#Q)"536L;SM\Q%U0RTB*%,R 9]01=20N1C.>80'A(>*0+ %(B:GE=<;N^:S
MZQ/PLG42TH[/B,M\']T?W$HJ5 KZ>4@]+WZV,]F5NL+WZ5"Q1OQA,8-,<Y-!
MAE.IO+>H:U0LF(U*'-4!8%+_ZV5#Q5K]/68@TR_NF RY2WV+5;/2Z4:V=W6U
MWC&(,ZW3PYR4+8@R?CND/5;L2$:_XY81]UB#W@G@@@>AI[ 0/B!KGGQEM,>T
M0"[P98TVN0A<(<&L:8ND\R)-$06A'#>%]R2[A6H,,Q$A&TIQA]-F#=<!F%WF
MTWLP:',=X=!;A=P)4R]IOA'\?>(^@W>8\'I\/'"(J2ZG6#LZW*O^R,BXI:,+
MFZ!S]>J?C)FCPNE1M>A4]JM[]86HV8!$'FY&(+>UE!$AB0C[3)+_1I(KC[N(
MDY..+)^"D>1IJ=QY52RPC?E/KE0,+0H ,71^98!>M"#>& Q],692@YKE37(E
M2CLS+ 3_H%5\?$"R%I]IB9R=>9YD2MD_E^"V.(^7L5H%9&R_0MJ S+,@% $7
M "GUIJ5M=W[0DX&J"1^OY:VX#YX DP/1+?4%.?/#F<WH50'1<G8M;\#\<%U[
ML#%C5JL63IM 0>@1</I8>&\$S.#_AP\?97HGP-2 GO5:I;8D GQ0*+"6Y-NV
M72B& 4,)-.%#ZA,V8FX4\CN,#D VF=I%]>='NA3A?WP(B/#8@F3&<\GD).[Z
MQ[O#JG-PK$C(?#;LBX"10"O -.3@UU -^H)D 8K*&;1[(L'K@-K]O<K.;&W"
MHQ.=EP+4[PTN[:DFO+97.-US]HOUFC-3/)&?\7P!VEZ5SUY>.CZ!O@%_P 3*
M4JL?>*1&9H"UNA@<!SV(E17J,^)3%>>DWL+E322-E[$6*/T^<[\3<.,('8)E
M *6&KEU'C$B'^>(>:88OD;++A5%O"9BL39?[J$.X H42LL #FH<"R#Z(_) &
M3$3*'Q,%,JBZ8SV#[2 Z@"[CW0@S=2K=$L$XP$_!.'[7A1!>W&,_M&H<73K5
MF,M)^X]-,*PU@9!D#2:9A-F4Q51*8Z6XH) 7[=??'R_V19$5%ZC1KY*'0#]T
MF:/ ^IWJR8Y(1PB_0X%V(7!:6M7N(_Z/#NKUXUE-^S ?VZPKQ0<D2WKR9+4\
M,YG%%2 GC2PRC*2*D'U! %H1L%.]NF=9&7FX#<X#=.0P]ID;DFWG@#0_M4BU
M5BE!PQVC!18X]V_\_13^;@M=RP)P? ;%!]K/WQQS'_S(S#U!% QM,#7+V4LM
MA%.G1:<:&XF)$)R/C&>0$8&EHU7KE9(9<2?EB+U)R\:DY48RM 18.*N+"-"P
MR^MN]Q'N]<I2<_@C2\U2%@:,%MT42F/16&9#5I TKUC=[NRL5];,F&_2]A+2
M=J%4Q.2SR-S1F\P]2N9JK%C?=M<K<W;,E65NW1%BRC\UH1B3$,RED0,M$&-&
M>!U4$'%\!JM=7US_MMW[JK9[9S>75LB-S%G!#._G5YFLF-MR-I#;NL5#=J:B
MRNT3%ZON$TE\RD;1HW'VZA D*4J@WJ9JCP?0;%OMO*$HDZ.U!42:A9BU"&;#
M-" @ _#M1,-F]?QKJ=28&T8;(S%VJATM*0]T3=9_(FSBS-3!A3/=8*W0;Y<,
MJ21WV)7\9#J3(1[EZ><6<CS/1O \O%JI,@+UFI#J8-G>Y1^O#5\Q'\;^UB,.
M$V\ ;=-^-\K^S!9LO0I*%'RF*ZH\^B?1XY+/5'YG(;F\;.9B^DTW;/8$8(HZ
M-3PJ8R9 GW=HIR"X=ZI5!VIV-Z-GM)ZG(0$GG]G)<-?8U4U_TA/^S37/9DE6
M-SKJZVM#[7,JJ4U@>#5UMO=(=?8,(>U%X&&4STAG3%R] 0HC?@<7C.EZMJE=
M1ZZT! .</<Q^]Z2X#_LHZD/<B:2*>*S+ U, ;O9W*GMQ #RUN0/?.D>U&ME&
MSCHXUGL\<6.N2\>'6#J.F^<K9ARJG6*23I^=,Y-V,)/7EP\:0X?9AYGQ4V"6
M-EOVD!(IO3M>.#W/I\$_WATZ1_7C)35*<>=?==^FZ;JQ%%H]WLG<STFA;1!K
MP-S=!>R*]3VYO,]G-MM!5Q#F,S<$S@Z$3O1$8,"P%>#+;NGCM3I<[]:;4]>(
M'SV7/\;)[SE,C5(2 'SP1K([4"[0B@<T<'$+B;HN5FMC8[Q@QZ/24V8SWUN8
M9:IMTR3+E.;RTHK,,+I-0#<'G3;'"0>K<L)3:E[^:N?(3>&++7_9VLH5%X<-
M9L0%OTKYP!T&9 (?V+^G8U4PAXFV3OJ)N^P*7\C&NR/]WW&\FN$HG?=S?48E
M^@1]G6';6E)?M-X; K:F-T)^N6Y]/&\5F]>7EV<W[?-&_.$U;X0XSHH[(8OK
MH2_ T\'*Q8IS#)SME%8MUG[V+8E%R2 S^SD>4,'2*$$HB2L/R$=T)+BN)#WK
M2:;]NA)Y2,9_?P/EAGETT9\;/(0UN873_]R"% O2PH.FH)._"NE[Y!(\R$"E
M5D*6%DNN ?K"Z1G:#[ SIL2,!@'8%Q=L"=B[F5O"C NWC48$&:L*NF?)\9$E
MF+!#)BO5?_30SC'8JX!<NZ$ )]HHND-]T+6^JZU8#(U6(]J;!.8(^Q _NL#.
M%)W+7/S>,CD@[3X#OWJ-"VE=?TV-/&<]VKS'T/'@#N 34NUFS+;):R)@0RJU
M4TJ1(70Y8,!Z(M0%A]"_)]!]H-IC !V$UA?]@YA[</?ISXA+TY-UN^ .1-A5
M13@^@JH0U-*" Z/FK/53&>PZ(/D'EM>)_TL4J'.]2E0'> 8[GPB[,5??0(PV
M #<^TJI/D8O +6&@L0YH,E/,888,W](<\5\W=F9F6,2E+3&F?CC^-XK09>B5
MU@N-!F0.@<S\DN%!82T1BLD[<TH '65AG%"4&BF\R WADR<46%<,.[5#/8A\
MNR6-'217J+Q0X[H@=\SHB#X%+NE "(YN-F:C?#0J$)K>,5\,C?K# UL!-.I3
MOXMZ)$/5=.6_EE8#C88!U5(W"B,Y^3J.>2%(H#$:;\P[NW"[^YV9)#EWP$80
M9N!4VWS'")'M##900ZPY)J$LH(2&9C: ^S.U@N<X*'CXK\;Q-5=]3GX7BB%[
M-$5IUY)Z/636P\^A,6+I(A1N/R+-/AN@!))/$L; 2\*:DY-PZX+%S#5/(R!1
M!CI"V]60;?,8R[K06RGA<HU/75XB=2#6CH80M,VB/*OJG'V-\8-=8*/P'MEM
MBHD,#2;HR )CC(%A-$8@A#.C6O]A.\738JAQJ,8*G+X=XI0.WT]S:$IZD"L@
M&$..UYR KZ\^-E<X/K*LP?[1WMY!T7&<8JV21;=>Y/)<2L>NL7U3=/!$D^F[
MC=4(1K?[8V/_UZ@9K2SELT>)8%HN7X.",84X'B)TJWPD&_JP&J4!S+H$F[>S
M7Y+JF7Q@IRP?Z6':PK@'II/1R@1B^9AE,@/IM6RG\G?ZQ /(,KE'!PM"%V!1
M83."@'0<X NXY]!29UT-BF+W!WA/<G!_T,/1Y^QT/G ^]""F; 3LK( %=I?S
M$=Y';2XQ9A+]_YB1=+"X"]; #(\0<6V(P<[Q #A+&!5@CT[X?LP<I(4]%<%+
M@B4R(Z@)LV$Q00BNG?%@)^4[6UP#CJUIV04Z!U&7NF@>=HGH:&S@E /XH!\D
MZZ$%$Q#QZ$,F=^B>@%W3!M#J'^ )W4GC^QYW2O":0<%##7.:J_7I.OVM2Q4B
M6_@@0W'B*1DN<X8DTY^(*,2 -7ZY/IINRL71O*HAF1-9Q#)M6Z<D(4LVNAJC
M31@SN83EH?RYFV%0C=681Z.47%N EPY_!</_X@OW.Y:8V)%O:*CC@NT<CC4Z
M%YR+"<%P*N"1!).Y_7:?D[/37#F??[.\.W\Y]LTGSOP%HCSM$"2J+KURN\AD
M\:M ^E3 2@3WH"8":SD#(<GR\#T'T9?,91@7[57>QUVN( !NX357$<LE+>FQ
M '@SC)VBS#2JCPK%1)7V9!G05J#= -TWI#J;/2-.>-U/LO<[#0/@A)(_(WT9
M$.BG#E5<;=YHWJ1"[T6F,V?UB2N.:?X)@0%VR:B":!RSD( B(<T6^(H"H?EE
M6@EK%1X2G^$)4-Q"_TS_"\WL_J"]P"6?C.C@06_GD.@[Q4!C=\.TGY -FJ?Y
M'=<%HO=3M5+9K<#_&!0A&?65^=1')0Z#@YK17!)$>OVAN-?[$CK5$&, =RU\
MZ&OQH!ZT]FG2I#1\:8K)#'$6T017Z'&?]Q#ZAQ-(:ZSE*CCKP.JP$$4F#N1F
MU)0IE+24%-E;0AZHE9]!;"0$$R'F"Q<STY3\9Y-2B0"!V@1RZ$M2**XU-&CA
M.OHV89..DW8G0=*40IIF6R1_OA2Z%-\QJSNGPR]L05V7#<$$ X](5&\LZ-&>
M\5>28"EAPYAA)]I?G\J5&!E@?)CC4"$Q,6^M^H &D[K068L2N0B25-XTZB9)
M0&!#T+/AE-I71BIC1P1@5Z'DG2C$)$8^#)D!)@RUR/W?/&.A7Z:3DVF@9QW'
M^#B"0K,QA_N,:XHY!3 OL?X!7X++C*^K#]5CBA3?)!CQ%KI+NS":C_=:F/LB
MI0:9!]KCW53:#O$_SYM]#JI,++R*!C#@> F)/ %CX$;X,)+ZDDW <<=D(7QF
MJ0,* 2R^G[D/$&_LD2P<HR.1_.Q$;)Z[$>A0?1O^PLE!'<!$0PVBS:$H/#$/
MLR %S38[EGOT>0<LDE,I.3$\DXN8;&, *PV)1?;6_,KH&623J<KHY?=_K^.F
MQIRMUJJ%?2N]6[P%:_E;;Q@_VUV9RP7^!B][#<FOX 5C1&K,RQSY>I[=P;F;
M-SJK -HU,&4FQC0N\IZ7[]?-7;W)<6XT?3 ]]Z*]B:SCD;]Y%Z]V8K=[R;+P
MO1<9#8AWB(#]@/]U?4Q@BEWS-P$F=WVH3%(@ESVL743#I&)+:%P+\,N9CDK#
M?NP&3*^^1*;C(C..5;K3S;,$-@ZXK4G*>AD:???VV@>P#;:V%WLU34D2/-D,
M6WXT,XV<.+SIHM7O@.\3H%GV0!FE7%-8NK99L=G7<<G,A!.O<H81XQ<3&J9I
M81:,Z@2G<$T(%#L$)!I:4JP&Q0L;\YFE/X\9G^6HAQKPZ@,->%X9F?[%@:><
MNGXK-L)BHZ,?O-CH4U)MF52+&Q5JV4T]>XU1X73;VYF:/I^#JQL^);P>#E_A
ME/#6ECDGK/]X9?MWE9.]LZ>(S?='SW>R]UF.[6[B2CK+8@^*3/31SQ4.G9+X
MYS'-[XP6.[@_L?Y#HY'Y\:T''Z1=\?#*8VFYDAY[-5C\R)0K^5#?4)Q1=58L
M<S3/C!#$%P7"B_+<-V#E4>T$'PK5E[QE/?>L2*7DO-L,$\&48% I,;_4Z1WN
M'=4/ZQX;.6 X^^$@*9%*QSJFZ&,GO\YD$I5UQMI4Y9:;3!6[8;N9.J^3,IUW
M5O(O3NSJ<].Z:FC]T+#W<1PP7<3[1OPT\>L;I'U3P+<0X4"8=X':E28I:DKP
M+O5=>S3&EDM<:+T.SEZ(/V*)KMDO<5AK?JU([QY!U!CAB-L<?Z\;CY8E&GKA
MO5*/=Q!_X!!GQ8NEEBO[E[^LJ6ES939N9C8DT.*,/Z[J13Y3)LSFD_@X5>TZ
MX#&CX5$RZ>F4DRGY-5N=F)UH%W\G&-"1?3!(NE:FE?H1'U1$>HYN)'$;*Q6K
M8R(DGF(1; Q_(LRD1K@M50<E-#>N^B&S[;6W;/M+9MMS?V#TXM>KL]LOK?/V
MLQ>6V(UODTQ8>O+85@\?U>QAEZESIB!)8[.3[1E!-Y>"V]R<@B7#"RM;MGZ]
M8ZZ-UGECVP"38Q%FX?5P0*"^D+ Z;YWYA1-S(/'ED@SUV1R#8=*\-,-49DPG
M#%9//,R[4NSP($D\3(5/S^/SI%ROVM(\WL(?EWN\;XB,,\<YU*]>AW=8./UE
MW%CW=1=Q\R<E5*;/_CY0&Y55F?R+<L6Q&IWV7_RR+'.YU\90G5GJBRY3W^"S
ML74V^YQUP7;$OZ=RK7]/16J/ZT8R7!<>\YH)#1;]3,)ZS!\6X#2F0]0#>^[O
MQZV@J,_QZ4[*'>&-X1DB>O_T_P%02P,$%     @ J8!;6D48G3XRGP  2]0#
M !$   !D.#4Y-#@T9&5X,3 Q+FAT;>Q]Z5,;V9+O=R+X'RKZS7T!$67:V.U>
M[)Z.D$&V=2\&!N%>YEM)=035+E7IU@)F_OJ7V]FJ2@*,L,0;3<QM"ZF6L^3)
M]9>9OWXX_WCTVZ\?^KW#W[:W?CT?G!_U?^O_^6S_^=[^K]_SG_#]]W)!\.O;
MD\._@K?O#TZ.3L[^\[L_/@S.^]\%P_._COK_^5V:9.K9I4HN+JO7QWDQC=+O
M?@NVM^#^ Y55JOCMU\/![_KBZR2N+E__O/<JR;X+HC2YR. !:E)]1Z\YU9=-
MH^(BR9Y5^>SU\UGU)I"_1WE5Y5/^:I)GU;,R^1_U>M_^/8FF27KS^CR9JC(X
M5M?!63Z-X$V]H\'[X__\KL!!?O?;KV]_ZW^Y3$9)%>",@U^_?_O;K]^?XI2[
M1K#_8HE#&-.:T!B.!H<G![W!<3\X&ASTCX?]H/?^K-__V#\^7]60XJA2<1"5
M03X)WJE144?%S?_-1N7LS8L78?#B^8M7JQK9Z":(LC@8J>I:J<R,HIMF'FL0
MPX/!4?_/[:W3#[VSC[V#_J?SP4'O:!@,C@_V;AG2,LG8&1%LU5$"?Y=YL:J=
MP6U9S7:<G?S5.SK_Z_?^\#PX.C_<0Y:URCU0RMV#[X'MP6=A@L#>Z/]_G05E
M=9,J?X'4M#4P_&H67:AGHT)%GY^-U"0OU.LHO8YN2F"POWX_PY=\. N&@_^&
M:;[\3C^7F/3K__,+_=]WP1^#P_,/__G=_O/G_S"#!VYSWC_[6C:-$J/W]J@?
M'/2/CH:GO8/!\?O__.[Y=_3W:>_P4/_MO?KMR=EA_XR^EY?P-\]@O$>]TV'_
MM?ZP< .:N]7:$)P2#?%,C_50#^3G?\!^?7]^:'_X76[F1;<CUA<V[O_:!RS^
M#/\Y<X:ME\?9_"0KDQ@V_RI/XN!^R_-;8Z! ;K!1)[AOQT@U[E$)_+,2=!X6
M^0JIX?7^WG.BTTI]J6"0,6S!ZV?ZR_N<JM]Z9\!*C_HL:P;!8?\=R,7# *CT
MXS#H'1\&9Y^.^L/@Y!V,_7AX?O;IX'QP<HPGS=VGQF[\QH_C_[K7'9_\<=8[
MG7/Y[1<VU(G]^SV:MMO?:F>IG"W[T!^\_W .9.<3H_W:[N.+VR_YX;O?YKW^
M\2CM0=3U<FG4-53C*LDSWH1]U''O0C<+KI!M_NU034#[C8-S54S+#25N*/&>
ME/AB:91X5J>*U/:#/"NKHJ;7K)XB?WETBO2$V5J2WMJ+VT%PUC\]ZP]!*^RA
M6&6)^T?O[*QW?#[H#]=$S#[?<+>GQ-U>+%'.?JRK.DJ#,S4K5 GCB_ UY!#X
M(RJ***L2M0[B=T.A3XQ"ER=_C1?&I]%R_8ATHR0^,2)]N7PB/<BO5 84N0;D
M^&)#CD^+'']8ME3?$..&&+^6&%\MSY63E.,T@M<5:T"'+S=F\Q,PFP<Z<+LN
M%O+CD\V&?2V1?;U<HH4L$<AU,# V5/C$J'!Y5O"P'J7K0X@_; CQ:1'B\BS=
MWGBLRC*H<@W-B(-?WYT<GQN PV52J6?E+!JKUUE^742P)/^"#\\^Y->_?H]7
MKH,\WQ#P$R/@Y=G&YZHHDBHO;OY7D.'&&GFP-?)[<-C_O7]T<HKXT36Q1UYM
M^-=3XE\_+!49<Z72?#:%H06C&P-2W1#EABCO2Y3+,T\ZB5*I#5%NB/*^1+D\
M4^4PJJ*@_V5\&647BL+%G\IU(,D?-UK?VFM]OP=G_?>?CGKG)V=_K8G.]_AD
ML^%D2^1DKY:H\YVIBSJ-T&@-SE0YRV'U1DF:K GN94.83XPPEZ?W'>1Y$2=9
MM!Z8Z TE/C5*7)ZRY[#(7EDF915EXW50]G[:D.33(LGE>9I[\94J2A7TKV!P
M)>)7\Z)*LHL-56ZH\KY4N3PXUIF:JCB)TJ!'+U@'!?+G#34^+6K\<6G4>)P'
MO3A.\.$$6)W.5%:NBSKY^'2Y<=0\V%$S"(:?3D^/UL5+L^%E3XJ7_;A$+\VP
MGLW2&TP5/BWRN!ZO ^Y^0XY/C!R7YYOYKSI*DPK,X8M"*8S,K0$Y;K+6GX)$
M'< 0/W[LGQT,8-C_W5NC@C"/3S\;=K9$=O;3$J5K;S;+DZPBB$%48EPWK<OD
M2@6'25D5R:BNU@($LZ'0)T:A2P3!)&ERH=;#[;PAPR=&ALN+A&C."+K?AA W
MA'A?0EQB_&.=XG ;.GQB=+B\B,>:@10VE/C$*'%YT0[Q"P;G110K&/OG-8B^
MO?B:VEKP'RQ4C'<%O\[F5(1N[5?@[L//2 /ZN=^RL'02T/NH0O.FE/2ZE9+^
MY:&EI']ZS%+2&Q^A\1$.@O<GO_?/CGO'!_WU\ Y^%2?;2-:52=:?E^@=_"?Z
M!H-AI5219!<())@F5;4.&4@;JGQJ5+D\CR!3)1*C*L8)R.C_X?JJZT2>FZJ5
M3XP\EUC+(TT3=,\$'Z,,%K%8!VMD4RCPB9'C\OR%PW$^4PB?>9]?J2);#\?A
M-R#(#63AP34Z_@S>#= 2&?2.N+7-FE@DFXIM3XJ;_;+4G,TKE=4J&%Y&Q3KP
ML0TI/C%27&(+&R%%SD#BROFGT0U":=9!Y=M0YA.CS.59($*%")B^2LKU2$?:
MT.-3H\?EF2!G:IP7<?DFZ-5QLA;,<5,B</W-CS^#P?%A_^/QX'Q-LI"^ =5L
M6-@R^Q4^7Z+A\7:=B@)N*/')4>+R[(ZWZU0)\,6F$N!3H\0EVAE%/E9QO1:.
MF T=/C4Z7)Y]<9Q3&V'U[QI&AT4X#J,IK.8Z&!J/3Y8;0^/!A@9F9AZ_&QSV
MC\\Q-W-M[(U-X;6GQ=/VEVAO $.;)#'SL[7(.=I0XY.CQN79'*>J(&A5'%#?
MP;Q<#Z5O0Y)/C227:'Q0[ZZ@EV5YG8W7I!3'B\<O ;C1]QZN[PVP#OE@>-X_
MZQ\&@]/@#%=N7= MF^)"3XNIO5BBUG=:Y*4:UP1G1CS!QRC)*K4NH+T-93XU
MRER>!MC/)GFQ-F)V0XE/C1*7I_B=7R9%_.PT*JJ;8)!-,#.)R#(XP'[HZ^#T
MV^2B/S7J7";6Y0(K9W%&4C[1H;H-56ZH\MY4N<SRY$B5JE QF3M($:5M-3PI
M\FE ;#5 MKH6_6^^ ;EN+.DE6-(#R@P)>L>']&%PO$:%+3<L[XFQO)=+-*7/
M53'=D."&!.]-@LNSF9$$I4+6>O5O?;FIGO#4J'*)]K-#E9.\" ZB>AWLDPU-
M/CF:7)[5W)],X-DE&LS]+[-$F\]%X!#K$R717Y]R4;=-5;=UKNJV__RA9=U^
MW)1U^Q96\N_!X6!X^NF\'YSUAR='G];'1'ZY*53TM*3N#TLTD=^K3!51NJ'"
M#17>FPJ7V>TZJY*LII)9H/^)<QK1#R<CD-2D^Y5!7%,)PE.%DQA3/[##I)S5
M%19@*/.T7A,5<4/)3XV2E]@CHAQ'Z;K8*IN2;T^-$)?8(Z(8)1*#WE#BAA+O
M38G+"SP/LK_K#!Y^A6(Z3=1D#>CQ\2O1;"++#[:9?P\^#H;H@.D=]T\^K0DV
M^QN0SH:5+9.5O5JBM?P.\:_!Q^AOM1;)3QM:?'*TN#R;^3BODO$ZP+0V5/CD
MJ'!Y]NZP'@,1EGG![AKL3'>Q#K4&7V[*(STUHEPB )O]ATD6O(VRST4]J\9K
MD#W_<E.?YJF1Y/*,X%-53/)BNAY9?!M*?'*4N+Q6B>_46BB-&Q)\:B3XTQ(]
M@K&:412O"HZC"FQIBOHI#IR4E\EL0Z ; KTW@?Z\Q$SG*@&B[%T4:DW2G3?D
M^.3(\9>ED>.O[TZ.SPV.\3*IU+-R%HW5ZRR_+B)8@.,\>X88BB*ZPG)A&/+#
M6];!7;ZAVZ=&M_O/EX<NHWYC"-HYBJXWQ+@AQOL3X_*"-T,%Q!B-DO6HI?AR
M4[CNR='B,@&/-4+[9U&Q#KU0-K3X]&AQB<UJP<*)J679F^ X#_Z(DJNUZ%B[
MH<JG1Y5++>ANRY'<""1\0Y0;HKP_42XOBG,>C5+R5:*QC1R3@MX?5!2#C?-4
MJ1,NUOFIG5FE^R^6D%;ZVZ^??NM_N4Q&"2S:K]]_^JV1Q>H\ZX5-AIV;&^OE
MPN)LGV;RYB\/3=XTV9^RD]\NX_)!A_W%UYQK(9^@]_IKD:#>^$WIJ].H,OU:
MGPZ_?- 2OEWR$GZ,BL__JQ;P8)D+R#4.BJ3*BYM.MOPDRP;\KZ@;\,W6\VAP
M>'+0&QSW@Z,!#'G8#WKOS_K]CS!Z6F<8^[UDMZMF_?"/>YX"4,S+8-&(=BJ\
MXO_^G_T??GH#@M^)HWWZ#;_]^<UN&,01-I.(J.+'.S4JZJBX85)]\2(,7CQ_
M\0J?H^QCN$((6*?;6X=PK_<P>-WHAK2QD:JNE<J"X<'@J/]G</JA=_:Q=]#_
M=#XXZ!T-@\'QP5X81,&A2J/KJ%#!."]FN50;V3'OLHT>G9?@X\]._NH=G?_U
M>W]X'AR=']*SWL+93<K+X/<$USD8E"E<62Y\LG*'O_=56_@0<H)Q_($#".##
M0'\XUQ^.]8>^_C!L?>BW[OJ 'UY_>VK\XT/_K-\;AJ8YI_V$QB."#': RF(U
M23*%])'FU[*9>B\"6A;X,<FJ/*@NHPHSBBNDS#_R(C474BV:8'BI5.71[_;6
MR;C*1ZI@^OV9R/>'!OG:>YVM?T/CF,^;'WG)9G51UA&L$$W;GQ_^/>-:H $>
M%+@D4Q=YE<"\$5MYD>?Q]M8D2JK+((KC!.D\2H-('_8R*-2_ZP27%6Y5='AK
MO+?YHB0;IS5:4 &Q#<,M>(^B,7:.AE_3&]C#,N&1T(;I[7)O^KJS]*#5!#LK
M#,YQ2=^=G/5Q/G#T2=.Q-8!I,0LU34K%1B-^,:UA0=P5"V')X*H2/DO..UX*
M;*J /<)]*%4%8RE@Q2^!7A/N$ "/S^%QA>P(?G45I379JMY >$\+-58)Z FT
MN#%L4<2Y]->7R?B2=AJ?C=QT_#G+KU,57ZB8;Y72L/#4*^Q((,_ X>,YF.0I
M'*WRZUC 0[B9ES8V6'":'D,RP\D^[+\#.<C53X?;6U@(]>S347\8G+S#MG+#
M\[-/!UCOI<OP?73J]-TA>_O(J@^%%^(I+(E_[P7GL+^\@W02\9<0=[5&!9^I
M+0PNHRL^O_9*(->9%LM3%6&TM^23>U%$TRD0WAAH_"HJ$B%I>@:<:;PQS^C<
MZ_M>?W-.:'64&+W>*NA?>7H*#0V/X4U09]= \K 8(%<NHV(ZJ5/X-<;I;6_E
MXW$-,\("%G@J@7'"08$# M>6]>AO6" X7SFJ*5$\33)=B3D*3HL\KL<>%^27
M$:^C,XPI%<&.\_LH0RAQ&J31"/4+,!L"V$_R0>%!'J?P EQT./QC561?J5\L
M:5TGDR1-/'6-US0,KE%R"/D@3\=YXZPO,I*LI[ ?R+/P:^9O_ W)9Q"_( G&
M%0B%'.6 _BO$25=%GI:H$VYOR5\I"GZ^M*2U+>"ZZ33/].4\F+(&#M@:PE[P
M#FX$43G+D7L3-T]$H4B8KYKIRN.<R<+ED1XY$Q/)@KR$9Y5T\[R9:+&17\-P
M87WX%[QJC/4:Z4?^S@H9.(-1%DDW!#R$LSQ-Q@D/FZ:GE_7Z4M&B5I=%7E]<
MTM/RZPQ^O4QF5(4/A#?U5T!2+5$XP0K2_"(>!6W*-4BTT$@T8ANMU8#5=Q8$
MKVU= ;3K7$(L0C,%YA6(#;U26D]! _ BAU]72MIMLP9&SOLK@W<$=I)I)2":
MPJE>Z<!G,R *XBV$R[G+P32G,46^<XVJ2ITJTE@NZM315D!9@TN1@!C]@PL$
MO*A75Y<YVDD*3F5D!P"/]\@2UPB( GDB/@/=Q:.Z!&E5PKN Z(@;\/>S(I\I
M4DA"_(RWE'0)'*VJW%N=+'DK PX.HQN[NBP>69;$T0V;&<!'LAQ.:C!$'#1\
M'09#X$_1C3E@="V<;U;/D&NI8HP=CD=1]IF2G' (?^7%Y^  SRLJ<!$O]O^P
ML#)J.)Q??^MQ]4$IC5!C38&YQ:NDRH./)W<]2)Y.\^/>_LY89-Q3=)7M;QQE
MCT-/YJ@D_R-U<&YC=&3C:(4,SRG9-RGH=S/L<U]JXRU"?9=XF0A@MG%+18(,
M)?=$4:TR+*Y<1G#8=GSU3AB@*< ,B_!95?PKR.P"1+9\!KU[.@(K723Z# 8"
MQEV)_C-L,I.,ZHI>&:LJ2OCMYF$P!]1JJZ2D/^#6:<[?S\"VBR[H8PGZ(WT
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M#Z/"Q<!Q;(2 C.:J_V@QSD\9B>TA!N] \-!3RE5.I F!NS]42KP]ACV"B),
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M[6-FYA1D$<0VTE<HOI)<,L4DM[,L:U+/."A#81]-G3JN(B==$6ZW3D7O'Q=
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MF#R!T*;:>:D;MP10_$PE6[0B-GD]MQYQ4$R?:2-+'V^7?*4!-=+V9RJ,BA'
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MMF['*21#(5?'E8XX4.YF[<##9!#F+U.=G]V,-C:#458:@A;&5K4S3<G=D\,
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MM[J TV%T$^KCV[S5G&:)WU'V+K63Y9D9O9MG1K_QU,PO,C-!FE'C=#M^[_Z
M=2[6S16I>?X@Z1CJRA'Z5E #J=B1BL4H@_O2%60@8O/,\TME.;-P"6]!N^QZ
M/6CA.DD13**D\!2V3"65M,B$W4/[%KO!5C!U-('('YX43IE1>#%C\OBW<43]
M07CG[/"8<N(":[;%>T$_,C=$8]-#3?I=)!5)=PK--H0Y^K)@#8M,W<S#6L/U
M5,U1BR1IC,RLR5^BKW,\/D1?[)V=#PZ.^JRJ#@:+WO\8ZBIZ8?NG9_TAZ(.]
M\\')\3#H'1\&?_3.SGK'YX/^,$!_[#?WQGK>XA=[^^@M_E@3//S,:;\H&_H'
M1=MU:02/E@RUL%)QS5>66L9*@6$F.XPOH'NK7.C/?3SW\[ VPP::C.OT1B=8
M(VNFJINIDUW/8HY;UU.'=_S20BS2Z-IH"AZT2TJ"&$?/*ISM(V^V.XF$-+0*
M3[[V,JFD^[@+<:MN3&"#<\D96@+[212-\:BV3LN%V*1(-,T^'Z62O@FZ@U&:
MI>Y<XHTG^@Q<AU5F/:I(5C*C9Z%B3+J+@/"4H&LUER$PKTJ!->K2P>W1M4N7
M-T89F$'N8<C9?8!AC40R_%X1>?):;C)D<\"1%Q-PK;K1Y51U4VJJ#(,+*Q07
M!J.$2<L.!B&D,-2Q(M>)B /Q$S'Y+G!1[@4]FU!)+:$$ LF5W(K*I-AI<%$K
MWD*:"TU67X*+,UI%['5G[%&R3S 61/D(!-,D@>VM^]. YGS?F@*>JG-G__G&
MN[/4TQ-[IX<<B6@?&(& D'+*U284.1=_1!5S!TE6@_?D(IM'$5+<ANP6<MQC
MC@X5T 9ZKHWSWJ8C!&HZ2_,;*0-IBHQ(]1%&G>.S$\+T& ^Y!O-+!4HZ5 28
M)>&,P'G*9&.(0XQ5C^,K8%>PYV\<&0/'1,TJ!ZKM3XY_-K4#"<O-T0@PFJ)K
M+)9%L2?I7XM1&VVD<*M@F$[%S8QI\29526_7K\<"&^[[XCQ3NXWZNHVJ!#,?
M%\-&$P<NJ%9PILO"8B$.R8:46JVJL+%#0AB?8^VO&IY[B#HZ><5UD.0$%YQ6
M]9T42^B5I;)MI71WR$_'E!97DVZ _0/&2:JM52_EA&JM=H'=J;LT&BS#D[<#
MG))1NRBX0OG0>D4(TX$!15Z^JR1'AX6_AO*E[)-3 YFF#/=+7K\3WD$Q7"5P
MLF[&<+B<- BGEJ,?KEA%6>H=((V>)]A0;$C-"9LOUI&1@$X@N+$S54;#RZ6*
M,E$7Q1NI3! WRG%S[W7B)Y.2+W3:]E]#3IJ".?*(%9CJ$S;5[ZL@MKJ<V)GK
M(].I+UIN"F>=6 H:0IK58M?T%-%!M%RPZ)JB.61(Z\[>F$F3 $.'3#F%IXBE
M'+AW[KBH4U.WOG4PS,6M7H)^)#6)ZE2 Y*'P)0Z\([^VT_>79P5[? $'94X;
MD)!#>^P+,YIAH:NE4DJ=+G_7H5D1V_UWC7E:7'N;ED&G1MIZ)O!>4M\(A]^B
M*>&/\G966>]PF-3RG2</6^=+/DLH9R,[*F4%6%O3;=3#3-!X,CVZM"T5.F5:
M827,\J)C&VXT2BU5HVN="QLI/K#7$\^&P;,SS1E4-K=6YV7DE)S%2ZZ!75:P
M5>*CU8F<'%$ERJCNL1JMHM?BGPW%5R)_=,]_>\OH!AW!],6+\,V/8P)DD@L0
M[$LRK:<Z^94SD:NN[->PU7]2*!XVW.*YM7/4T6";U92=^F71S&8:S>T<J16;
MCAZBZ@LIBT[AX#+H<KNOX"@V7'8$\'2Z@KE.N[+;:\=SB]PP'O9;2/-24$^V
MC;%?^2?8,0$9[#'O%-V2^U'_U4_@0 YH?Y\#S'O-"UT+I!161\=(I),C?9SZ
M0# (O#5TM?CNE\%&74=%_"S-<^H581["%T<)%OD/M61T'R;UAYQ'FNZGH,;"
M^<9(X3@B5@R*&*K]H" E)&:XLU+CU3 B*B"I=ITJL>PWH0)4I1<?,[VVK ?5
MV;IKLW5N_9/7W_Y<1[MP&.'(=94UQ^4R$Z6UYDY1[&6BD>?7&=<-9X."[( \
M%3.0W32XX"5\A\[8ZXPM KD>"T#MV+A'>K/KY@2NR*UZWNJ.%YAH"N?M=Y4$
M*Y3V]2 &*9$<< J66#_/BMQKYT['=(MN:S5-=\\J3E,(N95IN$;=V=#]88^B
M]GUK?S87X.8L5?&06BM)_*?S7*8:8N$8I:;<,'L_W#+B!&=S2H#KO TTUTLC
MJ/R*>]:JT&X0_?O"FBC&V\V%N\F63DPV%9S8Z[Q.XX95TEH#/;32G95-3+6>
M\B?K:-S?.!J7[;A8S!E=F\PM3<5L(W!H<X00LPEJAE@*T1R#$=:A1GMJ[/0=
MI'YZB)Q6U67.Z<4D;:5^!OV#93$4-T0R?0VE?BU[I6!0K"K$TG;'JD2=' XN
MXAM=G[ZYZM8\]7_!AV<?\FN=G-[J#T*^B/O5X0_]D]Y<!'<-3KO48Z^LTJ_#
M3X9P+!7\] J(X@K+#HVC]!F1VFN@)Z)PN&$%?9#1T8/*21Q5F,*5F8BK+@Y?
MUBEKD^BG+9*I%]36?1]-[KI;;\ Z=]#B"#MZXKJTC2XS,MQ4)2T2Q^,:"S22
MFIJF+>_!*DRT"Y;T'=I)6[#KRJ[L8*\2G7 8L8/8J7*-Z7"B-CO1N"R>WW$7
M3)<=U)'+FAS^*I/@,IN%3O^[SJ)TIE:*4[NOL](J#[BST,'Z]K9 =XNGL!CB
M-,-CIP#6BU>!T_L-_IV1]49&QJT\:) UVJ\$.XU:_NAW<?-8(DK CL)&DHHN
M)V5L-X'<[R[0 Y$,[S'"TA3^+NA 89G(@)1F%^[>$1!EN)6$1,F+E:4W=Z@K
MW/7J.9-AC-^]:[*OQ$,#EMR$<O&X+J)V:C71'%I4$PX&I36J->-+9 'B'N;8
MP15M-PM"%MP[1IF45\"2L2.-\:4S8!^@)QF0*O6@JH#D*>184,-&1*CR"\WK
MFE5.<,2Z?(C)FKJ9OPM[3H=ZK:SKY![)D!8MEWF&N=AVN7-S@>C:4*OY7@=U
M_.)6-;^;4A;JYEU@CGF*>9+M4>F O*[0YI@FE7:QF?SMT.<Q)M@S*Y*\T#[/
M!IWK)+Q2VWBFX)\M;K=@=JZU96M]FX'?&9EB:M00T(A!IZ9=,T5R48Q0,9W5
M]>9IB+N7GJ?N((>#$W'YD;V6HV@LO_K+LW+DG':JVVH9<WWJH1P;?63(T7^E
MN*0#I==Y?D;?YO73_@2U[.3'2;(HN?_056]QM6X4F''[ KJ)G8R !BEU'':$
M.LRP.!45A/-[!NH72LNNY@0Y:E@X.83ZRLZYKLA]U9@O\N&4H.Q&LKK5AQLU
MV:D8L:,F2TEU>89&_SG/<>.ES1BS7*\:3V2M^TYMFCKDM' ^@24G# 4H"&@A
MD1WA85:'Q?9@'2R?  >R2-%GY8<2I_)-KJM'5OFNED-H'4;(-\5$E40>H84[
MM)9JZV8D',8D')+I#.'C$GVL3:E*(Q?:\L"TOG6%)J</FBI<SMCN-#*OG<HW
M]U@.)@MD35*Z\YH(G^(6>*V=KJGPA'3'HT"?=ET3JMY9VKS8*:7&OP2$\NTM
M%FJ1=+$WLO^V=J!F@]#1+<7'.YD6D!BQP$ETE1?,VYR[J;>[353*%ZS*ZN-5
M/S@0<U\&.FAR3_PU\>.,A]+Y3[I3N; 1BL T$+UHG:HO:/Z5^F>O0GI+M= 9
M'&3+WQA#:%'H%=/YS*]A\/[C*?SGX)0YX_NC4T:.1T4L!JEE,(R)8QC.!:K%
M.@?P!H,D#NA8C:*BT,D8-W.J#R/KE%H) CSN\%.TP63T<"(5BXZ@'G/=A4R?
ML,/WQ<;A^XBG^Q6>[D,3<I6#_>=!__0\Z V#D_,/_;,_!L,^?(?),,.COX)A
M_SQX=W)V_B$8' ?G'P9#L$_]7)TP..X/\,[@%'[Y*_C8^U<?TV?^"IHI-2=G
M3D9-J%^"7P\^GAX-^H<AW/*^=W8X.'X/[^H'1P-8Z&'_D/CRX/V'<[CK].SD
M\-/!.=Z%[Z QPSO/83]"&./!T2>ZO?U^Y_5_.>_YV#\[^ #?]=X.C@;G?X7!
MN\'Y,0[K';Z!YC0X^'34.X,#^^GL] 16!WZXO5OPR?&SP?&[,WA%_R,,04MB
MN/=W(*)#>%5P\HZ&>=H[APN&P6 X_ 1SA2M.^\<XMJ^RB9:8A;6*-"S9<IMP
MM3*3\.7>/DQ=VX0"SWB T_T;(P*PC\O?QG5T9W/+]<*PL7M1M"S=)B(HXG9L
MU]BEG# H5'=@!YU/5.#"NN5W[]!;-LMA:<1L0WEM?)\"^^EJJ^(@F'S+SI_>
M+JL6II>#%T;%#D\AI=7CM];":5B_!Q;VX)E$#_:%HQ8<^KYPIX @ 8&D$;0[
M+*[$1OI0A):%H#0FC?K!'A#.@*9TDZ"."+7K?3>^JJ#;5;4(\O+-"K_=@6Y!
M$6^0Y_;6>M%G*-Y3QXFXV$[9Z4DP<4'0T:',[:W')DU]6N828(/XNM 1+NT)
M+.RM3-,P&G=:=(DS,7<076VA[O;F1>+WV]7O^RJR9JYK>?FZD#4&+4W]+>&P
M3@?TN;T8.[HP=K-A,C_A4%-1E6;?KF6QZ%M#EK<2EKF #4U3):J!>IK4A0MS
M<E</8S5%7E]<!M,ZK9(9N=,3@E%B*-<6M.<%M)[?U11E,/N#(,KB2G$16[#U
M53H10+TFX+E%\AVFEWA,S]%9NKG>H\OCQ4QO/L2Y@]$9=,B=.)U%H#SDU2N@
MB7'+R6W0>0X\U0E)>3&''6I#(6X@<@$V$/Q2L*GC7JEAR.S(=)[QJ.5N#?6$
M/GS2*JR*YC2^N</>W":%GJ(SY^7&F;/\-.&O,>K\6(.K1#BL,[J;BF 8M6GF
MO!::Q4*%6=TEH',,HWR;YN//5,J?1ZBQA V!T\%/UTG>M)7L+@GY<.&S%+''
M'9?OTL=(6M1V;),)Q.EJ\JMHJ(#@6IN\TRQ VTR1DHIW8XJVSH>DF':P,]T.
M5GLKJ$-&,C5M ;PRR:$N0W:G@*&&NIH3?>ZT2< <*XVHG32C/2M&;;S<>T$N
M.JONEK9N_K?VMRW4Z<-NY!NPLG:;)L)98JSIM<-W?/4&ZYR4KHXO  \Q%-RD
M9Q,#,XT8'?G1UJUWYZLE;WST<N0G3V"]%,?LF#NB^5I/1R$)KPOT]M9B]FE\
M>5*P@B;<$1\CG*RP-,)9?72;/S8;;S7 V 3<I++<?^<)-4C32=IF_".5J4E2
M4<5."V\R$T9(%NNE=@?=!=*UU.UV8XFYN-%;6B=CN:%EK\M,F[B02)V2HO(E
M&&<C6(GK5=J%YM 4BKNGF'ZAJ3+8@,@40FTJ^S0I]S0XX62GRUD[JMP\>YUG
M9!&LS_,\.!Z9SAJ0NJ I5H*6O%OJ)R#A8#V_RRCFD/+(!3:1I;R'E,C()YN9
MV$I')Q*UZ\%H36=]PN:J"WS93D52FFT!)0U;)L*TCWICD,_8*?4:CA3ZP6W&
MX0('1Z%B[!- .5<(I4R0AA![SZ3,%<@)0C"[L?AJQU.[&IOUW"<(%\>PF*Y,
M>5NA@J]42&5=P^#7P6]3*BU;!O@O*/\@^@8K$'V-N1*,LD=U_9T3$=]EOHV,
MFP;TTB=5C>Z*KJ(D[8#<J.:;[Y/I@P1,N.KY:9*!;B<0Q6QV1>E#YHJX?CG(
M-L^*#MO73V.<3Y47V]!0DP@1=L0LYF3V>^:5%^BQ14V3TB*R;IRDD@DGFW3F
MB#S$?ICK'YF3^-^C'+*2+2"F&E(CYE'F/19V_D%_N;V5X/J:,9M.%YA.C<-Q
MFG#:/>9QLL_:@-RHEO)M0R.<;0RG6X]MY(-AJ=36>!5)O8V5(5R9V< 5-K>Z
M14MO=[ZH9WG6*#@2L@";Y@(?=8J"55:;U1*L@WYWR"1WNFCCH^+ 6Q]CR)YW
M/X-$"CPGPQI3.6;4C:D8@C0LH5>W'LS*%/)1UK$E$0B+#VN8<.=M++^\]V!5
MZ5AD<K>9_X0]ES]L/)?+UO0'$V2,!,G'8]40/<UDET),OT8Q@+:+_C:CL--'
MWQV\P[-!H81&WJ'?&,B>=:]X7BO=WW-XN57?\9)&B\."@)S-0[<CPJ'SA2%+
M68>'7'!Z4!<3"9E1S,NB\/5_G;W8+++$&8,@6=OB+9])-52VNTA^C6X<L=O]
M+%<Y"87S-&=AVNH(7XNWMQJ<U5MH4T>MFSWYN C)BM,O, H>L7Q:_,:X=6LW
M'9>55 -)JA+3?-7%TW]?8 (\$FCOL/][_^CD%'&.R#!7#-S[@0NENPA[QTY?
MN>[A93583I0B9MS3_@X38-@X^K[-=]#I.Q[Y>[D$2,)23+)BK/UUQA50&>ZF
MPZ9Q#EKI7*^D$SMZ?Z3!\@2;UUB-9AG.YNP^*S6SI\ZQ%;@"@(JU(P>XQ 7E
M_J"B;M,$[C##.; T*0QE*OXI;-AHDBH;CI,L-BX3T&LP=[H(_EW#24:%J,4P
ML3HK;TXWSXS<B<8*Q!+B4S07@=LQIAVK<EPD(ZE&Q5<]<"4ZT_0=6!]\1U8+
MI3EP)"K/D NVC,.8B4ZRMDGX2H&&2C<YTL 3XI"Q]'VF/WB">US,F/\H#7_%
MBAUUB1:7U.>;*E41E$<L['\.#X(=7.QZ!+8K!?]@@TK,%4W*2YN\"M>M)+[3
MSLN[+2_)7?\15^[$4";#DJBZ"F>2L,<8N$!ABP-T[[B#TZ6RL*F5<(Y;2CS0
MY1T?AEX.<T6"UFJ@'S[7 =.D>Z^PP2VO,XH'V1W<L8!/ S74;;W32W^$P_SM
M\A^#6],?%T_598MFUHL6$I8Q4:9.,*L=);-M*87'!7*Y'+"4Q+2AOL6CV5O_
MQ,NN"3B%)EF1Q@B**U!N2[:<GX1_YZ3+6R@ZF4A];#@ZRQO="DI;-Q2I%W,5
M*:5<_ZSQIRS2:1:J,4HUMOPV/29X5#7&3,A18PB]^/5JC%*WJ3&-2A M/29X
MD!KCA'OFJ3$F]/.X:LR"O5Y0;HA/ZK=48^XF^E"(E%@LDFC/CWXU> $*%ZXQ
M0D&O5E7I6PGE6RE63])I]VKCM'M$44"!O<.HBA#D=!EE%WRT/I6JE1\^Q[UD
ML$.2^MRE\6"1.*\LG.;3V(,=J!X929R/:ULD;D?M7>SA.ZI\G&-!,0)G"(^B
M1J'([*/T!HYH,$NCK-P5SDJ%!]"7A$S+/7$6/W<'I+ZN/T C[ZQ2)[B0[:UY
MP!8#"\2_.[R8 H&(%^%2/(]EM\.KQ=#N/1FE;@7IN'/9WGK 9.;&$U;D5_M]
M)3T)WW\ZZIV?G/VU!OT'7[%;S=G2,XW2 6%K"YBO0UCOCFKH?9"Y=ZC(N;VU
M.$TRM'B^1QUO<[B@%J3P/.Q"JX*=?1G"Q^AON.QC5'Q6%34,JL@GSG$,A1Q!
M*0T2V_\9[;>LNBS%9O<0$=M;W-##AQ WILB:1U!=Y\$E*'%D8L-:E=3U!939
MJ"CE9?_QXOGS\/GSY[NA;LV -OD5JK4TG<])1GCE3/>)Q@+O4H!*NV"H<S&6
M"M%AI#LLTV*NV6T1(%2M;1+X,#)4.,E'P_JFJY%%=]3)SCUTR,)N#520I+I&
M )D3E'",@!U95/9%*;4K\T+[*M(]"4$]1O]/Z"5(!T)[51XR)-%TTL4W7>8I
MNB&H3_F\7#XK66\KZ+FR!+5;#R1/O<LY?R]V<BNV8WCZ;/_Y2U/:4O0@T_?4
M1?BSW3<G,CE?GMZSF &JU5C-X-Z._J4?AV_GAG42)]R=M&Z%K_+"=CWJ\9RP
MG6^[S0?K3'S%->CNX8/MFNE]7;!HF<_QP0;W<L%V#6:]/;#<RGPQW3S$TYF;
M3.9E>F27,$S&4MQKG"L&VKYBU^Q!3FWKZ=RL4/ONLOW9Y&_7AYN0&_4J@2=P
MWN*4&P$5P(C,H>O(]W>5-2RX%[$:&F6X>0E64F/M\>7S73!?;U +0L6;#QJ8
M_8@J >DBYV'/;;BJ%50P921#A;J)3R+MWY-!.K!T=T9=XJW#'R*U2IMW2^!#
M"N02_N26V0OT6$>$W#NU:P3=(#)FIW,F%2%'DRU&SVAI*R2(2*;EJ83><]MH
ME:<]KZJ=XXQO>7J"MJ-'8W\P1R[/J5*%<SBE=T24/F$_Y(\;/^2RM?/Y#*:+
MT@2M)2=+O.&Z:4C-\I!%_5R:[B@>XC&=8 ('0SC.J]W@K>XL>(B<AU4J/CWX
MYB:"KL5ZP#J/ ]-"L'O .H[ASG:>&X\0_AP@8>AB,M-M+N0EVUO=;Y%BSK"\
MU%1*-USF!KU=!F>IV_0YE9V[:U+VW/Z=.DXC$9%PSM0<SC#.N9^C*+M^BTX.
M:>%T=+988R6WM^PD]W1E6O=]<2Y5(QH+-G]'!%19-C=S(6E&1LTKZ^DT(F@H
M\T.CF_J1/1!7M:E9K1T7HEA9?LZI&=*9&[0DZG7#)A,0^6T[LXI$JL%DOD"I
MJ ]?SDW.2^<X)V3N5CJ9CA* J&JP>4AD(VJ<12B)?#J!\$JBJ9%L"IUSJ4_N
M5.R8M[?S9;BNO%]11\0DXW9XTKA:SZ!PQY<P$PF ?S CF<M$9I5Y@SQI!PT@
MT''E<5@QEGK77NM LDY4N,.+_&:H(P6* _GRKS%&K'_D%TDVPEU8D%'Q;@))
MYE2F7'#WIF/@%%/<T6NB<V#-=G /@7D:&W,THZ5Y"MS*%?67#:]YSP2+66/_
MA&CC)J+:<6<8%MGM!'!0?J*(6A"I#4LG[5>HQ_*#>X673;Y5=_>?MJKKE+RP
MC@#=F4F@4$;-M?.RH?]97@*M&9GIMKXP8VV8C4X']DGC)X?EWME5;+8(!IP;
M>>!LC 0SB>G$,5G_MI4U*=MN$I<1;EX\35L&VHBJ,RH$L3CO'5EE5,1W:S#6
M='R#V3L=44'O9FA39[!AGQ]&Z.#.C.NB4*T<:;T<@K2PG-O!4#C6-N43"G,U
M#9U7?J8IG:T77RE<C3[WV#E3$J!>H2$^)SV\V7E]5-.^@T9+_8%<O19#1#H^
M0T&@FV!G_^?GNEL]"@PW9<SLD]NEPT#,G;1/RE34 L!6BRVCB1(3<G89%=-H
M#-1QD:1$!U3L/*:NOZ:[II0_:";JVV*H+*Y*_62*9,-P"AV?5H)>"(/&_A5Z
M_P081? F2FS1790$;"2()ZO*1=KMM+VUXR7EG+:F9#Q47HH?&03F*1K9QO@J
M)0?,.GJ0%XUSJ@Q#"D:272'ON)"F>F8>H3=?TI]L\ST4GF-54-B^L1"B08MW
M@9<1M@(8U]1X*\ 8I/9B5(F0>++NY_WOFB%K@BZC[ZA2/PH69 M7>7K5?FNS
MTQS'N-B333(_;'6P$7^=8A>'5PX%7?].=P"\,P7.Y[F969=9L$4VO&5T\WH6
MDUF83(Q<V=["AD"TQ"2.?//(\P-)\2UICM,Q1MM%N;.RP.+1<F2NLQR>LU:B
M2<U?*SH_WC*M$&EO9 _UL/)K@O"@C<#K '."%GC53>(+=)<N1O9U;\<V&<5M
M+___)&'VIXW/ZY'+8V)X75?ZHS;M!!%.\Q%P-4?6C1#]IK.\38P8[S,P-",1
M_+Q%I,M^=H'Q5LWF77G!R9*1:R8B-]%6HB-.\$Z/Y*6Q*SJ=N3^*[6U2P%97
MQ/-'BNZ-P?@$/5 5$N8Q%J!C4VCWCCL\XZN&YWN%UK3O>GO++5>UX_0]=6QL
M-E?%8#!]].@1]$;G$;L>:R>8Q-UY[CRK67<U;L]/R@3I*VKNTMQ9@L-GZ-M;
M'0X[F>-4EW4C]\BZN8D:.O<KMJ.G*D8G5X^K)<W!GK*?AL-Z4DQO2C=6*A4>
M;V0Z51\JIIY_Q?:1(S>+@R/R]B2+M<W%[76=DJ_2>-$A,Z8M+)X0ZG:P%(0U
M,5MM\S:=6=)1Z#T),P*^IH[?Q+-78;/-#SN1FQWN+5NKOH2I*B9^%5$VQ:5
M2I@9G=B/[+WS'CNGNZNKQWLERIH1S055C=J#9'M10!JZ8&( 2LNELKH^!GAY
M@UH'"DMOE?ZIB17'F/E0\D_B+\3RJC67E8M:TVX:(\)_NC4,[2_O$O]=8&,J
M'8.GOE"MEU$'38IQH,>_*%ONS(X-NMUG0P!@-4X$-R"1Q+$PI>8C=5Q"BR6D
MTLXKV\?4[;4%XZD+29_H*._F<D_1RD+KJXIBX&=(KG"H<L0"6@/"%7!H?1;1
M6"#."08U1K691%T:Q()!?Z^8Y?V(+.\XAU-MJTP= -N"=7!"_N[9B,:FD9AK
M=E]*9HCVF/(1,%CN9A8>EF@GT(OKNW'K+&&()%4:&)V40CW*H,]GT0T+%_B@
MRT&X,"P+R:D+#'!T=#C^NNRWY>&]!]^^CL+PT^GIT5]K4$+A1\9Z2T-LZ_M<
M!]=6!P!9W%H-C=F K2?1&!'J7+8- T@\&9*M I4] :TW"8-!E8\O:]<(5-J_
M88'-M\$-65Q.^)GT*'XL,>4Q%PC6O2BYT"O9[\386WD6TV9MTM+LB<.I"$J'
MBC-")>.<^G>CJ%N1\3Z\I"ZHK04 J9*2>+5NX,A+"[EM63H[@\8:BJMWPFP\
MUC>7V(;QU<G[0A/<[>I1;1IG(Y\M<?US5A'L0,@H6+357O(B<[U9BM('6!X8
M8%3I&7,9O: */=4\[7OX11YH?4#-+O4$^8YH <@OD9%S#J,%,_:;X?,%L^C-
M0:/K-1"\">!W=LD/,2W N78-\"MQ]E*[#D?<6EX7>>KT9*>&Q2)P-"+3M6O\
ME5]EUXL%"65"L$X8"&T#1-#.*[PD95W\U@ .C+0!SR!-+2(;Q93%(H#NC<6<
MVG!:Y]4>DG^'3H%C;1Q\/'$LC-MYU)P(:'?8,U,78*-IV\1&/]D)_-6%=6PC
M81@]?N&_QPET5%*B5L#D5(&12T8Y>1?3L-ES%E'G.'TV^KRS@6\5MMXJ(^:;
M#F;1FY$&<W'S\+5,/=V( =''8^6>S;)!<Y1?C(IUVB**B(O2WYK#<.L%>5T]
MRR?/9OGXLZI,X5==P+3DO7%+AJ)3ELZ,\V7LE7"[W;&[X/!%8 )5K>F.\OQS
M*=%D8V"@<U>P(/Z:=J[S3O_//Y"T]"-%)P$S?9"-<Z:H%\]?/-_=[=B2"._<
MWM()WY/DBV)?H"'2N(%:==5M@YV AS3*2;98-;U"E'E-D]J;Z #2#7, <8YH
M30OEI2/G^Y><^7QE_TRQ!)ZB8_SGC6/\$:T4 L'_ET0</9Z'.7,7BOPP[?(*
M+17* =&X\9^6R-EQ2DW<+W73AN4<2=P4-5R?GQ:?$W$BYU"E-QZV!P]<76)%
M5A ,)NAJ#K(#8'7$BYO9OM(JA;^OI+GPP<E';/<\@%_^FWM"KSZM^B<VM7NS
M&?:3T)E@?=,.[U#[J73I0D-_.IS,=Y8.PR];$LRVUXOM\RCSY?;6A:U2K9XD
MU:,@PU:R<",[&4>MWY%V?R2C.?FOX>GC,+XSPG*W*:G)'6K$]3V[,-K!Z,AN
M1Y<6'%/#Z4H%GV52K3"/MQKM.-#\=C#P5U(L?)4#P_"7)5RP77FA@=Y.1JC4
MW? 20\4RZ-*5.!3%KU/H:,4D\3" [4N;+:DZMV#%GM.?I"_0H:X"])!:5?X$
M$1^%^75YT6JCW+497F6.9EY %\Z0P%43;&]Q#SGC&C7;6W/'3G9:,X$XN%.A
M>3\9N9ER/+_P\7VFK#2$91I]2:8XX#)*55?2N%<^>=7%[7]BA*_FV""&M?XA
M#CR83#V]4^Z^BW:ZOF3M!;M\M?AFE%D.L[T%/V \>U='2$(G2[1!O85QZ1CK
M/;+N'J?#IJRT _76HL3A-!+FBK*N1+^6=PF'.?)?YH;DDXD)U@C8"W08=86Q
M 3-7,O^\N088[V $V*5))</AX/?2C,:<TQ(Q%'8-8H,S=\>A/7\Y=L735ER!
M+6[R8A[?@Q_9<YD*_]5_A<VJXHL6= ]HK-TCSJJ#G*\4.<8:M>DQ>^9XPC"H
M#4LDU^3<3*[ WL%6'7:Z>ABXU\H9-R-K?8C\]M;78N0=?(3$BUU@-7E[%G5/
M['0:6!BT]P9EH<]L#'/OD0X0]"0O-$I53W/U/.Q5=SJQ&UM$W\=%AFQ$QQ/U
M8>%^9T[/I@985;(Z(EOGCYSO#(+7Z=>+=@)N+?*R%)5)-]F@DG@]UCE#+]*+
MPW)0#":%1=Y^C1*'0P&S(J'8D0U_EX1!170K)T2HF#P<#L9> L8:W3K+2PK.
MPLTFM<S$8S7L67>+$R !(Y(PB$\O:L_=&6V[KUPS] -$<:E?R:?#72-_:9HF
MK8T22R\YKN18>JD_5](USP%AI6D^-MM4-"I!(<0\!O/;' 4-P::V!4[ACX.#
M#O1.4U<62 !IR@)IML:,JS=;  <ZW70ZH+-0^)CJ_P.XY2\;K](C\D*"76BJ
ML;U0N\UOTTK9B0U:BWE[BQIK27CQ:UHW1T&1WT1I=?-L4N"S[]>D66OLHBY)
M5*SI'9!@GA0 ]/N.88&PLJM%\UR>3=-NVD:WU";D%V W6PL=:^(6&6GDM_EJ
MR&87R-YRXA>,\L&XTT6=8$0T4V5';T%6#I!5.) @?ST:[3PISXN>SZ+L#H9A
M3=TI18-VVNVF^44N>@=]'601$JN1%"811K^"9'&<3##4T.PYI7>/:ZR1/4 I
MJC(L?+0;\@L:V2MR CYJXG]0;^5EN@Y7 ,UY?_)[_^RX=WS07P-XSL_L,_PG
M.8F&E6+$XX$NG+5"E,X?.GZ9$,KZI4X<,T6I*8-L<79:6ULQA<" &V*M,(R2
M$[Y<A9)H' HGU2H?GT-'B<I]O:RK::"CWO @W)JPS8JE+K>[0QW6O-FD:)[G
MK2$E##3/RH8F):P(XX.6 >X%[=#K16/X<<X0Y"N4]S2$APTIV0W.;%DA*=,@
MGDN=ALQ:.ZSZ]\2LD0 =Y1T4&ZPO<:%U[KM4UR7YKOMU.2 BCO(#Y<0< R71
M0\ECDC]9Y;MO%G"Q;[1FW8OF'!2Q)DQ)=ZD]3NE^+#9-X^IUF$Y":!,&EN$>
MUE.I-U5*TJ$%2K-31Y\SI&0?BMH-6]_>:N+6X03N*.FA_8:=J:M>AJM=] @1
MKHVS^4C+B&NV2+FXMF>N$58%+&*M99!_&;T3%YE9HNTM7"-0>*<U83]:R:\-
M%HO=X CKR,8V*Y".3ZK5_J.IVJVJO;-A:@0G0XTR+[G- W;$)CA,5D]'5.H4
MSP,L)A<CQUHE'BJP,Z9,412EB^G8FA9[P2>NO>.**>MNI&5FL:2^(!QKP1BP
MJ."B(9CIA9T-SV$!T$R_SH.=%R*^&Z\ F]WU4W*!/08W-M)8<3&;XW/;0-+[
MN0YBLT=@RZ/\QM'5#: =;L+*$"8G4]BYV_K RSGA@ZW@8!/'1P4/#0Y4BY.L
MQN0"QG4Q\#/!XF=&63&)9S)93?51LZ:1.U_M5H&1K("FXR9-8RDC6Q"ZNL:E
MCH(;%14A!1)T3V*=40.K2Y4_HE)#W7!]&@T/>_!@?(5I/"$^='%V2?E6(/O9
M99X!U>$FYL^0'P!KD.)&W"RDY,P<X\AQ"[]V>(I&,&[3'(9OSU2JK2?0WKHJ
M4[A),O!84PI+&K%TH2?U>=RA!IY$($BYE]Q_VGJ9L60U+9SC6PP4V*3Y#=7&
M]0]"X^%D27+E+DVZNO 4+,F=[/ZKO'*:Q><C3.2 57FZGJX7SS>>KJ4R!%!5
M#B6WRWJ679$'KXP)0L)\KUP/U=Z.V67LWI"!4=19E"73O"X#. A:NG57OV\P
M:2NWB;TP=I[+P.ER'\#\\:F+F/BWT]H'+%2X?(N1AK@HII!=(2%Z9&1EW2Z9
MXK4U9KT8(:9W+$S&H>V*0I.E7SE4ZQ#X(?.3L8'%A;A1M\KZ4)(?J?H>O\95
MV7=Z7I,!Z^0[N$S4).A_4>.:]O4$:XJ@FJ33THK*\WAQ:L_;1LN"KWH:(IQT
M698K2C,VGK2ARE##,0]RO6F@'^>N;+:%N5U\;P/>*S4>X4).8$?SQJ0USNIJ
M<4#Q&UIC@TF("(!9HJ-PSB0D78>5VM82D4%2<V35F:-.@L=):C^[6Z.1J>[U
MHMS!KYG^+_>>?F_7S=FGX3(FLVS4(Y2BN!S>RL<4,-:-R[@G-=*8E%\HU'R?
M,D_=@;+. [F/2?63+%_2@Y&Q!;KI-9^WQ[!E[[^*;QD.;X%PVH!G)8PF8)1$
M,E%;[>Z^<OYKP.?!CG^'9@TPZ 198M:!#L'9L;/3GU[4F!PFI'T9"P89T42F
MIK/4U70+#GE^  66IG3+ZO*:KAJZ\#.#P-D7WO;0_B]QBA]T.<7OZ1.WM1T6
MA?9N[].U7/_VBU7ZMP^>GG_;P)/P<'ZO<1!S7-MW=%D3Y9#/VH6 H(,1E<<;
M_?2;=7 !=WN FY DJ^H[*6WZ7.C*>S$UZFP"I=;$R4LS7;J7ETA^!/;/__=>
MW@/'?G2<O(BQ_-_AY3U "^TZ!_/GX5[>@Q5[>0_NZ>5E]7%[:_E>WH.#)^QL
MV]\XVQ[%^WYP!^][<#_G._?0M=[W@\?UOG?B-!_N?7=&?6?G^_;6-_&^'RS9
M^_YM%=AN-^_!TW/SMH:\<?/2HJR)F_?@4=V\;2"*HW2T/(;A(E?J]M8#?:DK
M5_;OZ4K=WEJ6+W7E3L#[NE)!KUN.+W5)KD1K,2Z1OSZR+Y6/]I)<J<OVQC^B
M+[5C>@]QI=H<G[O[4E<(*Z9,5M G&87_,<I @R\D\>&.O26X(*N[K":;7:N8
M5 >/RAQ0/0S]NBF_CDN.FMPMO&2D)9-SSKO63TI1$>GQNQ 7;.-PS9EYH/9Y
M#1MM+>"F]')Z&"(@DCL74NTQ3%><1I]-$P8JN"T<-2G]^@AH(;26W&^M#:KL
M%/UL9AVDT=2<5:"4+N!N\-;B0O=?I@*K7+\6HY31*"]8)S+KK[*KI,BIPC#7
MK^.*K-RS-_:QT-M;"]/UYN<]^+YAO_QMUTJ8I$OJ<T:DXV==2NJGVZ#72]73
MWIK$U3H,@XL<L(TM1JN;\EA6B6W8T ]:1$EI>62)"12^VYR)6'I#=[?>"*5.
M'ZV4+L]V+Z3ZZF,NE*8['.<SFAR7IK8MK8[S"FFNK 1DS3X<%361>;CBM VJ
M>?8*9;)4.#DI#&;Y-1X,;@!EZR$[+7J3:@ZNO[G+UJI #9ID'[8'D7:'V$W%
M="WW7RX- .75TBR1%1-^@I3RIH8L:%"4NKUS>A-XD&G=Z=C9:7MEF4M*IN4]
M=#H8@]N>@1%<-$PZ).C'YT(5,5<I:Z](EMLRS\ZFP$V>U<4^73+H,YK?DW5O
MO=BXMQZPG/!P*0]]M]3%Q9+-D"V5Q?=.6>@?,Q-BB-PCXAS[JO,U79P G?NQ
MU_E*^J=W/L$,SYPJVT"=SU=SPH,*3SR]N:S0.C/)U>+,9C$B"C<)A)1DJZ]Y
M.V><NFMD*?Y ;2%T&J!^$+4=*%07E^&(,\@LJQAT*_KV=5^E?SHT].)!B7V#
M/U=0$NS= )/Z!KVC ,[<Q^$:% 3[A9/[SI! :[#F08D3L3K\N@SB-G0 D_&Y
M?,6QJ@+])M1BC3=PDDRP[1=H>/ ,W>CX^3]VW>+M+$9NOU*I5J*N&.,X-%N&
M! AR%MV(;]@HB)3Z?REM9O &=\Q^QJK[RRE7H'>1=JBI8ZF\ E8.3LHH*F&A
M.'"SO<6K:9;/K7 _^'/%AMDOC''14^-.@[SU,DVQT01I4B9?$&CR8S?0Q'KV
M%.I2.AIN+I(5:M=]:^RAU)3V-BN2##$,QU4"$J@N;<F3UDML^2'4$:,4_91:
M372VD[O=9E07"9TWCL$>C<=%S?RN\Q56_7.>AQ8J+1S,TF](8(8JM[]QBA9=
M>G64*0:1IZSA1E^H/H8,TFTZFD;7AO%*/,;WT3*T@E]*%:_87[0S[GZML2H*
M+EPBKVS$;3 =34(JCC,85@";B#(9F99)L')>1:T@1@,1!;%;9]LHA")K%MS8
M^>*@Z[U@C+*/SJLF]76CH2HH8C28IR:Z<Q4=<KZ;&U9<Y0GVH]K)"SLBKV8S
M5^/L*CDF0T*<0'*%Y";*SBT7.8 #(73T Y7ZD $Q%]&%87/>/@<[6&XEM?,"
M?AM\&O['_JY,S_8"-VV6Z3ZG?ZJ^E4\HKS]P%1SX'SBN856@U_R?>0VV7(H,
M)0P&*"@S^/;3WG OZ+.4P5C+]?7UWG7Y]Q[8VD1[,N@4'69N("%HL9<IL+U+
M7>BZ\\2NVKS]A?U@FD.<&HS:"C&$YPW!IP=77F+P%7;<XX78!"UB" ,R8Z,3
M3DP?EY9\,;2)#%&7 D(*(AU3 R+@:=M;<'S@HCTSA@ZYK'^24#1&[D(^B^29
MYX S;#9]J2O]ZXI#. )\]0K002/N3.]@5ZAO*/62KPHNG(DU0W1$3O<&A;7!
MR)B>!F<&%"T52R]+*TCG5.ND5:+Z5-:=5NIR="U5;EY4*_+Z3>=IS:84,PO<
M%5WDNU553?N^I]%G):S#=/,9H;'"Z!O-M)BCDA C-U?08%2.;+50NS&S8>3_
MHRC[;+N?R=.Y(DQ9)56M^U9)#VA3T?36H8A7GI]K$5+\;FDZP'QVEA1&Y^!6
M\MPLUMWS3@0NMQ=C(Y%+L%"T2?<!L'U(+IV.2%P[/[TQX6ROE"Z=SE8G#C,[
M,?E*;K!"9WZ$KYI%B=?AW"H]_I")3-VQC,G1?H$69DY43I%!GA!:X#,@:4*9
M2&$SN96%BYBCUMCTFN?2$-%V5SP2*GU9<@M5NMT@F$47L(= PF^M%S;IP#"M
M*/Z[+AU_P"50,3R>3V]ZX[T;)>*%::;WC#O"P*T%L9QS9\W<AKV\\%UA(_:1
MC0J-QFLN1 Y'@E$D%@=(?@*2_.TH+H=HO7W*KV%\K5993:$%W.L)@\]>;KQS
MRP:Z-@PVU)8SX*DIGQ,V1US6*?Z]#L,&.9UZ%L4Q-KRF[RS/EDM21*?3UQQW
M:D-1N)R@\+&NQG 2G>;G&QNJD6_MWN#VN#R/OI#9(2-W#7]A"E*"U]P]HV[V
M_)L+&9O7:3-#Z!FLY,1+(>0"LO[+.VM-=_<,PWZW5.S8X$X;SYJ[$-1QIC4<
M9WF<41@HS'S3'2[))ZR\&+6.G$4D$1N#PG*+;GN%<3Z3V)6486L%X/+"Z2\^
M9X6[[&*2/%0KN+$L7O=.E'92^=8T\G$5KRK7H9X2S+NJJU-ITPFGT^E<(6K*
M>5:@'-D=DT:MMFV8UU94 JF>VRK5X<7&K'9)UT-O5\PH]/3FFXLD5 ,ZN]MA
M<3U5M1=7:[6=[5^[Y-1X=^4.M1_8H4;=?-Y@VUPP;1W[[IL:'5&34]^M,:K3
M -5L#04<$/?D=D,EK0E3EZG1-M=W%6(E,*U'K=(WU; %O],1/WML^@]*/2AK
M8<ZQ+DV76-_#)Z4M'84TX[;?YHM.5QGW"L2>XGG,(\'3L/-2U&7$4[MNSI;3
M$55=\2/6CI7,98K+U9B=QA[1H$D!-C33U8F/4?L!<I5AVW5;CU]/E!'E#1G$
M.TL)+CC0F:+14G5F5N)GU&17FTCDO<7&V#  3IR2'C12!1H(5,?WW5P7;ZQN
M_6UJ$*(AB(Z=TFZW)5CQT'5K(+\4AW1&<3,+A@%#@T%LC)UGPIPDB$?@7E1\
M"C"WQVV1(JQZ7@OU!43?Q?L*QR=_.P$;2R_8<=R>>J1(WDR>MM@L>B93&&M\
MX^#ZL;LA-2QS@IUR]'9);K+L;FXH/(!L?QT_M,V%M7)VC?X',CJ<( "]"LF$
MSEV;O"(M#3N>)WAC6**;9XPZ_D'#CALQ"?(YF7F+HN+5U]4RUYN4IATY/2C#
M. Z1Z^F2UC)+ZY(3*_!HF7JIH'[ @88!6]<3"MV)@C72**K13>>+K<3U;?"\
ML)E,(=#H-1!,$>HN![QM:&*G.9>,YSW4NI>G%4^<\UXBW3&5!:3[2> MV/EI
M[]4_=DTU]2X:[5"YNW&NN)7,W8T>0$OA)7+<LBZM!B9.!ZS&"I*]RQ7BX3I[
M<MUV[4[>L"0W6YIOY&B"<$>&BE*/W#>4D@C; )RR<TOH$-R*=!4MW'&'-J81
M2H8;:4JF6SQ?B;L=>HV],L_BN%-ZB5!+7>BJSG"R_5X09A(6D\8M;KN6%&%:
M)M/(66A-SJR%MK:Q0AR7,0SF[%9DNU$Y?41I$ZK&M:ZN@Z)-GXE%C]>M,)RV
M'08E4G6UBW6L28GGN+5=?>0D0>A;/79U%X_*8*AG=8%)HV[<*BH[7&(=M/G@
M"LH/ UK\^>W+)P^.#_L?CP?GZ]#<?/\Y(RS>6E;=*.W.U(@OFV:@!&#>Q02T
M)295M-2 /Q13LN$L(^WJ"Y94NFRY2@IRK^KL%3I=^"B!%4X5)OHB]HEK#)6Z
MHPQU^Z+VSO+,9A[;G$:P QY]I;QJ0Z%VBR,N"95=CG30WS!E.'@E^7*2R+9R
MB*-I=-'D_CNV#H#;E1#VJ\C4C4[7T5(#ZVB65;D[MT+2$;W8]=FXK5-PB!T3
M0[6J3ID!:PC^.(V2*6X8[#MNV%A#,JF:*^<#CZ@!1:6?[#;_:?<RQN?-]R4U
M1H"LH4BXM'N-JKLN1/04';(_;!RRCQ'%=21/Z'8Q)AFS$%4_XE9^CMM/6S2(
MQ4)>X[7&LHF?;;"]!A\GA9M2Y[(O;BXJW$E1YP3X8U&%C\>SC7MP2JTSBUKG
MN%R0 IM1@8C0&P'7@^(;9;[MW Y1[8@D!\ZG4)/5F'Q4\5A3+Q!Y9#IJ<3Q2
MVQ\RHMTW^,9OCPD8\[)DZD)Z'(;!!?5(<K^1+MZ3.@VFH%?)_!P;I2VVNNB"
MQ4] 2!E?^&"!E!E7(2&?;*.0%)+.%Z3G4O\JK4:L 4P/-;UJ36&:K]R:KUB.
MK]3&EJJ/O/#T$=7=K_(>^DC7QB[61Y:B=L#Z?I7:P=)_CLCW'MHE\DE$WT<N
M(^9Q45;KXZ)XELG_&^JGS_[M6?9V^LDP^>">/%XW]?,1_TMF\M^Z5M'7\WCK
M[7PXDP^>$H_'\@9SF/PJ;<Z7TE6,>THPA^_IJ)U2G[D !;-XW6;09[*6#;H&
M"0D':LC!$5Y)6VWFJG8^:D)H>[K M[U,RBL5/B(.VRS,%&4.7]9>GDF4I!2N
MRH.+1)<8D/(/[,XEZ!G^:+Q3\K-U 46<'$ _ME^A/7+8BL-?+3?EQ\7O_^GX
MAAP98>IIM!>#_.T,K"K4WV#FCAU'IYZCG@_[BCL>,C>K'-/I<DX[(DG.;<9<
M&:^G1"OO'"5) W0$XKR7V,HF2C=01*2H&/"F_2G)3@GAU_!#:I+8X>+Q99Z7
M.OEP_@SQ;(*TM6WAG.'YJ,06[A$I]T[.SUD!%$-\0M?7B>@I!GFL%U+7(O3&
M;!=JG.<SRL!OC=:=5U2Z<2&)Q*'3>"[%:.JDRA/4\=)QE[37S\^01Z+'A(E4
M.0H-C@^="/Z"ZO?XU=2D8E)HP.!<0,G+<74K)1D026ASASCYE2@:W;XKUXDI
M0G^,/<QA,K ![#D^9&>4Y!F?G/\Q./\P/.\='PZ.WP>]X[_./^"'\Y/@_$,_
M. !".>N=_15\Z)_U!\=AT/_SH']Z'N!-P5E_>-H_.,=K>\';LW[OX$-P\JX1
M2_@!<2"-;UXTOGF%UYR<!;Z/=8!?-5_4A[_[9\$I7/H7[^0P.'E[-'C?.Q^<
M' _Q$O&4OOLK# [[[_K'AS"KP^##R1'\IW?V\:@_' :GG\Z&GWK'YSS/P;#Q
MZC XYA<]8>?3JXWSZ6&YND1CP?!#[^@H>-L/C@:]MT=]?3!.+!D2Y1[#/^^"
MP?DP^-C_^+9_-H2CY7T-?\$M@S--S(/?^T'OW;L!//:\/P3RA\\'<!\0[> ,
M?C_!C_V/IT<G?_7[0R+AWGM8JV'P3AZ,CQGTCD(D>+H%/QT,#N&BWA&\;WL+
M3N^P_U^?X M,SSSL?80GP%/_^-"GT<.#^L-^GZ8%SP1>8'\;',O9Q\?^T3L[
M@\,"!PJ&=8Z'XSUL7O_X@.ZCI?AC,.R'<(H&0^0>)Y_.<=Y\LMZ?]?L?80RR
M!,!"^F<'<+E>F;/!^P_P#W*83W!TST)8HO>]LT,ZJ' -SA7&-CB@.X:?@,O(
M5%8=!1JL(-T6=N4=[3%LZ0"(;_7IMOO[' TZ<.*3":O#>T'?9)XWTZJI4 XK
MF30'G ;]HQ<7_S0865O<-7:5:S32''BAGV-@(7YA,Q63:S/#4-,6% K!%3H)
M=S=@)!2A3@AAX57:\"V",\J!ZS0'6(WXK-3,B^(V([<$'RHO_4F;<*Y_;5TJ
M3#9>%$GUDI8ZG+>LZB06RJ*T':J, X$-4?&"BPVK<W2HN(MCQQH=>S>DW]R
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MFM.Y],9X,*S$@Z5,DU**\_^_]JZVJ6UD2W^GBO^@FJW=@BJ%"2')3#*SJ6O
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M\X8U1N=X"D<;N!(YI(5!G*1Y>IIYI/#!HF_1"<T4&1'9W/H><201'OKV<CF
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M0I*KKD[5E\T=30[DXE:,T<+#6J6$FQHR^&3.JR$DA-X9+4IQHGQ)A@A5V1?
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M0T,JD]!^@5-,G#"LD9\LP!KY6PPGZ22C>I#XR:EE?X4W2#G46"HO53)-A:$
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M<_M[(1AP_?Q-SX SPI ;H."$.9EBYIK[DX(=_J!R;D\$ 3-BTC0YFN:+N"M
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MJ%='S_;1)$.LA8T]W\8TTLRTMZ8=0',SP;.P2N]SXS5M@0=ZYQN&Z+81@9%
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M_I\DVI_O3[00-4:]3W"3/I+[?U!+ P04    " "I@%M:*4,>:5$$  "F$0
M$@   '-C;'AW+3(P,C4P,C(R+GAS9,U7;6_;-A#^7J#_@=6G#9@D2VG61DA2
M9$TR!,@;'+?;MX"FSC91BM1(*G'^_8Z4Y,@O<1RG79<OH7CWW-US=SS2^Y^F
MA2!WH U7\B!(HEY 0#*5<SD^""H34L,X#SX=OGVS_RX,R?'IV24)R<3:TF1Q
M?']_'^4C+HT2E44+)F*JB$D8MOJ?!U_(U]IZ1OH@@!H@!346-/FCXB+/TE[Z
M/DG2-$JZ, W4V2,YM9"1-$X_QJBX2Y(T2S]FR0=R=$%.O!E)!KR +E:5#YJ/
M)Y;\PGXE'G6LI 0AX(&<<DDEXU20FS;DW\B99!$Y$H+T'<Q@G ;T'>118W5J
M\LRP"13T[1M",&'29!)-5L5!X#+1)&(ZU")2>ASG5L?VH808E4+4 LU9T($^
MCUO"8"6<Q,R (VJ&'M1*7'[>=Q"&B>G]3!U39#6?1I"/J0Z5%%R"KY7+3R]-
MTPXR!S[#^=@,L&BL[F(4+'IQ<KZ:3=KK[<38&A83#AT(NOZV!N'$0^R2KI,E
MR/V.!R1[>WNQERZ$E-MY!HWUW;@6SB=V3&FY,J].\$B86LS@L+)PJG1Q#"-:
M"?12R7\J*OB(0^ZUL,4+D'9.9U[#4CT&>TD+,"5EL%6)L"-7Y0,I)O'?%^<W
MOEF#0P<@Q/<O+TJE+:G;^%PQ?[S6E,%]A6WU0K<5)FFXDT1H+"!R*?HUI2?Q
MJP-IFV*K0&8=M7$@YJG.=XO0+9[ROOJ\;)V!Q8G@^.\Y_LGO&_%?FBC?(1(E
M+U\;3&<L;E\323FKIUZ]W+PNC\A7]68[35P>=M<Z7AP_+R>]<BS%(*QI=];2
M7SW5OG<8_A[:.([.K=4$XL.@4BKK?7>#HV7)Y4@U6[CI#G76GNP^C(B_!C*J
MF58"UE\6<:E5"=IR]/\X'&H#$PVC@\!?GF$[>&\%'48X>%N=)0_S\\:)8X2
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M6;7US*4.7']EHEMU2Z8.WZ19Q843JROS.Z&=?^77OZQZ^OV0>O@/4$L#!!0
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MLQ:4%MC(3XY$4'4W,5M-X>A_0WZ[YJ\6Q.KC$&Q?@8GL^0T\T.1+8+ ,WY
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M5>47]670^2Z:?26RW/,_4$L#!!0    ( *F 6UHU85(VVP4  %8Z   6
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M J AWPI[A^%6J+%D_X,CHW?!3L9TP%_,SR'75\P_\^,^7?(W4$L! A0#%
M  @ J8!;6C_$]9M)%P  O8L   X              ( !     &0X-3DT.#1D
M.&LN:'1M4$L! A0#%     @ J8!;6D48G3XRGP  2]0# !$
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M+3(P,C4P,C(R7VQA8BYX;6Q02P$"% ,4    " "I@%M:-6%2-ML%  !6.@
M%@              @ %-WP  <V-L>'<M,C R-3 R,C)?<')E+GAM;%!+!08
1    !P ' ,8!  !<Y0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>d859484d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sclxw="http://imetrix.edgar-online.com/20250222"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sclxw-20250222.xsd" xlink:type="simple"/>
    <context id="duration_2025-02-22_to_2025-02-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2025-02-22</startDate>
            <endDate>2025-02-22</endDate>
        </period>
    </context>
    <context id="duration_2025-02-22_to_2025-02-22_us-gaap-StatementClassOfStockAxis_sclxw-CommonStockParValue0.0001PerShare2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclxw:CommonStockParValue0.0001PerShare2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-22</startDate>
            <endDate>2025-02-22</endDate>
        </period>
    </context>
    <context id="duration_2025-02-22_to_2025-02-22_us-gaap-StatementClassOfStockAxis_sclxw-WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclxw:WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-22</startDate>
            <endDate>2025-02-22</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2025-02-22_to_2025-02-22"
      id="Hidden_dei_EntityRegistrantName">Scilex Holding Co</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-298">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-02-22_to_2025-02-22"
      id="Hidden_dei_EntityCentralIndexKey">0001820190</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-325">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-326">2025-02-22</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-327">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-328">001-39852</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-329">92-1062542</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-330">960 San Antonio Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-331">Palo Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-332">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-333">94303</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-334">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-335">516-4310</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-336">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-337">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-338">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-339">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="duration_2025-02-22_to_2025-02-22_us-gaap-StatementClassOfStockAxis_sclxw-CommonStockParValue0.0001PerShare2Member"
      id="ixv-340">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2025-02-22_to_2025-02-22_us-gaap-StatementClassOfStockAxis_sclxw-CommonStockParValue0.0001PerShare2Member"
      id="ixv-341">SCLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2025-02-22_to_2025-02-22_us-gaap-StatementClassOfStockAxis_sclxw-CommonStockParValue0.0001PerShare2Member"
      id="ixv-342">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2025-02-22_to_2025-02-22_us-gaap-StatementClassOfStockAxis_sclxw-WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member"
      id="ixv-343">Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2025-02-22_to_2025-02-22_us-gaap-StatementClassOfStockAxis_sclxw-WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member"
      id="ixv-344">SCLXW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2025-02-22_to_2025-02-22_us-gaap-StatementClassOfStockAxis_sclxw-WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member"
      id="ixv-345">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-346">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2025-02-22_to_2025-02-22" id="ixv-347">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
